




# 71ST AACC ANNUAL SCIENTIFIC SCIENTIFIC MEETING & CLINICAL LAB EXPO



1D Ab detection







pe 1 in Children te 2 Pen as Carlies is cras Produces Ve Issuit

# AUGUST 4-8, 2019

ANAHEIM, CA USA

www.2019aacc.org





# The Evolution of Syphilis Testing



You Don't Have to Use Treponemal Anymore . . .

Fully-Automated RPR Screening is Here!

### **Experienced Partnership**

Arlington Scientific and Awareness Technology have created a synergistic partnership to meet an essential customer need for an affordable and fully automated nontreponemal RPR syphilis analyzer for diagnostic testing and blood donor screening. Both companies bring a combined 60+ year history of consistent quality, dependability and reliability to the relationship.

### **Automated Nontreponemal**

- Walk-away system
- 190 samples per hour
- Titers to 1:2048
- Objective results
- Proprietary advanced imaging algorithm
- Improve efficiency and workflow

# ARLINGTON SCIENTIFIC

#### AACC BOOTH #2805

For Additional Information 800-654-0146 info@arlingtonscientific.com



#### AACC BOOTH #3055

International Sales 772-283-6540 info@awaretech.com

# CONTENTS

Offices & Meeting Services 2 Registration Hours Clinical Lab Expo Hours AACC 2019 Mobile App
AACC Shuttle Schedule & Routes 4
Hotel Information
2019 Supporters
2019 Annual Meeting Organizing Committee
Governance & Special Events Schedule10
Scientific Poster Sessions Schedule12
Division Poster Activities
Oral Abstract Presentations
Student Oral Contest Presentations
2019 Student Poster Presenters
AACC Academy New Fellows & Award Winners
2019 Distinguished Abstracts Awards
Pathways
Session Information
Registration Types & Events

#### SESSIONS BY DAY

SUNDAY, August 4	24
SPECIAL SESSION: Consumer Genomics, Direct-to-Consumer Testing,	24
and Patient Empowerment	
MONDAY, August 5	
Global Lab Quality Initiative Workshop	40
SPECIAL SESSION: 2019 AACC Disruptive Technology Award Competition	55
TUESDAY, August 6	56
WEDNESDAY, August 7	76
SPECIAL SESSION: Laboratory Feud: Science and Practice Core Committee vs.	01
Education Core Committee	
THURSDAY, August 8	92
AACC Booth, Member Lounge & Store	
AACC access Program	
Speaker Index	100
ACCENT® Credit & Certificate of Attendance Information	
ACCENT® Frequently Asked Questions	103

# **OFFICES & MEETING** SERVICES

#### REGISTRATION

#### LOCATION: Exhibit Hall E

Saturday	12:00pm-5:00pm
Sunday	8:00am–6:30pm
Monday–Wednesday	7:00am–5:00pm
Thursday	8:00am-1:00pm

#### **AACC STORE**

#### LOCATION: Lobby B

Plan to visit the AACC store to browse some of AACC's bestsellers and AACC merchandise, including t-shirts, wearables and gifts.

#### **AACC Store Hours**

Sunday–Wednesday	9:00am–5:00pm
Thursday	9:00am–1:00pm

#### HOUSING

#### LOCATION: Exhibit Hall E

Representatives from Spargo, AACC's official housing agency, will be available to assist with your hotel accommodations.

#### **INTERNATIONAL TRADE CENTER**

#### LOCATION: Exhibit Hall E

The center is staffed by international trade specialists who will help international visitors identify and meet suppliers of products they wish to purchase, either for their own use or as distributors.

Monday-Wednesday...... 9:00am-5:00pm Thursday...... 9:00am-1:00pm

#### **AACC MEMBERSHIP**

To learn more about membership, visit the AACC booth #4353. To join immediately, stop by the AACC Conference Registration Desk. Membership is valid for one full year beginning on the date that you join. Dues are as follows: Professional \$239; Professional Affiliate \$141; Transitional \$81; Express \$65; Trainee \$39. Customize your membership by participating in one or more scientific divisions for an additional \$15, \$20 or \$25 each.

#### **CONTINUING EDUCATION CREDIT AND CERTIFICATE OF ATTENDANCE**

See page 102 for instructions on obtaining ACCENT® or CME credit, as well as a Certificate of Attendance. This information can also be found at www.aacc.org/AMcredits19. If you have additional questions, visit the AACC booth #4353 on the Expo show floor, or send an email to education@aacc.org.

#### FACULTY AND PLANNER DISCLOSURE INFORMATION

All individuals involved in planning, developing, and/or presenting the contents of the 2019 AACC Annual Scientific Meeting Scientific Sessions were required to disclose whether or not they (or an immediate family member) has had a relevant financial relationship (within the last 12 months) with a commercial interest, and one or more of the commercial interest's products/services are related to or relevant to the presentation contents. All disclosed information was reviewed, and if any conflicts of interest were identified, they were resolved prior to the meeting. Completed disclosure forms are on file in the AACC headquarters office. A summary of the disclosures is available when accessing the presentation handouts at www.aacc.org/handouts. A limited number of printed copies of the disclosure summary are available upon request at Conference Registration.

#### **AACC HEADQUARTERS OFFICE**

#### LOCATION: Room 303B Phone: 714.765.2004

Contact the AACC Office if you have general guestions at the meeting. Also use this number if you have an emergency

situation.

#### **AACC Headquarters Office Hours**

Friday	12:00pm–5:00pm
Saturday	12:00pm–5:00pm
Sunday	8:00am–6:30pm
Monday–Wednesday	7:00am–6:00pm
Thursday	8:00am–4:00pm
Nursing Poom Access	Poom 109

Nursing Room Access: Room 109

#### **BAGGAGE CHECK**

#### LOCATION: Lobby Hall E

Tuesday–Wednesday 7:00am–6:00pm
Thursday 7:00am-2:00pm
Per item: coat check \$3, bag or poster \$4

#### **CLINICAL LAB EXPO**

#### LOCATION: Exhibit Halls A-D

Tuesday-Wednesday...... 9:30am-5:00pm Thursday...... 9:30am-1:00pm Refer to the Exhibit Guide or the mobile app for exhibit listings and booth descriptions.

Note: AACC permits individuals age 16 and 17 with a photo ID to register for and attend the 71st AACC Annual Scientific Meeting & Clinical Lab Expo if accompanied by a registered adult. Children under 16 are not permitted on the exhibit floor or in the educational sessions at any time.

#### **FIRST AID/EMERGENCY**

#### Emergency Phone Number:

Dial 714.765.8975 from any telephone in the convention center. In hotels, dial 0 from any phone.

#### PRESS ROOM

#### LOCATION: 213AB Phone: 714.765.2002 and 714.765.2003

Sunday	9:00am–5:00pm
Monday–Wednesday	8:00am–5:00pm
Thursday	8:00am-1:00pm

Members of the media can register for the AACC Annual Scientific Meeting in the press room, and pre-registered media can pick up their badges and other meeting materials here. The press room is available for journalists who wish to hold interviews away from the exhibit floor and other public areas, and press room staff can also help to set up interviews between reporters and scientific session speakers. Additionally, registered media are welcome to work on stories here.

#### Materials

AACC media kits that include fact sheets and AACC press releases will be available, as well as Expo and conference program books. Phones, WiFi and laptop charging stations are available for the press. Free breakfast and lunch are also available for registered press Monday-Thursday of the meeting, and afternoon refreshments are available on Sunday.

The press room is available to exhibitors to display promotional materials and media kits. However, only registered media may use the rest of the press room, and company and public relations representatives will not be permitted beyond the entryway table after dropping off their materials.

#### Interviews

Registered media can inquire with press room staff to reserve space in Room 212A for conducting interviews. Use of this room is by appointment only and subject to availability.

#### **Press Conferences**

Press conferences take place in Rooms 213C and 213D. Details of scheduled press conferences are available from the press room. Press conferences are open to all registered journalists.

#### **PHOTOGRAPHY**

Except for photography specifically authorized by AACC, use of video and photographic equipment is prohibited on the exhibit floor and in the meeting rooms. Photography of poster sessions is permitted only with express permission of the presenting author.

#### LOCATION OF ACTIVITIES

#### **Anaheim Convention Center**

- Scientific Sessions, Plenary Sessions, Meet the Expert Sessions, Roundtable Sessions, AACC University, Oral Abstract Sessions, President's Invited Session, Chair's Invited Session
- Special Sessions
- Laboratory Feud

34225 Healthcare Forum: Laboratory Stewardship in Healthcare Innovation

11002 Consumer Genomics. Direct-to-Consumer Genetic Testing, and Patient Empowerment

- 12002 Disruptive Technology Award Competition
- AACC Clinical Lab Expo
- Product Showcase
- Poster Sessions
- AACC Opening Mixer & Division Networking Event
- Registration and Pre-Registered Badge Pick-Up
- Industry Workshop Theater Presentations
- Lecture Series Presentations

#### Anaheim Marriott and Hilton Anaheim

- AACC Governance Activities
- Affiliated Organization Meetings
- Industry Workshops
- Pre-Registered Badge Pick-Up (Marriott only)

#### **DOWNLOAD THE 2019 MOBILE APP**

With hundreds of exhibitors to navigate and dozens of educational sessions to attend, planning your busy days at the 71st AACC Annual Scientific Meeting & Clinical Lab Expo is essential to making the most of this dynamic event.

Now you can do all that and more with the FREE 2019 AACC Annual Scientific Meeting & Clinical Lab Expo app. Available for smartphones, tablets and desktops from the Apple App Store and on Google Play for Android devices.

- Plan each day with a built-in calendar.
- Browse exhibitors and map out your path through the Expo.
- Browse through new products available at the Expo.
- Take notes on scientific sessions or about exhibitors.
- Follow live tweets and other social media about the meeting.

#### To Download:

- Visit www.2019aacc.org/app.
- Search "AACC" for the app on the Apple App Store or on Google Play.

# **SHUTTLE** SCHEDULE

SHUTTLE BUS SERVICE					
Date Service Hours Frequency					
Saturday, August 3	11:30am-5:30pm*	Departures every 20 minutes			
	6:00am–10:00am	Departures every 15 minutes			
Sunday August 1	10:00am-4:00pm	Departures every 30 minutes			
Sunday, August 4	4:00pm-6:30pm*	Departures every 15 minutes			
	7:00pm-8:30pm	Departures from Opening Mixer/ Anaheim Convention Center to route hotels			
	6:00am–10:00am	Departures every 15 minutes			
Monday, August 5	10:00am-4:00pm	Departures every 30 minutes			
	4:00pm-6:30pm*	Departures every 15 minutes			
	6:00am–10:00am	Departures every 15 minutes			
Tuesday, August 6	10:00am–4:00pm	Departures every 30 minutes			
	4:00pm-6:30pm* Departures every 1				
	6:00am–10:00am	Departures every 15 minutes			
Wednesday, August 7	10:00am–4:00pm	Departures every 30 minutes			
	4:00pm-6:30pm*	Departures every 15 minutes			
	7:00am–10:00am	Departures every 15 minutes			
Thursday, August 8	10:00am–12:00pm	Departures every 30 minutes			
muisuay, August o	12:00pm-3:00pm	Departures every 15 minutes			
	3:00pm-6:00pm*	Departures every 30 minutes			

\* Indicates last time shuttle departs convention center to hotels. Last shuttle departs hotel coming to the center 1 hour prior to this time.

Shuttle schedule may vary due to traffic and weather conditions.

If you need to arrange wheelchair-accessible transportation, please call 877.875.2455 at least 12 hours prior to pick-up or see a shuttle supervisor at the convention center.

# LOCATIONS

#### HOTELS IN WALKING DISTANCE TO/FROM THE CONVENTION CENTER

Anaheim Marriott Clarion Hotel Cortona Inn & Suites Courtyard CC DoubleTree Suites Hilton Anaheim

#### SPECIAL TRANSPORTATION

Opening Mixer & Division Networking Event will be outside the Anaheim Convention Center in the Grand Plaza, Sunday, August 4, 6:30pm-8:00pm. Return transportation from the convention center from 7:00pm-8:30pm.

Industry Workshops will be at the Hilton Anaheim and the Anaheim Marriott, Tuesday, August 6, and Wednesday, August 7. Transportation provided from route hotels to the convention center from 6:00am-8:30am, every 15-20 minutes.

Route #/Color	Hotel	Boarding Location
	Hyatt Regency Orange City	Conference Center Entrance
	Residence Inn Garden Grove	Hyatt Conference Center Entrance
Route #1 — Red	Embassy Suites South	Bus Stop Near Lobby
	Hampton Inn Garden Grove	Embassy Suites South
	Hilton Garden Inn Garden Grove	Embassy Suites South
	Anaheim Hotel	Curbside Lobby Entrance
	Fairfield Inn Anaheim	Curbside at Panera
	County Inn & Suites	Parking Lot Near Pool
	Clementine Inn & Suites	On S. Zeyn St. at Circle
Route #2 — Yellow	Candlewood Suites	At Clementine Stop
	Wyndham Garden Inn	Bus Stop at Wyndham
	Hotel Indigo	Bus Stop at Wyndham
	Desert Palms	Curbside Bus Stop
	Marriott Suites	Curbside Near Lobby
	Delta Hotel	At Marriott Suites
Route #3 — Blue	Homewood Suites	At Marriott Suites
	Sheraton Garden Grove	Curbside Near Driveway
	Great Wolf Lodge	Curbside Near Driveway
	Staybridge Suites	Curbside Near Lobby
Route #4 — Green	Disney's Grand Californian	Outside Lane at Lobby
Koule #4 — Green	Disneyland Resort Hotel	Main Lobby Fantasy Tower
	Disney's Paradise Pier	Curbside Near Driveway
	Homewood Suites CC	Lobby Entrance
Route #5 — Orange	Red Lion	Curbside Lobby
Noute #5 — Orange	Hyatt House	Curbside Near Lobby
	Hampton Inn CC	Curbside Lobby Entrance



Hyatt Place CC Portofino Inn & Suites Residence Inn CC Sheraton Park Hotel

# **HOTEL** INFORMATION

Ho	tol	Address	Distance to Convention Center
1	Anaheim Hotel	1700 South Harbor Blvd	1/2 mile
2	Anaheim Marriott (Co-Headquarters Hotel)	700 West Convention Way	Adjacent
3	Anaheim Marriott Suites	12015 Harbor Boulevard	1 mile
4	Candlewood Suites Anaheim Resort Area	1733 South Anaheim Boulevard	1 mile
5	Clarion Hotel Anaheim Resort	616 Convention Way	1 block
6	Clementine Hotel & Suites (formerly Residence Inn Maingate)	1700 South Clementine Street	1 mile
7	Cortona Inn & Suites Anaheim Resort	2029 South Harbor Boulevard	1 block
8	Country Inn & Suites by Radisson Anaheim	1640 South Clementine Street	1 mile
9	Courtyard by Marriott Anaheim Resort Convention Center	2045 South Harbor Boulevard	4 blocks
10	Delta Hotels by Marriott	12021 Harbor Boulevard	1 mile
11	Desert Palms Hotel and Suites	631 West Katella Avenue	1 block
12	Disney's Grand Californian Hotel & Spa	1600 Disneyland Drive	1 mile
13	Disney's Paradise Pier	1717 South Disneyland Drive	1 mile
14	Disneyland Resort Hotel	1313 Disneyland Drive	1 mile
15	DoubleTree Suites by Hilton Hotel Anaheim Resort/Convention Center	2805 South Harbor Boulevard	3 blocks
16	Embassy Suites by Hilton Anaheim South	11767 Harbor Boulevard	1 mile
17	Fairfield Inn Anaheim Disneyland Resort	1460 South Harbor Boulevard	1 mile
18	Great Wolf Lodge Garden Grove	12681 Harbor Boulevard	1.7 miles
19	Hampton Inn & Suites Anaheim Resort Convention Center	100 West Katella Avenue	1/2 mile
20	Hampton Inn & Suites Anaheim-Garden Grove	11747 Harbor Boulevard	1 mile
21	Hilton Anaheim (Co-Headquarters Hotel)	777 West Convention Way	Adjacent
22	Hilton Garden Inn Anaheim-Garden Grove	11777 Harbor Boulevard	1 mile
23	Homewood Suites Anaheim Resort Convention Center	2010 South Harbor Boulevard	4 blocks
24	Homewood Suites by Hilton Anaheim–Main Gate	12005 Harbor Boulevard	1 mile
25	Hotel Indigo Anaheim	435 West Katella Avenue	1/2 mile
26	Hyatt House at Anaheim Resort/Convention Center	1800 South Harbor Boulevard	2 blocks
27	Hyatt Place at Anaheim Resort/Convention Center	2035 South Harbor Boulevard	1 block
28	Hyatt Regency Orange County	11999 Harbor Boulevard	1 mile
29	Portofino Inn & Suites	1831 South Harbor Boulevard	3 blocks
30	Red Lion Hotel Anaheim Resort	1850 South Harbor Boulevard	4 blocks
31	Residence Inn Anaheim Resort/Convention Center	640 West Katella Avenue	3 blocks
32	Residence Inn Anaheim Resort/Garden Grove	11931 Harbor Boulevard	1 mile
33	Sheraton Garden Grove	12221 Harbor Boulevard	1.5 miles
34	Sheraton Park Hotel at the Anaheim Resort	1855 South Harbor Boulevard	1 block
35	Springhill Suites Anaheim Resort/Convention Center	1801 South Harbor Boulevard	3 blocks
36	Staybridge Suites Anaheim at the Park	1050 West Ball Road	2 miles
37	Wyndham Garden Anaheim	515 West Katella Avenue	1/2 mile



# 2019 SUPPORTERS

Thank you to the supporters of the 71st AACC Annual Scientific Meeting & Clinical Lab Expo.



# **ANNUAL MEETING** ORGANIZING COMMITTEE



Jason Y. Park, MD, PhD, DABCC, FAACC University of Texas Southwestern Medical Center Dallas, TX

Paolo Fortina, MD, PhD, FAACC Thomas Jefferson University Philadelphia, PA

Nader Rifai, PhD Harvard Medical School and Boston Children's Hospital Boston, MA

Larry Kricka, DPhil, FAACC, FRCPath University of Pennsylvania Charlotte, NC

Linnea Baudhuin, PhD, DABMGG, FACMG Mayo Clinic Rochester, MN

Joshua Hayden, PhD, DABCC, FAACC Norton Healthcare Louisville, KY

Amy Saenger, PhD, DABCC, FAACC University of Minnesota Minneapolis, MN

Alison Woodworth, PhD, DABCC, FAACC University of Kentucky Lexington, KY

Deborah French, PhD, DABCC, FAACC University of California, San Francisco San Francisco, CA

St. Louis, MO Anthony A. Killeen, MD, BCh, PhD, DABCC, FAACC Professor and Vice-Chair for Clinical Affairs, Department of Laboratory Medicine and Pathology, University of Minnesota Minneapolis, MN

8 www.2019aacc.org

Lebanon, NH

Darci Block, PhD, DABCC Mayo Clinic Rochester, MN

> NRCC, FAACC The Ottawa Hospital Ottawa, ON

#### **2019 BOARD OF DIRECTORS**

Oakdale, MN

David G. Grenache, PhD, DABCC Chief Scientific Officer/Clinical Professor of Pathology, TriCore Reference Laboratories Albuquerque, NM

Rob Nerenz, PhD, DABCC Dartmouth-Hitchcock Medical Center

#### Christopher McCudden, PhD, DABCC,

Carmen L. Wiley, PhD, DABCC, FAACC Chief Clinical Officer, Veravas

Dennis J. Dietzen, PhD, DABCC, FAACC Professor of Pathology & Immunology and Pediatrics, Washington University School of Medicine, and Medical Director of Laboratory Services, St. Louis Children's Hospital

Steven Kazmierczak, PhD, DABCC, FAACC Professor of Pathology and Director of Clinical Chemistry and Toxicology, Oregon Health & Science University Portland, OR

#### Lorin Bachmann, PhD, DABCC

Co-Director of Clinical Chemistry, Co-Director, Point of Care Testing, Virginia Commonwealth University Health System Richmond, VA

Shannon Haymond, PhD, DABCC, FAACC Director, Clinical Chemistry and Mass Spectrometry, Ann & Robert H. Lurie Children's Hospital of Chicago, and Associate Professor of Pathology, Northwestern University Feinberg School of Medicine Chicago, IL

Mark Marzinke, PhD, DABCC, FAACC Associate Professor, Departments of Pathology and Medicine, Johns Hopkins Hospital Baltimore, MD

Stephen R. Master, MD, PhD, FAACC Director of Central Lab Services, Children's Hospital of Philadelphia, and Associate Professor of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine Philadelphia, PA

Octavia M. Peck Palmer, PhD, FAACC Associate Professor, Departments of Pathology, Critical Care Medicine, Clinical and Translational Science, University of Pittsburgh School of Medicine Pittsburgh, PA

David B. Sacks, MB, ChB, FRCPath Adjunct Professor of Medicine, Georgetown University, and Clinical Professor of Pathology, George Washington University Washington, DC

## 

Roger L. Bertholf, PhD, DABCC, FACB Director of Clinical Chemistry, Houston Medical Hospital Houston, TX

# CHAIR OF CLINICAL LABORATORY SCIENTISTS COUNCIL (EX-OFFICIO WITH

Steven J. Zibrat, MS, MT (ASCP) Assistant Director, Laboratory Quality Management and Point of Care Testing, University of Chicago Medical Center Chicago, IL

Janet B. Kreizman AACC Washington, DC

#### www.2019aacc.org

# **GOVERNANCE &** SPECIAL EVENTS

TIME	MEETING NAME	HILTON	MARRIOTT	ROOM	
	SATURDAY, AUGUST 3, 2	019			
1:00pm–5:30pm	SYCL Workshop		•	Marquis Northeast	•
6:00pm–8:00pm	SYCL Mixer		•	Platinum Patio	•
	SUNDAY, AUGUST 4, 20	)19			
8:00am–10:00am	Lipoproteins and Vascular Diseases Division Executive Committee Meeting		•	San Diego	
9:00am–10:00am	Critical and Point-of-Care Testing Division Executive Committee Meeting		•	Platinum 8	
12:00pm–1:30pm	Management Sciences and Patient Safety Division 24th Annual Leadership Symposium	•		Huntington	•
12:00pm-2:00pm	International Travel Grant Luncheon	•		Santa Monica	
1:00pm–2:00pm	Pediatric and Maternal-Fetal Division Board Meeting		•	Newport Beach	
1:00pm–3:00pm	ABCC Clinical Chemistry Committee Meeting		•	Los Angeles	
1:00pm–3:00pm	ABCC Toxicology Committee Meeting		•	La Jolla	
1:30pm–4:30pm	Management Sciences and Patient Safety Division Executive Committee Meeting	•		Redondo	
2:00pm-4:30pm	NGSP Steering Committee	•		Manhattan	
4:00pm–5:30pm	Tumor Markers and Cancer Diagnostics Division Board Meeting	•		Lido C	
6:45pm–8:00pm	AACC Opening Mixer & Division Networking Event Supported by Sekisui Diagnostics LLC			ACC, Grand Plaza	
8:00pm–9:30pm	Joint Mixer of the Clinical Translational Science, History, and Pediatric and Maternal-Fetal Divisions	•		Oceanside	
	MONDAY, AUGUST 5, 2	019			
6:30am–8:00am	Michigan/NEO/Ohio Valley Local Sections Breakfast	•		Capistrano	
7:00am–8:30am	Southeast/Florida Local Sections Breakfast		•	Orange Salon 2	
7:00am–8:30am	Hematology and Coagulation Division Breakfast		•	Platinum 1	
7:30am–8:30am	Molecular Pathology Division Executive Board Meeting		•	Grand D	
3:00am–12:00pm	ABCC Board of Directors Meeting		•	Platinum 8	
12:00pm–2:00pm	Annual Therapeutic Drug Management and Toxicology Division Meeting		•	Platinum 7	
12:00pm–3:30pm	Endocrinology Division Luncheon Mixer	•		Santa Monica	
12:30pm-2:30pm	ABCC Molecular Diagnostics Committee Meeting		•	Los Angeles	
1:00pm–2:00pm	Student Oral Presentation Contest			ACC, 201AB	
1:00pm–5:00pm	Industry Division Membership Meeting		•	Platinum 3–4	

To purchase tickets for events, visit Registration in Hall E.



TIME	MEETING NAME	HILTON	MARRIOTT	ROOM	TICKET SESSIC
	MONDAY, AUGUST 5, 2019	cont.			
2:00pm-4:00pm	NGSP IFCC Manufacturer Forum	•		California B	
2:15pm-3:30pm	Student Poster Contest			ACC, 201CD	
4:00pm-6:00pm	POC Professional Certification Board Meeting		•	Los Angeles	
5:30pm-9:30pm	Lipoproteins and Vascular Diseases Division Membership Reception, Poster Viewing, Dinner Lecture and Awards		•	Orange Salons 2–4	•
6:15pm–7:45pm	ABCC-SYCL Awards Reception		•	Elite Ballroom	
	TUESDAY, AUGUST 6, 20	19			
7:00am-8:30am	A Race Against Time: The Challenge of Sepsis for Clinicians and Laboratorians	•		Pacific AB	
7:00am-8:30am	The Clinical Use and Performance of High-Sensitivity Troponin Assays: Overcoming Challenges in Implementation		•	Platinum Ballroom 1	
7:30am–9:00am	Capital Local Section Networking Breakfast		•	Marquis Northwest	
7:30am–10:00am	ComACC Program Directors' Breakfast Meeting		•	Platinum 7	
11:00am-3:00pm	Division of Animal Clinical Chemistry Business Meeting and Lunch and Learn		•	Grand Ballroom G	
11:30am–2:00pm	Informatics Division Membership Meeting and Luncheon	•		Capistrano	
12:00pm-1:00pm	Biomarkers of Acute Cardiovascular Diseases Division Meeting		•	Platinum 2	
12:00pm-1:30pm	History of Clinical Chemistry Division Executive Committee Meeting		•	Gold Key III	
12:00pm–2:00pm	IFCC Committee on Clinical Applications of Cardiac Bio-Markers Meeting		•	Platinum 3	
12:00pm–2:00pm	Luncheon Symposium of the Clinical and Diagnostic Immunology, Molecular Pathology, Personalized Medicine, and Tumor Markers and Cancer Diagnostics Divisions		•	Grand E	•
12:00pm-2:30pm	Clinical Translational Science Division Lunch and Learn	•		Santa Monica	
1:00pm-2:30pm	Pediatric and Maternal-Fetal Special Session: The Importance of Developing Accurate Pediatric Reference Intervals		•	Platinum 4	
5:00pm-6:30pm	Midwest Local Section Mixer		•	Platinum 10	
5:00pm-7:00pm	CDC Clinical Standardization Programs Forum		•	Grand F	
5:30pm-7:00pm	Clinical and Diagnostic Immunology Division Mixer		•	Platinum 1	
6:00pm-8:00pm	Chicago Local Section Awards Dinner		•	Platinum 9	
6:00pm-8:00pm	Mass Spectacular hosted by the Mass Spectrometry and Separation Sciences and Proteomics and Metabolomics Divisions	•		Pacific D	•
6:00pm-8:00pm	Nutrition Division Symposium		•	Platinum 8	•
6:00pm–10:30pm	Critical and Point-of-Care Testing Division Member Meeting, Awards Ceremony and AfterGlow		•	Orange County Ballroom	
	WEDNESDAY, AUGUST 7,	2019			
7:00am–8:30am	The Fourth Universal Definition of Myocardial Infarction in Conjunction with the Clinical Laboratory Practice Recommendations for the Use of High Sensitivity Cardiac Troponin in Acute Coronary Syndrome	•		Pacific CD	
8:00am–10:00am	C-Peptide/Insulin Standardization Manufacturer Meeting	•		Huntington	
12:00pm–2:00pm	AACC Academy Annual Awards Luncheon and Membership Meeting	•		Pacific AB	•
1:00pm–3:00pm	CDC Clinical Standardization Programs (CDC CSP)/Cholesterol Reference Method Laboratory Network (CRMLN) Annual Meeting		•	Platinum 8	
	THURSDAY, AUGUST 8, 2	019			
7:30am–10:00am	17th Annual Point-of-Care Coordinators Forum			ACC, Ballroom E	•

If no location is specified, the session will take place at the Anaheim Convention Center. Meeting rooms are subject to change.

# **SCIENTIFIC POSTER SESSIONS**

Posters of accepted abstracts can be viewed in the Poster Area on the Expo show floor of the Anaheim Convention Center on Tuesday, August 6, and Wednesday, August 7. All posters will be displayed from 9:30am until 5:00pm. Presenting authors for all posters will be in attendance from 12:30pm until 1:30pm. Please refer to the onsite Abstracts Titles Guide for a complete schedule of posters.

### **TUESDAY,** AUGUST 6

9:30am–5:00pm	
Animal Clinical Chemistry	A-323 – A-332
Biomarkers of Acute Cardiovascular Diseases	A-001 – A-037
Clinical and Diagnostic Immunology	A-038 – A-125
Clinical Translational Science	A-126 – A-143
Endocrinology	A-150 – A-225
Factors Affecting Test Results	A-226 – A-273
Hematology and Coagulation	A-274 – A-310
Infectious Disease	A-389 – A-459
Informatics	A-311 – A-322
Proteomics and Metabolomics	A-144 – A-149
Tumor Markers and Cancer Diagnostics	A-333 – A-387

### WEDNESDAY, AUGUST 7

9:30am–5:00pm	
Critical and Point-of-Care Testing	B-182 – B-228
Lipoproteins and Vascular Diseases	B-001 – B-022
Management Sciences and Patient Safety	B-023 – B-066
Mass Spectrometry and Separation Sciences	B-067 – B-110
Molecular Pathology	B-111 – B-139
Nutrition	B-140 – B-150
Pediatric and Maternal Fetal	B-152 – B-181
Proteins/Enzymes	B-229 – B-259
TDM and Toxicology	B-260 – B-310
Technology/Design Development	B-311 – B-352

# **DIVISION POSTER ACTIVITIES**

#### **POSTER WALKS**

Led by AACC Division subject matter experts, the walks highlight posters selected by the division for further discussion. Poster walks are free and limited to 20-30 participants. Participants must have full or daily conference registration and are asked to meet poster walk leaders outside the entrance to the poster display. Tours will leave at the following times:

### WEDNESDAY, AUGUST 7

DIVISION	TIME
Critical and Point-of-Care Testing	12:30pm-1:30pm

#### **NEW!** ePOSTER SESSIONS

Interactive poster sessions will be conducted by presenting authors and moderated by AACC Division subject matter experts. The presentations will be shown on screens located in the poster section's seating area in the exhibit hall.

ePoster sessions are free and limited to 20-30 participants. Participants must have full or daily conference registration and are asked to meet session moderators at the ePoster Stations located in the Poster Theater area on the Expo show floor.

### TUESDAY, AUGUST 6

DIVISION	TIME	DIVISION	TIME
Biomarkers of Acute Cardiovascular	10:00am–10:45am	Proteomics and Metabolomics	10:00am–10:45am
Diseases	10:00am–10:45am	Mass Spectrometry and Separation Sciences	10:45am–11:30am
Personalized Medicine	10:45am-11:30am	Clinical and Diagnostic Immunology	11:30am–12:15pm
	10:45am–11:50am	Clinical Translational Science	12:15pm-1:00pm
Tumor Markers and Cancer Diagnostics	10:45am–11:30am	Management Sciences and Patient Safety	2:00pm–2:45pm
Therapeutic Drug Management and	4:15pm–5:00pm	Pediatric and Maternal-Fetal	2:00pm-2:45pm
Toxicology			2.00pm=2.45pm



### WEDNESDAY, AUGUST 7

# **ORAL ABSTRACT** PRESENTATIONS

New this year, Oral Abstract Presentations can be viewed on ePoster stations located in the poster section's seating area on the Expo show floor of the Anaheim Convention Center.

On Tuesday, August 6, from 11:30am-5:00pm, and Wednesday, August 7, from 10:00am-2:00pm, attendees with full or daily conference registration badges will be able to independently view the oral abstract posters on one of the ePoster stations. Viewing will be first-come, first-served.


Interactive poster sessions will be conducted by authors at the ePoster station on Tuesday, August 6. Participants must have full or daily conference registration.

#### **INTERACTIVE ePOSTER ORAL ABSTRACT PRESENTATION SCHEDULE:**

### **TUESDAY,** AUGUST 6

11:30am–12:15pm	Endocrinology
12:15pm–1:00pm	Immunology
2:00pm-2:45pm	Technology/Design Development
2:45pm-3:30pm	Point-of-Care
3:30pm-4:00pm	Utilization





# **STUDENT ORAL CONTEST** PRESENTATIONS

The AACC Student Poster Contest showcases AACC's finest young scientists. The contest consists of two sessions. The first session is an oral competition with four pre-selected students presenting their work. A panel of judges rate the presentations on the basis of scientific content, originality/novelty and presentation (including slide appearance, verbal presentation, style and clarity). Four awards are given: first place, second place, and two honorable mentions.

The second session of the competition consists of poster presentations. Over 60 posters will be displayed and reviewed. Judges will evaluate each poster individually in timed rounds. Student presenters are rated on their ability to convey their work concisely, as well as the scientific merit and visual presentation of their poster. Four awards are given: first place, second place, and two honorable mentions.

### MONDAY, AUGUST 5 | Anaheim Convention Center

1:00pm-2:00pm

Room 201AB

2:15pm-3:30pm Room 201D

#### A-333 Lutao Du

Expression Signatures of Exosomal Long Non-coding RNAs in Urine Serve as Novelnon-invasive Biomarkers for Diagnosis and Recurrence Prediction of Bladder Cancer

#### A-227 Christopher Farnsworth

Parameters for Validating a Hospital Pneumatic Tube System: Lessons Learned from Closing a Satellite Laboratory

#### A-117 Katherine Turner

Going Gel Free: Adding M-protein Quantitation to MASS-FIX in the Clinical Lab

#### A-166 Jeffrey SoRelle







# 2019 STUDENT POSTER PRESENTERS

#### A-143 Ghaith Altawallbeh

Plasma Metabolites to Predict Response to Exercise in Alzheimer's Disease

#### A-217 Ghaith Altawallbeh

Evaluation of ARKRAY ADAMS HA-8180V for HbA1c Measurement

#### A-211 Ghaith Altawallbeh

Hyperthyroidism Diagnostic Test Utilization: An Evaluation of Current Ordering Practices

#### B-155 Enoch Anto

Algorithm of Suboptimal Health Status, Serum Magnesium and Calcium Levels as a Novel Approach for Prediction and Identification of Pregnant Women Likely to Develop Preeclampsia and Adverse Perinatal Complications in a Ghanaian Population

#### A-253 Amir Babalhavaeji

Evaluation of Hemolysis, Lipemia, and Icterus Interference in 19 Assays Performed on the Alinity c System

#### B-061 Emily Bachert

Daily Labs Quality Improvement: Pilot Program for Decreasing Unnecessary Lab Orders

#### B-308 Adina Badea

A Validated, Rapid Method for Detecting a Broad Panel of Pain-Management Drugs in Oral Fluid by High-resolution LC-MS/MS

#### A-032 Mustafa Barbhuiya

Analytical and Clinical Evaluations of the Elecsys 5th GEN Cardiac Troponin T Assay

#### B-165 Mary Kathryn Bohn

Pediatric Reference Intervals for 17 Roche cobas 8000 e602 Immunoassays in the CALIPER Cohort of Healthy Children and Adolescents

#### A-153 Raul Bortolin

Circulating miR-421 Expression Is Associated with Insulin Resistance in Metabolic Syndrome Patients

#### A-136 Teofilo Borunda

Clinical Laboratory Data Analytics for Identification and Progression of Non-alcoholic Fatty Liver Disease in New Mexico

#### A-139 Teofilo Borunda

Opportunity of Real Time, Longitudinal Clinical Laboratory Data to Enhance Diabetes Disease Surveillance

#### A-278 Madeleen Bosma

Automated and Cost-Efficient Early Detection of Hemolysis in Patients with Extracorporeal Life Support: Use of the Hemolysis-Index of Routine Clinical Chemistry Platforms

#### A-054 Bei Cai

Analysis of Aging Characteristics of Peripheral T Lymphocyte Subsets in Healthy Population in Western China

#### **B-140** Chibuike Chukwunyere

Comparison of Serum Calcium Level in Normotensive and Hypertensive Pregnant Women

#### B-292 Sarah Delaney

Assessment of Mass Spectrometry-Based Urine Opioid Screening in Clinical Laboratories: How Well Does Your Assay Perform?

#### A-333 Lutao Du

Expression Signatures of Exosomal Long Non-coding RNAs in Urine Serve as Novel Non-invasive Biomarkers for Diagnosis and Recurrence Prediction of Bladder Cancer

#### A-178 Cristina Fajardo

IRS2 rs1865434 Variant Is Associated with Adiposity and Insulin Resistance in Brazilian Subjects

#### A-227 Christopher Farnsworth

Parameters for Validating a Hospital Pneumatic Tube System: Lessons Learned from Closing a Satellite Laboratory

#### **B-003** Renata Freitas

miRNA Predictive Profile Based on <LDLR>, <APOB> and <PCSK9> 3'UTR Variants as Potential Biomarker for Familial Hypercholesterolemia

#### B-244 Cameron Furey

Do We Still Need Amylase in the Management of Acute Pancreatitis?

#### B-248 Kornelia Galior

Using NASH-FibroTest to Assess Liver Fibrosis, Steatosis and Inflammation in Patients with Nonalcoholic Steatohepatitis (NASH): Between-Laboratory Comparability of Results and Correlation with Biopsy/Imaging Studies for a New, Non-Invasive, Blood Test

#### A-172 Emily Garnett

Comparison of Two Vitamin D Immunoassays to Detect 25-OH Vitamin D2 and D3  $\,$ 

#### B-036 Emily Garnett

Improving Thyroid Function Test Utilization via Implementation of a Reflexive Testing Algorithm

#### A-213 Keisha Hardeman

Review of Thyroid Function Test Ordering Patterns in Routine Pregnancy across Two Academic Medical Centers

#### A-154 Sara Hassan

Assessment of the Relation Between Body Fat Composition and Serum Kisspeptin Level in Obese versus Non Obese Women at the Time of Ovulation in Egypt

#### **B-103** Rongrong Huang

Hunting Down the "Ghost": A Practical Lesson Learned from Investigating an Interference Peak in 1,25-Dihydroxyvitamin D Assay

#### A-285 Jose Jara-Aguirre

Evaluation of the Stability of Bivalirudin Effect on Activated Partial Thromboplastin Time (aPTT) in Citrated Whole Blood Samples

#### B-192 Choong Eun Jin

Rapid Diagnosis Platform Based on Combination of Microfluidic System and Homobifunctional Imidoester in Clinical Specimens

#### B-284 Christopher Koch

Evaluation of Drug Adsorption to the  $\mathsf{PIVO}^{\mathsf{TM}}$  Needless Blood Collection Device

#### B-264 Grace Kroner

Comparative Cannabinoid Cross-reactivity in THC Immunoassays

#### B-136 Hongjin Lai

16 www.2019aacc.org

Cross Priming Amplification for Rapid Detection of Acinetobacter Baumannii and blaOXA-23 Carbapenemase Gene

#### B-153 Ruibing Li

Noninvasive Prenatal Diagnosis of Fetal Achondroplasia Using MALDI-TOF Mass Spectrometry

#### A-342 Jieli Li

Potential Role of Nuclear PD L1 Expression in Epithelial Mesenchymal Transitioned Circulating Tumor Cells as a Prognostic Marker in Prostate Cancer

#### B-278 Y. Ruben Luo

A Rapid Plate-Format Label-Free Immunoassay for Quantitation of Monoclonal Antibody Drugs and Detection of Anti-Drug Antibodies in Serum Samples

#### A-116 Anu Maharjan

Contribution of Autoantibody Testing in the Evaluation of Patients At-risk of Interstitial Lung Disease

#### B-325 Zahraa Mohammed-Ali

Analytical Performance Evaluation of 8 Assays on the Abbott Alinity ci Integrated Analyzer

#### A-381 Penn Muluhngwi

Comparison of Electrophoretic Systems to Detect Occult IgA Monoclonal Immunoglobulins

#### B-321 Penn Muluhngwi

Validation of Newly FDA-approved Kappa and Lambda Free Light Chain Assays on a Previously Untested Platform

#### A-131 Vijayalakshmi Nandakumar

Symmetric Dimethylarginine as an Alternative Marker for Estimation of Glomerular Filtration Rate

#### B-135 Camila Nobre

Intronic Variant in SPTB Gene as Suspected Cause of Hereditary Spherocytosis in a Brazilian Family: Segregation in the Family and RNA Analysis

#### A-269 Jayson Pagaduan

Utility of IFCC Standardized LDHI Method in a Pediatric Hospital

#### B-282 Heather Paul

Detection of Cannabinoid Compounds in Dried Blood Spots by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

#### A-240 Heather Paul

How High Can We Go? Expanding the Reporting Range of Ferritin to Facilitate The Acute Diagnosis of Hemophagocytic Lymphohistiocytosis

#### B-290 Heather Paul

Pre-analytical Contamination of Pediatric and Newborn Urine Drug Screening Samples with Tributoxyethylphosphate

#### **B-100** William Phipps

Quantitative Amino Acid Analysis by LC-MS/MS Using a Low-Cost Derivatization Approach and Automated Liquid Handler

#### **B-159 Jason Robinson**

Evaluating Hemoglobin A1C Devices for Testing at the Point of Care in a Hub and Spoke Laboratory Model

#### A-027 Kwabena Sarpong

Urine Derived Renal Cells as Tools to Diagnose Salt Sensitivity

#### A-128 Kaori Sato Sato

CRISPR/Cas-mediated Generation of Mutant Mouse Models with Alzheimer's Disease Associated Mutations

Checkmate: Evaluating the Cardio Check POC Device for Accurate

#### B-019 Erin Schuler

Patients

#### A-229 Cierra Sharp

A Case of Falsely Elevated Troponin Levels Using AccuTnI Assay: The Presence of an Unknown Interferant

#### A-166 Jeffrey SoRelle

Long Term Effect of Hormone Therapy on Lab Values in Transgender Individuals

#### B-349 Daniel Szulc

Non-invasive MRI for Assessment of Medical Grafts and Biomaterials in Vivo

#### B-170 Jennifer Taher

Assessing the Feasibility of Common Reference Intervals across Different Analytical Platforms: Evidence from CALIPER Pediatric Reference Intervals Database

#### A-186 Jennifer Taher

Choosing fT3 and fT4 Wisely: A Data Driven Reflexive Testing Approach to Reduce Thyroid Hormone Testing

#### A-187 Jennifer Taher

Best Practices in Medicine (BPiM): An Audit and Feedback Approach to "Right Size" Laboratory Test Utilization

#### A-144 Stefani Thomas

Enhanced Efficiency of Large-scale Clinical Proteomic Studies Using Sequential Window Acquisition of All Theoretical Mass Spectra (SWATH-MS)

#### A-084 Katherine Turner

Correlation Between Kappa Prozone Effect and IgA Kappa M-proteins in Serum Free Light Chain Assay

#### A-117 Katherine Turner

Going Gel Free: Adding M-protein Quantitation to MASS-FIX in the Clinical Lab

#### A-238 Hana Vakili

Complete Depletion of Residual Therapeutic Monoclonal Antibody Interference in Serum Samples from Multiple Myeloma Patients to Improve Detection of Endogenous M-proteins

#### A-004 William van Doorn

From Conventional to High-Sensitivity Assays: Re-evaluation of Cardiac Troponin T and I Kinetics after Acute Myocardial Infarction

#### B-098 Ruhan Wei

A Rapid and Sensitive LC-MS/MS Method for Quantitative Analysis of GSK-3 Inhibitors in Mouse Plasma

#### B-106 Ruhan Wei

Measurement of Monosialogangliosides in GM3 Synthase Deficiency Patient Plasma by a Novel UPLC/MS/MS Assay

#### A-301 Kenya Wilcots

Ubiquitin Specific Protease 7 (USP7) Role in Platelet Activation and Formation

#### B-072 Li Zha

Analysis of Vitamin A and Vitamin E on a Multiplexing LC-MS/MS Platform for Therapeutic Drug Monitoring (TDM)

#### B-131 Yu Zhang

Investigate MicroRNA-122 to Identify Liver Injury in Patients with Rhabdomyolysis

#### A-281 Ling Zhong

Circulating Long Noncoding RNA STAiR18 to Predict Disease Progression for Patients with Multiple Myeloma

Determination of Lipid Profiles and Cardiovascular Risk in Ambulatory

# AACC ACADEMY HONORS **NEW ACADEMY FELLOWS**

AACC Academy is proud to announce its Academy Fellows. As members of AACC Academy, these distinguished scientists are all doctorate-level professionals dedicated to enhancing the scholarship and practice of laboratory medicine. New Fellows will be honored during the Academy Awards Luncheon on Wednesday, August 7, during the AACC Annual Scientific Meeting.

AACC Academy honors the achievements of its members and through an active education and publication program enlists their support and expertise to bring about positive change in the current practice of laboratory medicine. To learn more about the Academy and its activities, visit https://www.aacc.org/community/aacc-academy.

#### **NEW ACADEMY FELLOWS ACCEPTED SINCE JUNE 2018**

- Richard Baltaro, MD, PhD Sharmistha Chatterjee, MD Jessica Colon-Franco, PhD Purnachandra Ganji, PhD, DSc
- Nazar Haddad, MBCh Tetsuya Hirano, MD, PhD Mayowa Osundiji, MD, PhD Ghzaleh Pourmahram, PhD
- Tiffany Roberts, PhD Rajitha Samarasinghe, MD Randal Schneider, PhD Nilika Wijeratne, MD

#### ASSOCIATE FELLOWS WHO BECAME ACADEMY FELLOWS SINCE JUNE 2018

Sultan Alouffi, PhD

Jianxin Lyu, PhD

Vinita Thakur, PhD

#### **NEW ASSOCIATE FELLOWS ACCEPTED SINCE JUNE 2018**

Mirza Baig, MD Hoon Lee Chong, PhD

Iklas Darkhalil, PhD Abhajeet Jaqtap, PhD

Bin Wei, PhD Fang Wu, PhD

### 2019 AACC AWARD WINNERS

Wallace H. Coulter Lectureship Award DAVID R. WALT, PhD Harvard Medical School & Wvss Institute for Bioinspired Engineering at Harvard University

**Outstanding Lifetime Achievement** Award in Clinical Chemistry and Laboratory Medicine

MITCHELL G. SCOTT, PhD Washington University School of Medicine **Outstanding Contributions to Education** in Clinical Chemistry WILLIAM A. CLARKE, PhD Johns Hopkins University School of Medicine

**Outstanding Contributions Through** Service to the Profession of Clinical Chemistry MARIO PLEBANI, MD

University Hospital of Padova

**Outstanding Scientific Achievements** by a Young Investigator LIVIA SCHIAVINATO EBERLIN, PhD The University of Texas at Austin

**AACC Past President's Award** DENNIS J. DIETZEN, PhD Washington University School of Medicine

#### 2019 AACC ACADEMY AWARD WINNERS

AACC Academy Award for Outstanding Contributions to Clinical Chemistry in a Selected Area of Research KHOSROW ADELI, PhD Hospital for Sick Children

AACC Academy Professor Alvin Dubin Award for Outstanding Contributions to the Profession and the Academy DAVID KOCH, PhD Emory University/Grady Memorial Hospital

AACC Academy George Grannis Award for Excellence in Research and Scientific Publication GABRIELLE WINSTON-MCPHERSON, PhD Henry Ford Hospital

# 2019 DISTINGUISHED **ABSTRACTS AWARDS**

The AACC Academy is pleased to announce the winners of the 2019 Distinguished Abstracts Awards. A group of Fellows selected these 20 abstracts for their scientific excellence from a pool of 813 abstracts accepted for the AACC Annual Scientific Meeting.

in Anaheim, CA.

#### A-026 Bernard Cook, Detroit, MI

A Baseline Novel High Sensitivity Cardiac Troponin I Level Below the Limit of Quantitation Rules Out Acute Myocardial Infarction in the Emergency Department

A-071 Oliver Senscheid, Mountain Lakes, NJ

Laboratory Diagnostics of Autoantibodies in Autoimmune **Myopathies** 

#### A-117 Katherine Turner, Chardon, OH

Going Gel Free: Adding M-protein Quantitation to MASS-FIX in the Clinical Lab

A-143 Ghaith Altawallbeh, Cleveland, OH

Plasma Metabolites to Predict Response to Exercise in Alzheimer's Disease

#### A-148 Rebecca Bearden, Cleveland, OH

Protein Assisted Digestion Improves Sensitivity of Immunocapture-MRM Method to Quantify Stool Biomarker of Colorectal Cancer

#### A-238 Hana Klassen Vakili, Dallas, TX

Complete Depletion of Residual Therapeutic Monoclonal Antibody Interference in Serum Samples from Multiple Myeloma Patients to Improve Detection of Endogenous M-proteins

#### A-272 Mark Zaydman, St. Louis, MO

Extending the Analytical Measuring Range of Turbidometric Homogeneous Immunoassays Using a Novel Kinetic Calibration Method

#### A-278 Madeleen Bosma, Nieuwegein, Netherlands

Automated and Cost-Efficient Early Detection of Hemolysis in Patients with Extracorporeal Life Support: Use of the Hemolysis-Index of Routine Clinical Chemistry Platforms

A-311 Guixi Zheng, Jinan, China

Genome-Wide DNA Methylation Analysis by MethylRAD Reveals the Potential Biomarkers and Mechanism of Colon Cancer

#### A-320 Mark Cervinski, Lebanon, NH

The Average of Delta: Monitoring Assay Performance Through the Use of the Mean Intra-Individual Delta

#### A-349 Oscar Berlanga, Birmingham, United Kingdom

A Novel Mass Spectrometry Method for Monoclonal Free Light Chain Detection

#### Winning abstracts will display the Academy blue ribbon during the AACC Annual Scientific Meeting poster sessions

#### A-387 Xiao-An Fu, Louisville, KY

Detection of Lung Cancer by Breath Analysis with Chemoselective Microreactors

#### B-061 Sara Bachert, Lexington, KY

Daily Labs Quality Improvement: Pilot Program for Decreasing Unnecessary Lab Orders

#### B-137 Nicholas Bevins, San Diego, CA

Quantitative Impact of Including or Excluding Synonymous Mutations from Tumor Mutational Burden Utilized as a Pan-Cancer Prognostic Marker

#### B-144 Irina Kirpich, Louisville, KY

Decreased Endogenous ω-6 PUFAs Induced Intestinal Mucosa Transcriptional Reprogramming That Contributed to Amelioration of Intestinal and Liver Injury in Mice in a Context of Systemic Inflammation and Chronic Ethanol Exposure

#### B-155 Enoch Anto, Kumasi, Ghana

Algorithm of Suboptimal Health Status, Serum Magnesium and Calcium Levels as a Novel Approach for Prediction and Identification of Pregnant Women Likely to Develop Preeclampsia and Adverse Perinatal Complications in a Ghanaian Population

#### B-174 Joshua Hunsaker, Salt Lake City, UT

Comparison of Disclosed Smoking Status to the Presence of Serum Nicotine and Metabolites in Maternal Quadruple Screen Specimens

#### B-199 Bonhan Koo, Seoul, Republic of Korea

Rapid and Accurate Multiple Detection Bio-Optical Sensor for Diagnosis of Emerging Infectious Diseases

#### B-203 Eberhard Spanuth, Heidelberg/Dossenheim, Germany

D-dimer, Presepsin and gSOFA for Early Assessment of Organ Dysfunction and Mortality Prediction in Patients Admitted with Sepsis to the Emergency Department

#### B-281 Jennifer Colby, San Francisco, CA

Large-Scale Analysis of Electronic Health Record Data Enables Systematic Discovery of Cross-Reactivity in Urine Drug Screening Immunoassays

# **PATHWAYS**

These seven pathways highlight different dynamic areas of clinical laboratory medicine. Check out the sessions that support your area of interest and make the most of your educational experience in Anaheim.

DA	TA ANALYTICS	SESSION NUMBER	DAY
TICKET	Pathology and Clinical Laboratory Informatics Boot Camp	193014	Sunday
TICKET	Getting Started with R for Laboratory Medicine	193017	Sunday
	Data Science and AI in Laboratory Medicine: What You Should Know Now and Will Need to Know in the Future	32107	Monday
	Learning from Predictions: What We Need to Know about Machine Learning	33220	Tuesday
	Storytelling with R: Application Showcase	33227	Tuesday
TICKET	Artificial Intelligence and Data Science in Laboratory Medicine: Perspectives and Challenges	43102/53202	Tuesday
TICKET	Predictive Analytics in the Clinical Laboratory	44124/54224	Wednesday

GEI	NOMICS	SESSION NUMBER	DAY
	Consumer Genomics, Direct-to-Consumer Genetic Testing, and Patient Empowerment	11002	Sunday
TICKET	Clinical Laboratory Genomics: Practical NGS for Laboratorians	193015	Sunday
	Chair's Invited Session: Race, Genomics and Medicine	32223	Monday
	Clinical Chemistry's Hot Topics of 2019	33109	Tuesday
	Quality Indicators that Determine the Performance of NGS Assays in Precision Oncology	33223	Tuesday
	Meet the Expert: Using Biomarkers to Tailor Treatment for Breast Cancer	63101	Tuesday
ТІСКЕТ	Pharmacogenomics and Mass Spectrometry in the Clinical Lab: A Fledgling Partnership	44128/54228	Wednesday

INF	ECTIOUS DISEASES	SESSION NUMBER	DAY
TICKET	Maximizing the Impact and Value of Laboratory Automation: Lessons Learned from Clinical Chemistry and Microbiology	192009	Sunday
	Sepsis: Novel Biomarkers, New Technology, and Predictive Analytics	32433	Monday
	Journal of Applied Laboratory Medicine's 2019 Hot Topics: Sepsis Diagnosis and Management: Role of Novel Biomarkers and Procalcitonin Confounders	34108	Wednesday
TICKET	The Trials and Triumphs of HIV Testing	44102/54202	Wednesday
TICKET	HIV Diagnostics: Past, Present and Future	44107/54207	Wednesday
	Opportunities and New Approaches to Guide Utilization of Urine-Based Testing for Diagnosis of Infectious Disease	35105	Thursday

AB MANAGEMEN	п	SESSION NUMBER	DAY
Ethical Issues in Lal	poratory Medicine	32101	Monday
The Value Proposit	ion: Actionable Strategies for Enhancing the Value of Laboratory Medicine	33105	Tuesday
Breaking Down Ge	nder from Cis to Trans	33216	Tuesday
Institutional Labora	tory Stewardship Programs: Best Practices, Interventions, Informatics	33224	Tuesday
Strategies and Tact	ics for Practical Test Utilization Management	34102	Wednesday
Healthcare Forum:	Laboratory Stewardship in Healthcare Innovation	34225	Wednesday
IATERNAL-FETAL		SESSION NUMBER	DAY
Predicting and Diag	gnosing Gestational Diabetes Mellitus (GDM): Are We Making Progress?	32106	Monday
	nerging Role of Anti-Müllerian Hormone (AMH) in Ovarian Reserve, tion, Polycystic Ovary Syndrome (PCOS), and Other Diseases	32431	Monday
	tory Results to Increase Quality Care for Affected Newborns Identified Screening: What Is the Optimal Workflow?	33106	Tuesday
Non-Invasive Prena KET Beyond	tal Testing: Utilization of Cell-Free DNA in Fetal Aneuploidy Screening and	43115/53215	Tuesday
Preeclampsia Scree	ening and Diagnosis: A Novel Approach	43116/53216	Tuesday
Umbilical Cord Tes	ting—Moving Beyond Blood Gases	44115/54215	Wednesday
Diagnosing Inborn	Errors of Metabolism: Challenging Cases in Biochemical Genetics	44126/54226	Wednesday
OINT-OF-CARE TE	STING	SESSION NUMBER	DAY
	ESTING e Essential Elements of a Point-of-Care Testing Boot Camp (Part 1)	SESSION NUMBER	DAY Sunday
Rise and Shine! The			
Rise and Shine! The Afternoon Reveille (Part 2)	e Essential Elements of a Point-of-Care Testing Boot Camp (Part 1)	191005	Sunday
Rise and Shine! The Afternoon Reveille! (Part 2) Racing Against Tim	e Essential Elements of a Point-of-Care Testing Boot Camp (Part 1) Continuing the Essential Elements of a Point-of-Care Testing Boot Camp ne: Point-of-Care Testing in Mobile Health Settings erships between Clinical Laboratorians and Emergency Medicine	191005 192007	Sunday Sunday
Rise and Shine! The Afternoon Reveille! (Part 2) Racing Against Tim Value-Added Partn Professionals to Im	e Essential Elements of a Point-of-Care Testing Boot Camp (Part 1) Continuing the Essential Elements of a Point-of-Care Testing Boot Camp ne: Point-of-Care Testing in Mobile Health Settings erships between Clinical Laboratorians and Emergency Medicine	191005 192007 32218	Sunday Sunday Monday
Rise and Shine! The Afternoon Reveille! (Part 2) Racing Against Tim Value-Added Partn Professionals to Im Digital Medicine ar	e Essential Elements of a Point-of-Care Testing Boot Camp (Part 1) Continuing the Essential Elements of a Point-of-Care Testing Boot Camp e: Point-of-Care Testing in Mobile Health Settings erships between Clinical Laboratorians and Emergency Medicine prove Patient Care	191005 192007 32218 32434	Sunday Sunday Monday Monday
Rise and Shine! The Afternoon Reveille! (Part 2) Racing Against Tim Value-Added Partn Professionals to Im Digital Medicine ar Worldwide Challen	e Essential Elements of a Point-of-Care Testing Boot Camp (Part 1) Continuing the Essential Elements of a Point-of-Care Testing Boot Camp e: Point-of-Care Testing in Mobile Health Settings erships between Clinical Laboratorians and Emergency Medicine prove Patient Care and the Connected Health Consumer: What You Need to Know	191005 192007 32218 32434 33104	Sunday Sunday Monday Monday Tuesday Tuesday
Rise and Shine! The Afternoon Reveille! (Part 2) Racing Against Tim Value-Added Partn Professionals to Im Digital Medicine ar Worldwide Challen Managing the Wilc	e Essential Elements of a Point-of-Care Testing Boot Camp (Part 1) Continuing the Essential Elements of a Point-of-Care Testing Boot Camp e: Point-of-Care Testing in Mobile Health Settings erships between Clinical Laboratorians and Emergency Medicine prove Patient Care and the Connected Health Consumer: What You Need to Know ges in POCT—A Focus on Molecular POCT	191005 192007 32218 32434 33104 33218	Sunday Sunday Monday Monday Tuesday Tuesday
Rise and Shine! The Afternoon Reveille! (Part 2) Racing Against Tim Value-Added Partn Professionals to Im Digital Medicine ar Worldwide Challen Managing the Wilc	e Essential Elements of a Point-of-Care Testing Boot Camp (Part 1) Continuing the Essential Elements of a Point-of-Care Testing Boot Camp e: Point-of-Care Testing in Mobile Health Settings erships between Clinical Laboratorians and Emergency Medicine prove Patient Care and the Connected Health Consumer: What You Need to Know ges in POCT—A Focus on Molecular POCT	191005 192007 32218 32434 33104 33218 44133/54233	Sunday Sunday Monday Monday Tuesday Tuesday Wednesday
Rise and Shine! The         Afternoon Reveille!         (Part 2)         Racing Against Time         Value-Added Partn         Professionals to Im         Digital Medicine ar         Worldwide Challen         Managing the Wilc         OXICOLOGY         Opioids and Beyor	e Essential Elements of a Point-of-Care Testing Boot Camp (Part 1) Continuing the Essential Elements of a Point-of-Care Testing Boot Camp e: Point-of-Care Testing in Mobile Health Settings erships between Clinical Laboratorians and Emergency Medicine prove Patient Care ad the Connected Health Consumer: What You Need to Know ges in POCT—A Focus on Molecular POCT Wild West of Point-of-Care Testing	191005 192007 32218 32434 33104 33218 44133/54233 SESSION NUMBER	Sunday Sunday Monday Monday Tuesday Tuesday Wednesday
Rise and Shine! The Afternoon Reveille! (Part 2) Racing Against Tim Value-Added Partn Professionals to Im Digital Medicine ar Worldwide Challen Managing the Wilc OXICOLOGY Opioids and Beyor Impact of Hormone	e Essential Elements of a Point-of-Care Testing Boot Camp (Part 1) Continuing the Essential Elements of a Point-of-Care Testing Boot Camp e: Point-of-Care Testing in Mobile Health Settings erships between Clinical Laboratorians and Emergency Medicine prove Patient Care nd the Connected Health Consumer: What You Need to Know ges in POCT—A Focus on Molecular POCT I Wild West of Point-of-Care Testing nd: The Clinical Laboratory's Role in the Opioid Epidemic	191005 192007 32218 32434 33104 33218 44133/54233 SESSION NUMBER 32220	Sunday Sunday Monday Monday Tuesday Tuesday Wednesday DAY Monday
Afternoon Reveille! (Part 2) Racing Against Tim Value-Added Partn Professionals to Im Digital Medicine ar Worldwide Challen Managing the Wilc OXICOLOGY Opioids and Beyor Impact of Hormone Interactive Pain Ma	e Essential Elements of a Point-of-Care Testing Boot Camp (Part 1) Continuing the Essential Elements of a Point-of-Care Testing Boot Camp e: Point-of-Care Testing in Mobile Health Settings erships between Clinical Laboratorians and Emergency Medicine prove Patient Care nd the Connected Health Consumer: What You Need to Know ges in POCT—A Focus on Molecular POCT Wild West of Point-of-Care Testing nd: The Clinical Laboratory's Role in the Opioid Epidemic es on Drug Testing: From the Bench to the Bedside nagement Case Studies: Clinician and Laboratory Perspectives munoassays for the Poisoned Patient: Analytical Approaches and	191005 192007 32218 32434 33104 33218 44133/54233 <b>SESSION NUMBER</b> 32220 33108	Sunday Sunday Monday Monday Tuesday Wednesday Wednesday DAY Monday Tuesday
Rise and Shine! The Afternoon Reveille! (Part 2) Racing Against Tim Value-Added Partn Professionals to Im Digital Medicine ar Worldwide Challen Managing the Wild OXICOLOGY Opioids and Beyor Impact of Hormone Interactive Pain Ma Moving Beyond Im Interactive Case St Supporting Opioid	e Essential Elements of a Point-of-Care Testing Boot Camp (Part 1) Continuing the Essential Elements of a Point-of-Care Testing Boot Camp e: Point-of-Care Testing in Mobile Health Settings erships between Clinical Laboratorians and Emergency Medicine prove Patient Care nd the Connected Health Consumer: What You Need to Know ges in POCT—A Focus on Molecular POCT Wild West of Point-of-Care Testing nd: The Clinical Laboratory's Role in the Opioid Epidemic es on Drug Testing: From the Bench to the Bedside nagement Case Studies: Clinician and Laboratory Perspectives munoassays for the Poisoned Patient: Analytical Approaches and	191005 192007 32218 32434 33104 33218 44133/54233 <b>SESSION NUMBER</b> 32220 33108 33219	Sunday Sunday Monday Monday Tuesday Wednesday DAY Monday Tuesday Uesday
Rise and Shine! The         Afternoon Reveille!         (Part 2)         Racing Against Time         Value-Added Partn         Professionals to Im         Digital Medicine ar         Worldwide Challen         Managing the Wild         Opioids and Beyor         Impact of Hormone         Interactive Pain Ma         Moving Beyond Im         Supporting Opioid	e Essential Elements of a Point-of-Care Testing Boot Camp (Part 1) Continuing the Essential Elements of a Point-of-Care Testing Boot Camp e: Point-of-Care Testing in Mobile Health Settings erships between Clinical Laboratorians and Emergency Medicine prove Patient Care nd the Connected Health Consumer: What You Need to Know ges in POCT—A Focus on Molecular POCT Wild West of Point-of-Care Testing nd: The Clinical Laboratory's Role in the Opioid Epidemic es on Drug Testing: From the Bench to the Bedside nagement Case Studies: Clinician and Laboratory Perspectives munoassays for the Poisoned Patient: Analytical Approaches and udies Addiction Programs with Unexpected Testing—Ethanol Metabolite Test Appalachian Laboratory	191005 192007 32218 32434 33104 33218 44133/54233 <b>SESSION NUMBER</b> 32220 33108 33219 33219 34109	Sunday Sunday Monday Monday Tuesday Wednesday DAY Monday Tuesday

# SESSION **INFORMATION**

# **REGISTRATION TYPES & EVENTS**

#### SESSION LEVEL CONTENT

**BASIC** — Introductory content appropriate for participants who lack previous training or experience in the subject, or whose previous experience or training is minimal.

**INTERMEDIATE** — Requires knowledge of the basic theory applicable to the general subjects as well as some prior training and education in the subject.

**ADVANCED** — Specialized content appropriate for those with working knowledge of current theory and practices and who wish to refine their skills or learn the newest principles and techniques.

#### SPECIAL SESSIONS

#### SUNDAY, AUGUST 4

#### Consumer Genomics, Direct-to-Consumer Genetic Testing, and Patient Empowerment

During this session, two well-renowned experts in the field of consumer genomics and direct-to-consumer genetic testing will discuss the nuances between the different types of tests, regulatory aspects, clinical validity and utility, and how consumer genetic testing fits into medical care. Details on page 34.

#### MONDAY, AUGUST 5

#### **Disruptive Technology Award Competition**

The Disruptive Technology Award Competition searches for the next innovative testing solution that will improve patient care through diagnostic performance or access to high-quality testing. Three finalists will present brief lectures showing the detailed data supporting the performance of their novel development. Following the presentations, there will be a Q&A session between the judges and presenters whereby they will be scored, and a winner will be announced at the close of the event. Details on page 55.

#### WEDNESDAY, AUGUST 7

#### Laboratory Feud: Science and Practice Core Committee vs. Education Core Committee

This session will use the "Family Feud" game show-style format in which two teams (five members of the AACC Science and Practice Core Committee vs. five members of the Education Core Committee) will compete in an educational challenge covering various laboratory medicine topics. Details on page 91.

#### Healthcare Forum: Laboratory Stewardship in Healthcare Innovation

The healthcare delivery system is changing, and the clinical laboratory has a critical role to play in value-based care. Through laboratory stewardship programs and other collaborative efforts, laboratory professionals are well-positioned to help administrators achieve the oftenconflicting objectives of reducing costs and improving patient

care. By engaging stakeholders in the quality measurement community, laboratories can have greater involvement in shaping the future of healthcare. Join us for this year's healthcare forum and learn from our experts how you and your laboratory can succeed in this competitive healthcare environment. Details on page 90.

#### SESSION DESCRIPTIONS

All of the following sessions are open to conference registrants.

#### PLENARY SESSIONS

Designed for all levels, and featuring visionaries in clinical practice, research, business and policy.

#### SCIENTIFIC SESSIONS

These sessions are presented by highly regarded speakers, offering in-depth learning about specific areas of clinical laboratory practice.

#### MEET THE EXPERT SESSIONS

Attendance limited to 75 participants per session. Admission is first come, first served. These sessions are intense interactive discussions with plenary speakers.

#### CHAIR'S INVITED SESSION

The Chair of the 2019 Annual Meeting Organizing Committee created this special session of particular importance to attendees. Details on page 54.

#### PRESIDENT'S INVITED SESSION

The AACC President has created this special session of particular importance to attendees. Details on page 46.

#### ORAL ABSTRACT PRESENTATIONS

Selected abstracts identified by the Annual Meeting Organizing Committee will be presented. Details on page 14.

#### **CONFERENCE RECORDING**

The 71st AACC Annual Scientific Meeting will be recorded. Access to the streaming content is available for purchase as an 11-month subscription that will commence in August 2019 and close at the end of June 2020. The content is made available as streaming content only and is not available for download. The recording will include audio and presentation slides from most of the scientific sessions.

The recordings will be available approximately two weeks after the close of the meeting.

PRICE: \$199 with registration or at the meeting/\$299 after close of the meeting (August 8, 2019, 1:00pm PDT). To purchase, visit www.2019aacc.org or go to Conference Registration in Hall E.

Registration Type	Full Conference	Guest/ ce Spouse	Daily	Expo Only	Exhibitor	No Registration
EVENTS	<ul> <li>AACC Member</li> <li>Non-Member</li> <li>Trainee/Student Me</li> <li>Emeritus Member</li> </ul>	Limit 1 per full mber conference registrant	Admission/ tickets for day registered only	Exhibit Hall access		
Plenary Sessions 10000 Series	$\checkmark$	$\checkmark$	$\checkmark$	X	$\checkmark$	X
Scientific Sessions 30000 Series	$\checkmark$	$\checkmark$	$\checkmark$	X	$\checkmark$	X
Meet the Experts 60000 Series	$\checkmark$	$\checkmark$	$\checkmark$	X	$\checkmark$	X
AACC University 190000 Series	TICKET \$	(	\$	(	\$	8
Roundtable Sessions 40000 Series morning 50000 Series afternoon	TICKET \$	8	\$	8	\$	8
Poster Sessions Abstracts	$\checkmark$	$\checkmark$	$\checkmark$	X	$\checkmark$	X
Special Events	TICKET \$	\$	\$	\$	\$	\$
AACC Opening Mixer & Division Networking Event Sunday, August 4	$\checkmark$	$\checkmark$	$\checkmark$	X	$\checkmark$	X
Clinical Lab Expo Exhibit Hall, August 6–8	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	X
Industry Presentations (Hotel and Expo Floor)	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	X

#### AACC REGISTRATION RESOURCE CENTER

**OPEN THE RESOURCE CENTER** 

#### LOG IN

Badge Number: Listed on left side of badge Last Name: Exactly as entered when registering



🗸 Included with registration type 👖 Ticket required 💲 May purchase ticket 🔇 NOT eligible to purchase ticket 🗙 May NOT attend



# SUNDAY AUGUST 4

### **PLENARY & SCIENTIFIC SESSIONS**



# **SUNDAY** | AUGUST 4

#### **AACC UNIVERSITY**

#### MORNING

#### 8:30am-11:30am

**Preanalytical Variations: Basics and** Beyond

191002 Room: 204C

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 3

#### **MODERATOR/SPEAKER**

Ana-Maria Simundic, PhD Croatia

Т

#### 8:30am-11:30am

Presentation Level: **BASIC** 

**MODERATOR/SPEAKER** 

Developed in cooperation with Hematology and Coagulation Division

ACCENT<sup>®</sup> Credits: 3

John Mitsios, PhD

191003

Park, NJ

Т

Room: 204A

Hemoglobin Electrophoresis

**INTENDED AUDIENCE:** This session is intended for clinical chemists, laboratory technologists, residents and pathologists. **LEARNING OBJECTIVES:** After this session, participants will be able to:

- BioReference Laboratories, Elmwood

#### **SPEAKERS**

Laboratory Diagnosis of Hemoglobinopaties John Mitsios, PhD BioReference Laboratories, Elmwood Park, NJ

**Clinical Presentation and Clinical Case Studies** Amy Chadburn, MD WCMC-NYPH, New York, NY

clinical setting.

INTENDED AUDIENCE: This session is intended for all laboratory personnel, including laboratory directors and technologists.

**SPEAKERS** 

University Hospital Sveti Duh, Zagreb,



Registration fees apply for each course.

SESSION OVERVIEW: The most frequent occurrences of laboratory errors occur in the preanalytical phase. This session will review the basics of the preanalytical phase, discuss approaches to improve quality in the preanalytical phase, and provide guidance for overcoming various preanalytical challenges. In addition, this course will also provide a series of interactive case presentations of some of the most common preanalytical errors in the

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Identify the most important sources of errors related to venous blood sampling and design approaches to address them.

2. Identify ways to detect and manage hemolysed samples and choose a most suitable strategy to overcome challenges related to hemolysis in the particular clinical context.

3. List and categorize preanalytical errors related to coagulation testing relative to their effect on sample quality and accuracy of test results and set up procedures to control preanalytical variability related to coagulation testing.

4. Recognize various preanalytical problems by analyzing real-life preanalytical cases and decide on the most appropriate strategy to address the problem.

#### Preanalytical Errors Related to Venous Blood Sampling

Ana-Maria Simundic, PhD University Hospital Sveti Duh, Zagreb, Croatia

Blood Sample Hemolysis Giuseppe Lippi, MD, PhD Section of Clinical Biochemistry, University of Verona, Verona, Italy

#### Preanalytical Errors in Coagulation Testing

Dorothy Adcock, MD Laboratory Corporation of America, Burlington, NC

SESSION OVERVIEW: This session will review specialized testing used for the diagnosis of hemoglobinopathies. In addition, this session will also provide an overview of the clinical presentation of patients with hemoglobinopathies.

1. Describe the physiology of hemoglobin disorders.

2. Describe the methods/techniques used for hemoglobin electrophoresis.

3. Differentiate normal from abnormal hemoglobin electrophoresis.

4. Contrast different approaches to diagnosing different hemoglobinopathies.

# **SUNDAY** AUGUST 4

#### **AACC UNIVERSITY**

#### **MORNING**

#### 8:30am-11:30am

#### The Laboratory Test Life Cycle: Using CLSI Guidelines to Meet FDA, CLIA and **ISO Requirements**

191004 Room: 201AB

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 3

#### **MODERATOR/SPEAKER:**

J. Rex Astles, PhD, FAACC, DABCC Centers for Disease Control and Prevention, Atlanta, GA

Developed in cooperation with CLSI



8:30am-11:30am

#### **Rise and Shine!** The Essential **Elements of a Point-of-Care Testing** Boot Camp (Part 1)

191005 Room: 210B

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 3

#### **MODERATOR/SPEAKER**

Peggy Mann, MS, MT (ASCP)

University of Texas Medical Branch, Galveston, TX

Developed in cooperation with Critical and Point-of-Care Testing Division



SESSION OVERVIEW: This session will examine how quality can be ensured through establishment, validation, and verification of performance specifications for laboratory developed tests (LDTs). The test life cycle, related concepts, and definitions will be introduced. For each step in the test life cycle, speakers will discuss the FDA, CLIA, and ISO requirements. A specific LDT example will be provided to demonstrate how the CLSI documents can be used to meet the regulatory requirements.

Registration fees apply for each course

INTENDED AUDIENCE: This session is intended for pathologists, laboratory directors, clinical chemists, researchers, medical technologists and trainees.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Explain the establishment and implementation stages in the laboratory test life cycle.

- 2. List the steps in the establishment and implementation stages.
- 3. Explain the FDA and CLIA regulations and guidance, and ISO standards requirements for each life cycle step.
- 4. Describe how CLSI guidelines can be used to meet these requirements.
- 5. Explain how checklists provided in EP19-A can help users document how to demonstrate acceptable evaluations during each step of the establishment and implementation stages.

#### SPEAKERS

#### Introduction to the Assay Life Cycle Model, Terminology and Illustration of How CLSI Guidelines Can Be Used to Meet Requirements Paula Ladwig, MS, MT (ASCP) Mayo Clinic, Rochester, MN

FDA QSR Requirements Marcia Zucker, MS, PhD, FAACC

ZIVD LLC, Plaistow, NH

#### **CLIA Requirements** J. Rex Astles, PhD, FAACC, DABCC

Centers for Disease Control and Prevention, Atlanta, GA

#### ISO Requirements

Lucia Berte, MA, MT (ASCP), SBB, DLM Laboratories Made Better!, Broomfield, CO

SESSION OVERVIEW: This session will focus on important elements of procedure writing, including process mapping as well as training and competency assessments of testing personnel. The importance of building clinical partnerships for successful point-of-care testing delivery will be incorporated. Lectures will include audience response (polls) and a breakout session will add hands-on table exercises. (See Part 2 for focus areas in the afternoon boot camp session).

INTENDED AUDIENCE: This session is intended for point-of-care coordinators, medical technologists, lab managers/supervisors, pathologists, lab directors, clinical chemists and IVD industry scientists.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Describe a process for writing effective and efficient P&Ps.
- 2. Construct procedural documents that are understood by the non-laboratorian.
- 3. Compile and analyze a Process Map.
- 4. Build a basic training program that includes components, tools and strategies utilized for successful training.
- 5. Discuss competency assessment plans and procedures based on testing complexity.

#### **SPEAKERS**

#### Drill This! Training Is Different Than Competency Assessment Peggy Mann, MS, MT (ASCP)

University of Texas Medical Branch, Galveston, TX

#### Ten-Hut!! Writing Procedures to Achieve Compliance Lou Ann Wyer, MS, MT (ASCP), CQA (ASQ)

Sentara Healthcare, Virginia Beach, VA

#### **FULL-DAY COURSES**

#### 8:30am-3:15pm

#### The Secrets to Success: Implementing Robust LC-MS/MS Methods in the Clinical Laboratory

193012

Room: 205AB

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 6

#### **MODERATOR/SPEAKER**

Grace van der Gugten, BSc St. Paul's Hospital/Mass Spec Laboratory, Vancouver, Canada



#### Part 1 Julianne Botelho, PhD

SPEAKERS

Part 2 Grace van der Gugten, BSc

#### 8:30am-3:15pm

#### How to Truly "Excel" at Data Analysis and Visualization: An Introduction to the R Programming Language

193013

Room: 206AB

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 6

#### **MODERATOR/SPEAKER**

Patrick Mathias, MD, PhD University of Washington School of Medicine, Seattle, WA





Joseph Rudolf MD

**SPEAKERS** 

Method Validation Tasks Using R Daniel Herman, MD, PhD University of Pennsylvania, Philadelphia, PA

SESSION OVERVIEW: This session aims to assist clinical laboratories interested in implementing mass spectrometry. It will cover the fundamentals of liquid chromatography and tandem mass spectrometry. There will be a discussion of sample preparation techniques, considerations for method development, validation, post-implementation monitoring, and

# troubleshooting.

INTENDED AUDIENCE: This session is intended for laboratory directors, clinical chemists, laboratory administrators, laboratory managers and supervisors, IVD industry scientists, pathologists, physicians, and medical technologists.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Describe the basics of liquid chromatography.

2. Describe the basics of tandem mass spectrometry.

3. Describe common sample preparation strategies.

4. Create a plan for method development and pre-validation.

5. Create a plan for method validation testing.

6. Develop a program for post-implementation monitoring.

#### The Secrets to Success: Implementing Robust LC-MS/MS Methods in the Clinical Laboratory—

Centers for Disease Control and Prevention, Atlanta, GA

#### The Secrets to Success: Implementing Robust LC-MS/MS Methods in the Clinical Laboratory—

St. Paul's Hospital/Mass Spec Laboratory, Vancouver, Canada

SESSION OVERVIEW: Analyzing data is a key element of effective laboratory practice and quality improvement activities. Outside of simple descriptive statistics and standard plots, data analyses in spreadsheets can be time-consuming and error-prone. R is a free statistical programming language that supports the complex data manipulation and analysis activities needed for efficient clinical laboratory practice. This session will introduce basic concepts of R programming and discuss overall best practices in working with large laboratory data sets.

INTENDED AUDIENCE: This session is intended for pathologists, laboratory directors, clinical chemists, medical technologists and industry scientists.

**LEARNING OBJECTIVES:** After this session, participants will be able to:

1. Describe the benefits of applying a programming language to analysis of clinical laboratory data.

2. Perform a simple set of analyses on a structured data set using R.

3. Use R to perform routine analyses of data for operational and quality improvement purposes at their home institution.

#### Basic Data Exploration Using the Tidyverse

Patrick Mathias, MD, PhD University of Washington School of Medicine, Seattle, WA

More Advanced Data Exploration and Manipulation

University of Minnesota Medical School, Minneapolis, MN

# **SUNDAY** AUGUST 4

#### **AACC UNIVERSITY**

#### **FULL-DAY COURSES**

#### 8:30am-3:15pm

#### Pathology and Clinical Laboratory Informatics Boot Camp

193014 Room: 207AB

Presentation Level: BASIC ACCENT<sup>®</sup> Credits: 6

#### **MODERATOR/SPEAKER**

David McClintock, MD Michigan Medicine, Ann Arbor, MI

Developed in cooperation with Informatics Division

SESSION OVERVIEW: Informatics is best described as delivering the right information to the right person, at the right place and time, and in the right way. Unfortunately, most laboratory professionals haven't had formal training in informatics, even though they utilize its tools every day. This session serves as an informatics boot camp, providing participants the basics needed to understand and navigate this rapidly evolving field. Topics include LIS, EHR, and middleware; information system selection and life cycle; IT data governance; cybersecurity and information assurance; data extraction and analytics; and artificial intelligence and machine learning.

Registration fees apply for each course

**INTENDED AUDIENCE:** This session is intended for clinicians, pathologists, laboratory directors, laboratory managers, clinical chemists, medical technologists, laboratory administrators and IVD industry scientists.

**LEARNING OBJECTIVES:** After this session, participants will be able to:

- 1. Define and describe the field of pathology and clinical laboratory informatics and understand its importance within clinical laboratory practice.
- 2. Describe how to best select health information systems and understand the system life cycle process.
- 3. Understand the basic principles behind the LIS, system middleware, and the EHR.
- 4. Understand the basic tenets of IT data governance, including the extra measures needed to ensure proper cybersecurity and information assurance.
- 5. Understand how data extraction and analytics help drive decision support tools, including artificial intelligence and machine learning applications.

#### **SPEAKERS**

#### Introduction/Information Systems—Overview, Selection, Life Cycle

David McClintock, MD Michigan Medicine, Ann Arbor, MI

IT Governance/Cybersecurity Issues Christopher Williams, EE, MD University of Oklahoma Health Sciences Center, Edmond, OK

#### Data Extraction/Analytics/Artificial Intelligence

Bryan Dangott, MD East Carolina University, Greenville, NC

#### 8:30am-3:15pm

#### **Clinical Laboratory Genomics:** Practical NGS for Laboratorians

193015 Room: 208AB

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 6

#### **MODERATOR/SPEAKER**

Christina Lockwood, PhD, DABMGG, DABCC

University of Washington, Seattle, WA

Developed in cooperation with Molecular Pathology Division



8:30am-3:15pm

193016

Т

Room: 209AB

**Clinical Laboratory Leadership** 

**Essentials for the 21st Century** 

**MODERATOR/SPEAKER** 

Sedef Yenice, PhD, MBA

Group Florence Nightingale

Hospitals, Istanbul, Turkey

Ann Mover, MD, PhD Mayo Clinic, Rochester, MN

Avni Santani, PhD

Josh Deignan, PhD, ABMGG

SESSION OVERVIEW: An essential component to leadership is relationship building, and good leadership is a learnable skill. Many people find themselves in leadership positions or aspiring to become leaders in laboratory medicine despite very little training on how to be an effective leader. This session attempts to fill in this apparent gap through discussion of leadership effectiveness and self-management as well as management of workplace relationships, including conflict resolution and leading teams.

INTENDED AUDIENCE: This session is intended for clinical chemists, laboratory directors, pathologists, laboratory supervisors, laboratory managers and medical laboratory

Presentation Level: INTERMEDIATE technologists. ACCENT<sup>®</sup> Credits: 6

1. Identify the most effective leadership styles and describe strategies to improve their effectiveness as a leader.

- developing and managing their team.
  - 3. Describe how to resolve conflicts.

#### **SPEAKERS**

as Visionary and Motivator Sedef Yenice, PhD, MBA

and Project Management Fundamentals Edward Randell, PhD, FCACB Memorial University, St. John's, Canada

Matthias Orth, MD, PhD Institut für Laboratoriumsmed, Stuttgart, Germany

#### SPEAKERS

clinical tests.

Christina Lockwood, PhD, DABMGG, DABCC University of Washington, Seattle, WA

SESSION OVERVIEW: Genetic testing using next-generation sequencing is advancing precision medicine. This session will describe key aspects of quality control, quality assurance, and regulatory considerations for NGS, the relative advantages and limitations of targeted versus comprehensive NGS tests, and NGS data analysis and particularly variant interpretation in the diagnosis of hereditary disorders. The speakers will use interactive case studies to emphasize the essential components of each topic.

**INTENDED AUDIENCE:** This session is intended for healthcare professionals, including clinical pathologists, physicians, laboratory directors, clinical chemists, laboratory managers, medical technologists, post-doctoral fellows and IVD industry scientists.

**LEARNING OBJECTIVES:** After this session, participants will be able to:

1. Discuss the basic concepts, benefits, and limitations of next-generation sequencing as

2. Understand the key challenges associated with external quality assessment for NGS tests. 3. Recognize the need for both targeted and comprehensive testing.

4. Describe the recommendations for variant classification and result interpretation in inherited disorders.

#### Variability In, Variability Out: Essentials of Quality Assurance in NGS

#### Choosing Wisely: Targeted Versus Genomic Tests

#### Challenges of Interpreting NGS Data for Inherited Disorders

Children's Hospital of Philadelphia, Philadelphia, PA

#### Clinical Exome Sequencing: Best Practices for Variant Interpretation

University of California, Los Angeles, Los Angeles, CA

**LEARNING OBJECTIVES:** After this session, participants will be able to:

2. Identify the expectations of followers and how to respond to those needs when

4. Describe how to select and manage a team toward success in projects.

### The Leader Versus the Manager, Leading and Managing the Laboratory Team and the Leader

Group Florence Nightingale Hospitals, Istanbul, Turkey

# Leadership Attitudes and Styles, Learning Style and Impact on Relationships in the Workplace

### Defining Conflict and Personal Responses to Conflict and Conflict Resolution Process

# **SUNDAY** | AUGUST 4

#### **AACC UNIVERSITY**

#### **FULL-DAY COURSE**

#### 8:30am-3:15pm

#### Getting Started with R for Laboratory Medicine

193017 Room: 210A

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 6

#### **MODERATOR/SPEAKER**

Shannon Haymond, PhD, DABCC, FAACC

Lurie Children's Hospital of Chicago, Chicago, IL



SESSION OVERVIEW: This hands-on course will teach the basics of interaction with the R statistical programming language through the RStudio interface with a goal of providing attendees the ability to perform the core statistical analyses and data visualization required for laboratory medicine clinical practice. Attendees will use R and RStudio on their personal laptops to participate in this interactive session.

Registration fees apply for each course.

**INTENDED AUDIENCE:** This session is intended for pathologists, laboratory directors, clinical chemists, fellows and trainees, medical technologists, and research scientists. Anyone involved in quality assurance activities, such as method validation analysis, research and development, or the preparation of academic laboratory medicine manuscripts will benefit.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Navigate and use the basic features of RStudio, produce publication-quality figures using R, and create reproducible reports and data workflows using R Markdown.
- 2. Import and export data in .csv or .xlsx formats.
- 3. Perform basic data cleansing and wrangling on large data sets.
- 4. Perform descriptive and graphical exploratory data analyses: mean, SD, quantiles, extrema, boxplots, violin plots, stripcharts, histograms, scatterplots and regression plots.
- 5. Perform statistical analyses in R: t-test, Wilcoxon signed rank and rank sum, ANOVA, repeated measures ANOVA, corrections for multiple comparisons, Deming and Passing Bablok regression, nonlinear regression, and CLSI precision calculations.

#### **SPEAKERS**

#### Moving from IDK to IDE Daniel Holmes, MD University of British Columbia, British Columbia, Canada

Data Cleansing: I've Tried Scrubbing, Even Soaking Dennis Orton, PhD

Dr. C. J. Coady Associates, Surrey, Canada

#### The Stat of the Union Address Stephen Master, MD, PhD, FAACC Children's Hospital of Philadelphia, Philadelphia, PA

#### Dealing with My Vizness

Shannon Haymond, PhD, DABCC, FAACC Lurie Children's Hospital of Chicago, Chicago, IL

#### **AFTERNOON**

#### 12:15pm-3:15pm

Afternoon Reveille! Continuing the Essential Elements of a Point-of-Care Testing Boot Camp (Part 2)

192007 Room: 201AB

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 3

#### **MODERATOR/SPEAKER**

Jeanne Mumford, MLS, MT (ASCP) Johns Hopkins Hospital, Baltimore, MD

Developed in cooperation with Critical and Point-of-Care Testing Division



#### POCT Kerstin Halverson, MS

Jeanne Mumford, MLS, MT (ASCP)



SESSION OVERVIEW: This session will focus on important elements of integrating quality management into point-of-care testing (POCT), creating strong multidisciplinary team communications and integrating POCT connectivity. The importance of building clinical partnerships for successful POCT delivery will be incorporated. Lectures will include audience response (polls) and a breakout session will add hands-on table exercises. (See Part 1 for focus areas in the morning boot camp session).

standards.

practices.

**SPEAKERS** 

INTENDED AUDIENCE: This session is intended for point-of-care coordinators, medical technologists, lab managers, supervisors, pathologists, lab directors, clinical chemistry scientists and IVD industry scientists.

**LEARNING OBJECTIVES:** After this session, participants will be able to:

1. Discuss options for meeting the most difficult accreditation and regulatory POCT

2. Develop meaningful indicators for a POCT quality program, including analytics.

3. Outline implementation steps for connectivity and review troubleshooting strategies.

4. Identify key communication skills for successful multidisciplinary partnerships.

5. Identify the difference between the "one-size-fits-all" approach and working with best

#### Integrating Quality Management and Compliance into POCT Kimberly Skala, MT (ASCP)

Instrumentation Laboratory, Oak Lawn, IL

#### Connectivity: Get Out the Tin Cans and String! Saving Your Sanity Using Connectivity for

Instrumentation Laboratory, Farmington, MN

#### Leading Your Team with Successful Communication Skills

Johns Hopkins Hospital, Baltimore, MD

#### FOLLOW AACC @ AACC AND USE THE HASHTAG #2019AACC TO JOIN THE CONVERSATION.





# **SUNDAY** AUGUST 4

#### **AACC UNIVERSITY**

#### **AFTERNOON**

#### 12:15pm-3:15pm

**AACC/IFCC Clinical Laboratory** Practice Recommendations for Use of High-Sensitivity Cardiac Troponin Assays: Real Laboratory and **Clinical Experience in the USA** 

192008 Room: 207CD

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 3

#### **MODERATOR/SPEAKER**

Fred Apple, PhD, DABCC Hennepin County Medical Center, Minneapolis, MN

SESSION OVERVIEW: Evidence-based presentations with case studies, with interactive audience participation, will be presented to communicate and discuss practical implementation and experience with high-sensitivity cardiac troponin (hs-cTnI, hs-cTnT) assays. The session will cover the role of the central lab and point-of-care testing in the early rule-out/rule-in of myocardial infarction, risk assessment, and primary prevention in clinical practice. The AACC/IFCC clinical laboratory practice guidelines for defining guality control, normality and gender-specific 99th percentile upper reference limits will be addressed.

Registration fees apply for each course.

INTENDED AUDIENCE: This session is intended for for any laboratory/physician scientist, including pathologists, lab directors, clinical chemists, technologists, IVD industry scientists and regulatory experts.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Demonstrate an understanding of how to implement a high-sensitivity (hs) cardiac troponin assay into the clinical laboratory (central lab and POC), addressing sex-specific 99th percentiles, revising reporting units to whole numbers, quality control utilization, the role of the limit of detection (LoD) for early rule-out utilization, and how to implement a serial hs-cTn order set strategy (i.e., 0h and 1-3h) for early diagnostic accuracy for MI.
- 2. Describe unique aspects of required analytical validation for high-sensitivity troponin tests, and define approaches to address analytical interferences and outliers.
- 3. Describe how to establish a partnership and communication plan between the laboratory and emergency medicine and cardiology/all providers on how to implement hs-cTn testing into clinical practice along international evidence-based and expert opinion guidelines.
- 4. Address the appropriate need to measure hs-cTn in non-acute coronary syndrome (ACS) patients to detect myocardial injury and the role of hs-cTn testing in these patients' triage, management and outcome assessment.
- 5. Describe the subtle analytical and clinical interpretation differences between the different hs-cTnI and cTnT assays.

#### **SPEAKERS**

One-Year Experience of the Analytical Performance Following Implementation of the Gen 5 cTnT Assay into Laboratory Medicine Practice Brad Karon, MD, PhD, FAACC

Mayo Clinic, Rochester, MN

One-Year Experience of the Clinical Performance Following Implementation of the Gen 5 cTnT Assay into Emergency Medicine Practice Judd Hollander, MD

Thomas Jefferson University, Philadelphia, PA

One-Year Experience of the Clinical Performance Following Implementation of the Gen 5 cTnT Assay into Cardiology Practice Allan Jaffe, MD

Mayo Clinic, Rochester, MN

Experience from the Clinicaltrials.gov "CONTRAST" Study on the Direct Comparison between hs-cTnI and Gen5 cTnT Assays in Patients Presenting to the Emergency Department: Are There Differences? Fred Apple, PhD, DABCC Hennepin County Medical Center, Minneapolis, MN

#### 12:15pm-3:15pm

#### Maximizing the Impact and Value of Laboratory Automation: Lessons Learned from Clinical Chemistry and Microbiology

192009

Room: 204A

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 3

#### **MODERATOR/SPEAKER**

Jonathan Genzen, MD, PhD University of Utah/ARUP Laboratories, Salt Lake City, UT



#### 12:15pm-3:15pm

#### Multiple Myeloma Diagnostics: Interpretation and Reporting of **Protein Electrophoresis and Serum Free Light Chains**

192010 Room: 204C

Presentation Level: ADVANCED ACCENT<sup>®</sup> Credits: 3

Developed in cooperation with Clinical and Diagnostic Immunology Division

#### **MODERATOR/SPEAKER**

Ronald Booth, BSc, MSc, PhD, FCACB, FAACC The Ottawa Hospital, Ottawa,

Т

Canada

SESSION OVERVIEW: Automation has the potential to improve laboratory accuracy, efficiency and throughput. Total laboratory automation is widely used in clinical chemistry laboratories, and instrumentation to automate culture-based testing is now available and is being implemented in microbiology laboratories. This multi-disciplinary session for AACC University will bring together laboratory medicine professionals from chemistry and microbiology to discuss total laboratory automation, including validation, implementation, and clinical impact.

1. Explain the role and impact of total laboratory automation in clinical chemistry and clinical microbiology laboratories.

**SPEAKERS** 

Jonathan Genzen, MD, PhD

Anna Merrill, PhD, DABCC University of Iowa, Iowa City, IA

Carev-Ann Burnham, PhD

Microbiology Melanie Yarbrough, PhD Washington University, St. Louis, MO

SESSION OVERVIEW: This session will provide an interactive series of myeloma cases that include serum protein electrophoresis, immunofixation and serum free light chains. Attendees will be provided standardized approaches, examples, and advice on how to interpret and report these results, with a focus on the subtleties of effectively communicating relevant laboratory findings. Laboratory testing and discussion will include capillary electrophoresis and agarose gels. Case examples will include the clinical history and context as well as challenging interpretative aspects, such as monoclonal proteins that migrate in the alpha and beta region as well as samples with interferences from monoclonal therapeutic agents.

INTENDED AUDIENCE: This advanced session is intended for pathologists, laboratory directors, clinical chemists, medical technologists, and laboratory administrators.

1. Interpret serum and urine protein electrophoresis and immunofixation tests.

- conditions.

#### **SPEAKERS**

David Keren, MD

Fractions

Case Studies: Bridging the Old and the New Maria Alice Willrich, MSc, PhD, DABCC, FAACC Mayo Clinic, Rochester, MN

Т

**INTENDED AUDIENCE:** This session is intended for pathologists, lab directors, clinical chemists, technologists, managers, supervisors and industry scientists.

**LEARNING OBJECTIVES:** After this session, participants will be able to:

2. Discuss items to consider when evaluating potential automation solutions.

3. Identify best practices for implementation of automation in the clinical laboratory.

#### Avoiding Costly Mistakes in Automation Plans and Proposals

University of Utah/ARUP Laboratories, Salt Lake City, UT Implementation of Total Laboratory Automation in Clinical Chemistry

#### Planning and Implementation of Automation in Microbiology

Washington University School of Medicine, St. Louis, MO

#### Post-Implementation and Workflow Considerations of Total Laboratory Automation in

LEARNING OBJECTIVES: After this session, participants will be able to:

2. Describe approaches to quantitation of monoclonal proteins and other fractions.

3. Identify and resolve interferences that are encountered with protein electrophoresis.

4. Interpret serum free light chain results in the context of myeloma and other clinical

5. Effectively convey myeloma-related tests to clinicians.

#### Initial Detection and Measurement of a Monoclonal Protein

#### University of Michigan, Ann Arbor, MI

#### Clinical Reporting Considerations for Serum Free Light Chains and Monoclonal Protein

Ronald Booth, BSc, MSc, PhD, FCACB, FAACC The Ottawa Hospital, Ottawa, Canada

# **SUNDAY** | AUGUST 4

#### **AACC UNIVERSITY**

#### **AFTERNOON**

#### 12:15pm-3:15pm

Trust, but Verify: Getting the Most **Out of Verification Protocols for FDA Approved Methods** 

192011 Room: 210B

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 3

#### **MODERATOR/SPEAKER**

David Koch, PhD, DABCC, FAACC Emory University/Grady Memorial Hospital, Atlanta, GA



#### SPECIAL SESSION

3:30pm-4:30pm Room: 204B

#### **Consumer Genomics, Direct-to-Consumer Genetic Testing, and Patient Empowerment**

11002

Presentation Level: INTERMEDIATE | ACCENT<sup>®</sup> Credits: 1

SESSION OVERVIEW: Consumer-initiated genetic testing is experiencing exponential growth with many new applications in the areas of health, wellness, and entertainment. However, while the uptake of these tests are high, the limitations of consumer genetic testing may not be well-understood by most consumers. During this session, two well-renowned experts in the field will discuss nuances between the different types of tests, regulatory aspects, clinical validity and utility, and how consumer genetic testing fits into medical care.

INTENDED AUDIENCE: This session is intended for pathologists, laboratory directors, clinical chemists, technologists, physicians and IVD industry scientists.

#### MODERATOR

Cathy Wurzer

Minnesota Public Radio, Saint Paul, MN

#### **SPEAKERS**

Consumer Genomics in 2019 Jill Hagenkord, MD Ruby Consulting Group, San Jose, CA

DTC Genetic Testing and Patient Care: Hype, Harm and Hope Theodora Ross, MD, PhD UT Southwestern, Dallas, TX

SESSION OVERVIEW: This session will discuss the process of selecting and evaluating clinical laboratory methods. Attendees will develop an understanding of the correct approach to this key clinical laboratory task. This course uses a series of examples taken from the clinical laboratory evaluation process to focus attention on the critical aspects of method validations. This session emphasizes protocols that are essential for validation of FDA approved methods and instruments.

Registration fees apply for each course

INTENDED AUDIENCE: This session is intended for clinical chemists, pathologists, laboratory directors, laboratory managers, IVD industry scientists and clinical laboratory scientists in the regulatory industry.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Evaluate the claims of manufacturers about method performance and discern whether these claims are well-grounded and pertinent.
- 2. Evaluate validation studies published in the literature.
- 3. Perform evaluation experiments designed to verify claims, confirm literature reports, compare achieved performance with desired performance, and make justifiable decisions about the method being tested.

#### **SPEAKERS**

Verification Experiments Janetta Bryksin, PhD, DABCC Emory University Hospital, Atlanta, GA

Introduction and Setting Clinical Performance Goals David Koch, PhD, DABCC, FAACC Emory University/Grady Memorial Hospital, Atlanta, GA



**PLENARY SESSION** 

#### **Biomarker Discovery: From Technology Development to Clinical Applications**

# David R. Walt, PhD

Boston, MA

5:00pm-6:30pm Room: Ballroom ABC

11001

SESSION OVERVIEW: In this presentation, Dr. Walt will describe how biomarker discovery is performed today and will discuss how we can compress the timeframe from discovery to clinical impact. He will draw upon his experiences in translating research from an academic lab to the commercial sector. Some successful examples of how novel technologies have found their way to the clinic will be described. The goals of the presentation are for the audience to understand how new technologies can accelerate biomarker discovery and to realize that there are multiple challenges and barriers to implementing these new technologies for impactful diagnostic tests.

clinical settings.

1. Understand how new technologies can accelerate biomarker discovery. 2. Realize that there are multiple challenges and barriers to implementing these new technologies for impactful diagnostic tests.

#### WALLACE H. COULTER LECTURESHIP AWARD

The Wallace H. Coulter Lectureship Award recognizes an outstanding individual who has demonstrated a lifetime commitment and made important contributions to laboratory medicine and patient care, and who has significantly advanced education, practice or research. This award honors Wallace H. Coulter, founder of Coulter Corporation and inventor of the Coulter Principle, a simple but elegant innovation that revolutionized hematology and the practice of laboratory medicine, pioneered the field of flow cytometry and defined particle

AACC's most prestigious award—presented annually at the AACC Annual Scientific Meeting & Clinical Lab Expo—commemorates Coulter's outstanding contributions to diagnostics and his championship of research and innovation. It is fitting that his legacy will be celebrated with lectures by renowned leaders in healthcare.

### 2019 WALLACE H. COULTER LECTURESHIP AWARD

Harvard Medical School & Wyss Institute for Bioinspired Engineering at Harvard University,

#### Presentation Level: **BASIC** | ACCENT<sup>®</sup> Credits: 1

INTENDED AUDIENCE: This session is intended for pathologists, lab directors, clinical chemists, technologists, physicians and IVD industry scientists with an interest in biomarker discovery and translating research from academia to routine

**LEARNING OBJECTIVES:** After this session, participants will be able to:

# MONDAY AUGUST 5

### **PLENARY & SCIENTIFIC SESSIONS**











### **PLENARY SESSION**



#### Translating Genes, Brain and Behavior: A Next-Generation Human Framework

Julie Korenberg, MD, PhD University of Utah, Salt Lake City, UT

8:45am-10:15am Room: Ballroom ABC

12001

SESSION OVERVIEW: Peering into the brain's black-box for how we think/feel/ communicate reveals neural circuitry as a common language that yokes the power of human genetics to its influences in development and disease, on brain architecture and behavior. Uncommon partial aneuploidies (Williams and Down syndromes) provide genes influencing human cognition/social-emotional behavior, and these unexpectedly implicate primate hypothalamic circuitry. The trail leads, via neural imaging, to dysregulated hormones, a perturbed transcription factor (neuronal development), and an unknown tract spanning the brain limbic system. This is the next era of brain diagnostics and therapeutics in which new gene-disease associations are rapidly translated to brain circuitry.

**INTENDED AUDIENCE:** This session is intended for pathologists, lab directors, clinical chemists, technologists, physicians and IVD industry scientists with interests in brain diagnostics and therapeutics.

Presentation Level: BASIC | ACCENT® Credits: 1

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Understand how human genetic analyses of DNA, RNA, and protein can be used to describe individuals with brain disease.

2. Understand that rare individuals with only subsets of genes imbalanced exist and can be used to evaluate the genetic contributions of their gene differences to their phenotypes, in ways similar to knockout or transgenic mice.

3. Understand three types of neural imaging with magnetic resonance (MRI) that generate different brain information: volumetric, functional, and diffusion spectrum imaging (used for tractography or neural circuit definition).

#### **ROUNDTABLE SESSIONS**

7:30am–8:30am (40000 Series) or 12:30pm–1:30pm (50000 Series)

Registration fees apply for each course.

Roundtable sessions are presented twice daily. Attendance is limited to 10 participants per session. Advance registration and session fees are required. AACC does not provide meals for these sessions. You will be able to purchase your own food in the convention center prior to the session.

ACCENT® Credit: 1.0 (per session) unless otherwise noted in the mobile app, or at www.2019aacc.org | ACC, Ballroom DE

SESSION #				
TITLE	AM	PM	SPEAKER	LEVEL
Promoting Laboratory Medicine to the Public: The Time to Act Is Now!	42101	52201	<b>Alan Wu,</b> PhD, University of California, San Francisco, San Francisco, CA	BASIC
Interferences with Thyroid Function Tests: Where Do We Stand?	42102	52202	<b>Damien Gruson,</b> PhD, Cliniques Universitaires Saint-Luc, Kraainem, Belgium	INTERMEDIATE
How Statistics Influence Our Clinical Decisions Developed in cooperation with Management Sciences and Patient Safety Division	42103	52203	Oswald Sonntag, PhD, Sonntag, Eichenau, Germany	BASIC
How People Try to Beat Drug Testing and Defend Positive Results	42104	52204	<b>Amitava Dasgupta,</b> PhD, DABCC, University of Texas–Houston Medical School, Houston, TX	BASIC
Measuring Scientific Impact with the H-Index	42107	52207	William Schreiber, MD, LifeLabs, Burnaby, Canada	BASIC
Hemoglobinopathies: Techniques and Interpretation	42108	52208	<b>Sean Campbell,</b> PhD, Montefiore Medical Center, Bronx, NY	INTERMEDIATE
Six Sigma and Your Lab Quality Management System—Have You Incorporated It Yet?	42109	52209	<b>Laura Smy,</b> PhD, MLS, University of Utah/ARUP Laboratories, Salt Lake City, UT	BASIC
Thrombotic Disorders in the Pediatric Population: Current Issues in Diagnosis and Management	42110	52210	<b>Olajumoke Oladipo,</b> MD, DABCC, FAACC, Penn State Milton S. Hershey Medical Center, Hershey, PA	BASIC
The Impact of the NGSP on HbA1c Measurement in the Clinical Laboratory	42111	52211	<b>Randie Little,</b> PhD, University of Missouri at Columbia, Columbia, MO	INTERMEDIATE
Follow-Up of Positive Newborn Screen Positive Results for Metabolic Disorders Developed in cooperation with Pediatric and Maternal- Fetal Division	42112	52212	<b>Uttam Garg,</b> PhD, DABCC, FAACC, FABFT, Children's Mercy Hospital, Kansas City, MO	BASIC
Biotin Interferences and Strategies for Mitigating Interference in Immunoassays	42114	52214	<b>Jieli Li,</b> MD, PhD, MD Anderson Cancer Center, Houston, TX	BASIC
Utility of Procalcitonin Measurement: Current Evidence and Clinical Utility in Pediatric and Adult Populations	42115	52215	<b>Jayson Pagaduan,</b> PhD, Texas Children's Hospital, Houston, TX	BASIC
The CDC Lipids Standardization Programs— Ensuring the Quality of Cardiovascular Disease Biomarker Measurements	42116	52216	<b>Uliana Danilenko,</b> PhD, Centers for Disease Control and Prevention, Atlanta, GA	INTERMEDIATE

Advances in Laboratory Testing for the Diagnosis and Management of Syphilis	42118	52218	<b>Mahesheema Ali,</b> MSc, PhD, Upstate Medical Hospital, Manlius, NY	INTERMEDIATE
Intraoperative Parathyroid Hormone Testing	42119	52219	Xander Van Wijk, PhD, DABCC, The University of Chicago Medicine & Biological Sciences, Chicago, IL	BASIC
Clinical Laboratory Management of Dyslipidemia in Children and Adolescents: Standing Plasma Test to Genetic Testing	42120	52220	<b>Mustafa Barbhuiya,</b> PhD, (MB) (ASCPi)CM, Penn State University College of Medicine, Hershey, PA	BASIC
Control Your Competencies: Transitioning from Paper to an Electronic System for Personnel Competencies	42121	52221	<b>Van Leung-Pineda,</b> PhD, DABCC, Children's Healthcare of Atlanta, Atlanta, GA	BASIC
Detecting Alzheimer's Disease with Biofluid Biomarkers: Innovations and a Research Framework That Inform Clinical Practice	42122	52222	<b>Danni Li,</b> PhD, DABCC, University of Minnesota, Minneapolis, MN	INTERMEDIATE
Implementing Blood Gas Instrumentation with Intelligent Quality Management	42123	52223	<b>Yachana Kataria,</b> PhD, DABCC, Boston Medical Center, Boston, MA	BASIC
Laboratory Strategies for Mitigating Pre-Analytical Errors	42124	52224	<b>Qing Meng,</b> MD, PhD, DABCC, FAACC, University of Texas/MD Anderson Cancer Center, Houston, TX	INTERMEDIATE
Pearls and Pitfalls of Estradiol and Testosterone Testing	42125	52225	<b>Amy Pyle-Eilola,</b> PhD, Nationwide Children's Hospital, Columbus, OH	INTERMEDIATE
Pharmacogenomics and Precision Medicine: Transferring Pharmacogenomics Findings into the Clinic	42126	52226	<b>Carmen Gherasim,</b> PhD, University of Michigan, Ann Arbor, MI	INTERMEDIATE
To Quant or Not to Quant? Limitations of Quantifying Low Concentration Monoclonal Proteins by Serum Protein Electrophoresis	42127	52227	Katherine Turner, PhD, Mayo Clinic, Rochester, MN	INTERMEDIATE
Issues Surrounding Automated Health Information Exchanges (HIEs) on External Lab Resulting Developed in cooperation with Informatics Division	42128	52228	<b>David McClintock,</b> MD, Michigan Medicine, Ann Arbor, MI	BASIC
Use of Test Result Normalization to Allow Mobile Real-Time Reporting of Both POC and Central Laboratory Results Developed in cooperation with Informatics Division	42130	52230	<b>Kenneth Blick,</b> PhD, University of Oklahoma Health Sciences Center, Oklahoma City, OK	INTERMEDIATE
Genetic Testing for Immunodeficiency Disorders	42131	52231	Ann Moyer, MD, PhD, Mayo Clinic, Rochester, MN	INTERMEDIATE
Current Cybersecurity Threats, Medical Devices and the Clinical Laboratory Developed in cooperation with Informatics Division	42132	52232	<b>Sharon Geaghan,</b> MD, FRCP(c), ABP Informatics, Stanford University, Menlo Park, CA	BASIC
Retrospective Analysis of Drugs in Patient Urine Assists in the Assessment of Patient Adherence and Improves Lab Operation	42133	52233	<b>Sheng Feng,</b> PhD, Hospital of the University of Pennsylvania, Philadelphia, PA	INTERMEDIATE
Drug Screening in Maternal and Newborn Populations	42134	52234	<b>Stephen Roper,</b> Washington University School of Medicine, St. Louis, Missouri	INTERMEDIATE

#### **GLOBAL LAB QUALITY INITIATIVE WORKSHOP**

#### 9:00-17:15 Room: California A, Hilton Anaheim

#### Taller de la Iniciativa Mundial de Calidad de Laboratorio Clínico: Manejo de riesgos en el laboratorio clínico: Herramientas para asegurar resultados de alta calidad

**RESUMEN DE LA SESIÓN:** Los análisis de laboratorio están sujetos a errores en la fase preanalítica, analítica y post analítica, que podrían causar daño al paciente. Asi mismo, la seguridad del paciente ha sido considerada un problema global de salud pública. No existe un esquema único de aseguramiento y control de calidad para mitigar los riesgos de los análisis de laboratorio. Por ello, el diseñar un plan de aseguramiento y control de calidad en base a manejo de riesgos para minimizar estos errores y mitigar los riesgos, es un elemento clave para mantener y mejorar las buenas prácticas de laboratorio.

Esta sesión está dirigida a científicos de laboratorio, tecnólogos médicos, supervisores, gerentes, directores, patólogos clínicos, y profesionales de química clínica.

#### INSCRIPCIÓN

La tarifa de inscripción es de \$35 dólares antes del 20 de junio y \$50 dólares después esta fecha. El espacio está limitado a los primeros 100 inscritos. El registro incluye el taller y el almuerzo.

#### **MEET THE EXPERT**

#### 10:30am-11:30am

Translating Genes, Brain and **Behavior: A Next-Generation Human** Framework

62102 Room: 210C

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 1

#### **SPEAKER**

Julie Korenberg, MD, PHD

representatives.

**SPEAKERS** 

#### **SCIENTIFIC SESSIONS**

**MEET THE EXPERT** 

#### 10:30am-11:30am

**Biomarker Discovery: From Technology Development to Clinical** Applications

62101 Room: 210B

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 1

SESSION OVERVIEW: This session will provide an excellent opportunity for attendees to meet with Dr. Walt in a more intimate setting and listen to him discuss his talk, "Biomarker Discovery: From Technology Development to Clinical Applications."

Т

INTENDED AUDIENCE: This session is intended for pathologists, lab directors, clinical chemists, technologists, physicians and IVD industry scientists with an interest in biomarker discovery and translating research from academia to routine clinical settings.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Understand how new technologies can accelerate biomarker discovery.
- 2. Realize that there are multiple challenges and barriers to implementing these new technologies for impactful diagnostic tests.

#### **SPEAKER**

David R. Walt, PhD

Harvard Medical School & Wyss Institute for Bioinspired Engineering at Harvard University, Boston MA

#### MORNING

10:30am-12:00pm

**Ethical Issues in Laboratory** Medicine

32101 Room: 207AB

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 1.5

#### MODERATOR

Carey-Ann Burnham, PhD Washington University School of Medicine, St. Louis, MO

Developed in cooperation with Management Sciences and Patient Safety Division

> Ethical Issues in Emerging Infections and the Clinical Laboratory Sheldon Campbell, PhD, MD Yale School of Medicine, West Haven, CT

**SESSION OVERVIEW:** This session will provide an excellent opportunity for attendees to meet with Prof. Korenberg in a more intimate setting and listen to her discuss her talk, "Translating Genes, Brain and Behavior: A Next-Generation Human Framework."

INTENDED AUDIENCE: This session is intended for pathologists, lab directors, clinical chemists, molecular biologists, technologists, physicians and IVD industry scientists with interests in brain diagnostics and therapeutics.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Understand how human genetic analyses of DNA, RNA, and protein can be used to describe individuals with brain disease.

2. Understand that rare individuals, with only subsets of genes imbalanced, exist and can be used to evaluate the genetic contributions of their gene differences to their phenotypes, in ways similar to knockout or transgenic mice.

3. Understand three types of neural imaging with magnetic resonance (MRI) that generate different brain information: volumetric, functional, and diffusion spectrum imaging (used for tractography or neural circuit definition).

University of Utah, Salt Lake City, UT

SESSION OVERVIEW: Ethical issues in laboratory medicine have been given limited attention by professionals in laboratory medicine. The first talk in this session will describe the basics of biomedical ethics, along with a review of the history of biomedical ethics and the core principles of modern biomedical ethics, including autonomy, beneficence (nonmaleficence) and justice. The second session will examine the ethics of emerging infections and the clinical laboratory in light of those core principles. Both sessions will use interactive case studies to illustrate their points.

**INTENDED AUDIENCE:** This session is intended for laboratory directors, clinical chemists, pathologists, physicians, laboratory medicine residents and fellows, and IVD industry

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Describe the guiding principles of bioethics.

2. Explain some of the ethical issues facing laboratory medicine today.

3. Describe emerging infectious disease risks to laboratories in the context of historical responses to infection and historical outbreaks.

4. Recognize the ethical value conflicts and knowledge gaps involved in laboratory response to emerging infections.

#### Ethical Issues in Laboratory Medicine

Ann Gronowski, PhD, DABCC Washington University School of Medicine, St. Louis, MO

#### **SCIENTIFIC SESSIONS**

#### MORNING

#### 10:30am-12:00pm

The Quest for Laboratory Quality through Competency Assessment

32102 Room: 206AB

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 1.5

#### **MODERATOR/SPEAKER**

Elia Mears, BHS, MS, MT (ASCP) SM The Joint Commission, Houma, LA

#### 10:30am-12:00pm

**Clinical Utilization of D-Dimer Testing: Practical Guidance to** Reduce Unnecessary Imaging **Procedures While Improving** Patient Care and Optimizing Healthcare Resources

32104

Room: 204A

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 1.5

Developed in cooperation with Hematology and Coagulation Division

#### MODERATOR

#### Sean Campbell, PhD Montefiore Medical Center, Bronx, NY

SESSION OVERVIEW: Regardless of the simplicity of laboratory tests, errors can occur if not performed correctly, leading to significant patient harm. Competency assessment is a focused approach to achieve confirmation that personnel training is effective. In addition, established procedures produce quality results. All testing personnel, including nursing staff and physician providers, are required to be assessed for competency. This session will discuss regulatory requirements associated with competency. Further, strategies focused on the design and integration of competency assessment programs into the laboratory's quality management plan will be discussed.

**INTENDED AUDIENCE:** This session is intended for pathologists, laboratory directors, laboratory managers, laboratory supervisors, point-of-care coordinators, medical technologists, clinical laboratory scientists and other testing personnel.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Evaluate competency of testing personnel utilizing the regulatory assessment criteria.
- 2. Identify who is qualified to perform the assessment.
- 3. Integrate a competency assessment program as part of the laboratory's Quality Management Plan.

#### **SPEAKER**

#### The Quest for Laboratory Quality through Competency Assessment Elia Mears, MS, MT (ASCP) SM

The Joint Commission, Houma, LA

SESSION OVERVIEW: Pathological blood clots, known as venous thromboembolism, include both deep venous thrombosis (DVT) and pulmonary embolism (PE). These are lifethreatening conditions that require rapid actions for proper diagnosis and treatment. Clinical guidelines recommend the use of pretest probability scoring along with high-sensitivity D-dimer laboratory assays to screen for DVT and PE in patients presenting to the emergency room. This session will address institutional experiences and translational clinical research studies to fill knowledge gaps and provide actionable findings.

INTENDED AUDIENCE: This session is intended for clinical chemists, medical technologists, laboratory supervisors, laboratory directors, pathologists, hematologists, primary care physicians and hospital pharmacists.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Discuss the epidemiology and pathophysiology of VTE/PE/DVT.
- 2. Present clinical guidelines regarding use of PTP and D-dimer methods to screen DVT and PE in at-risk patients.
- 3. Illustrate case studies and institutional experience highlighting use of pretest probability and D-dimer to properly stratify patient risk and improve long-term outcomes.
- 4. Assess laboratory pitfalls regarding D-dimer reporting and commonly encountered issues potentially leading to clinician confusion and non-ideal patient outcomes.

#### **SPEAKERS**

#### Pathophysiology and Utility of the D-Dimer Assay in an Emergency Clinical Setting Jeffrev Kline, MD

IU School of Medicine, Indianapolis, IN

D-Dimer Utilization at Montefiore Medical Center: Perspectives from the Laboratory Morayma Reyes-Gil, MD, PhD

Montefiore Medical Center, Bronx, NY

#### 10:30am-12:00pm

Universal Non-Targeted HCV Screening and Linkage to Care: **Emergency Department and** Laboratory Perspectives on Design, Implementation, and Results

32105 Room: 205AB

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 1.5

#### **MODERATOR/SPEAKER**

James Moore, MD, FACEP UK HealthCare, Lexington, KY

policy experts.

# patients in the United States.

and treatment.

#### **SPEAKERS**

# James Moore, MD, FACEP

UK HealthCare, Lexington, KY

Adult Emergency Department (ED) Universal Non-Targeted HCV Screening: A Laboratorian's Guide to Providing Accurate and Comprehensive HCV Testing Results That Affect Patient Care Morgan McCoy, MD, PhD University of Kentucky, Lexington, KY





SESSION OVERVIEW: This session will discuss the value of implementing a non-targeted hepatitis C virus (HCV) screening program, with direct linkage-to-care, within a large academic medical center. A multi-disciplinary approach to HCV screening will be described to demonstrate its effectiveness in designing, developing, implementing, measuring clinical success, and improving patient outcomes. Laboratory data and its impact on clinical care will be presented, with a focus on contemporary quality metrics.

**INTENDED AUDIENCE:** This session is intended for clinical chemists, physicians (pathology, emergency medicine, primary care, gastrointestinal medicine, infectious disease, public health, behavioral health, addiction specialists), medical directors, hospital executives, and

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Identify benefits to a non-targeted ED HCV screening program with linkage-to-care for
- 2. Discuss needs and expectations for such a program from the perspective of the ED physician and other ED care givers, including their role in implementation.
- 3. Discuss needs and expectations for such a program from the perspective of the clinical laboratory medical director and other laboratorians, including their role in implementation.
- 4. Identify strategies to close the gap between current healthcare limitations regarding identifying patients at risk, diagnosing HCV infection, and connecting patients with care

5. Recognize the financial impact a non-targeted ED HCV screening program with a linkageto-care program could have on a healthcare system and patient quality of life.

Adult Emergency Department (ED) Universal Non-Targeted HCV Screening: An Emergency Physician's Perspective Addressing Public Health While Not Affecting Patient Flow



#### **SCIENTIFIC SESSIONS**

#### MORNING

#### 10:30am-12:00pm

Predicting and Diagnosing **Gestational Diabetes Mellitus** (GDM): Are We Making Progress?

32106 Room: 209AB

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 1.5

#### **MODERATOR/SPEAKER**

David Sacks, MD National Institutes of Health. Bethesda, MD

Developed in cooperation with American Diabetes Association

**SESSION OVERVIEW:** Glucose intolerance with onset or first recognition of pregnancy is termed gestational diabetes mellitus (GDM). Both the fetus and the mother develop complications, which are reduced by therapy. Nevertheless, there is controversy surrounding the optimal screening and diagnostic strategies for GDM. Both the screening and diagnostic criteria vary among countries and between obstetric and diabetes organizations in a single country. In addition, there has been substantial interest over the last few years in earlier detection of GDM (i.e., before the current evaluation at 24-28 weeks of gestation). This session will review screening and diagnostic approaches for GDM, including early prediction strategies.

INTENDED AUDIENCE: This session is intended for pathologists, lab directors, clinical chemists, technologists, IVD industry scientists, students, trainees and endocrinologists.

**LEARNING OBJECTIVES:** After this session, participants will be able to:

1. Describe methods for screening and diagnosing GDM.

2. List advantages and limitations of the two most widely used GDM diagnostic criteria.

3. Discuss rationale and approach to early diagnosis of GDM.

#### SPEAKERS

We Should Use the IADPSG to Detect GDM Florence Brown, MD Joslin Diabetes Center, Boston, MA

We Should Use the Two-Step Method to Detect GDM Amy Valent, D.O. Oregon Health and Sciences University, Portland, OR

Let's Not Wait: Predicting GDM in the First Trimester David Sacks, MD National Institutes of Health, Bethesda, MD

#### 10:30am-12:00pm

Data Science and AI in Laboratory Medicine: What You Should Know Now and Will Need to Know in the Future

32107 Room: 207CD

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 1.5

#### MODERATOR/SPEAKER

Daniel Herman, MD, PhD University of Pennsylvania, Philadelphia, PA

laboratorians.

- 1. Identify factors to consider when evaluating commercially available or laboratorydeveloped clinical multi-variable models or multi-analyte assays. 2. Describe different methods for time series prediction, as well as differences and
- requirements for each. 3. Recognize how decisions they make in the laboratory affect secondary use of data for clinical data science.
- data science.
- delivery.

#### **SPEAKERS**

Disease Daniel Herman, MD, PhD

Jason Baron, MD

Medicine Tyllis Chang, MD, CP

#### FOLLOW AACC @ AACC AND USE THE HASHTAG #2019AACC TO JOIN THE CONVERSATION.





SESSION OVERVIEW: As laboratorians, we report countless patient results. These data, in aggregate, can be leveraged to achieve operational and clinical goals. Much attention has been focused on the incorporation of machine learning and artificial intelligence (AI) into healthcare. But beyond analytics, realizing data-driven clinical goals requires clinical expertise and forward-looking data collection, storage, and access. This session will review the application of AI in laboratory medicine, drawing from the literature and speakers' experiences. We will also illustrate the data science process, applied to clinical data, comparing it to laboratory medicine practice, and will highlight the critical roles for

**INTENDED AUDIENCE:** This session is intended for pathologists, laboratory directors, clinical chemists, and academic and industry scientists.

**LEARNING OBJECTIVES:** After this session, participants will be able to:

- 4. Identify potential aspects of their own laboratories that could be enhanced through clinical

5. Realize some valuable secondary uses of data for the enhancement of medical care

#### How to Use Laboratory and Other Electronic Health Record Data to Screen for Undiagnosed

University of Pennsylvania, Philadelphia, PA

#### Applying Machine Learning to Clinical Laboratory Data to Identify Anomalies, Integrate Information and Enhance Laboratory Diagnosis

Massachusetts General Hospital, Boston, MA

#### Lab Medicine Beyond the Lab: Applying Lab Data and Data Science to Further the Practice of

Clinical Informatics (ABP), Northwell Health Laboratories, Lake Success, NY

#### **PRESIDENT'S INVITED SESSION**

#### 10:30am-12:00pm

Beyond the Clinical Laboratory **Director: Careers for Clinical** Chemists

32108 Room: 204B

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 1.5

#### MODERATOR

Carmen Wiley, PhD, DABCC, FAACC VERAVAS, Inc., Spokane, WA

SESSION OVERVIEW: This will be a panel discussion where each panelist will share his or her career experience outside of the traditional laboratory director. This will be followed by a moderated panel discussion where the participants' questions on how to explore other career opportunities in laboratory medicine will be answered.

INTENDED AUDIENCE: This session is intended for physicians, laboratory directors, clinical laboratory scientists/medical technologists, residents/fellows and IVD industry.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. List the career opportunities available for clinical chemists.

2. Describe what roles clinical chemists play in these careers.

3. Create a plan for exploring these career opportunities.

#### **SPEAKERS**

My Career Beyond the Clinical Laboratory Director Sky Countryman, BS InSource Diagnostics, Monrovia, CA

My Career Beyond the Clinical Laboratory Director Nathan Gochman, PhD, FAACC Consultant, Anaheim, CA

My Career Beyond the Clinical Laboratory Director Susan Evans, PhD, FAACC BioDecisions Consulting, Los Gatos, CA

#### **SCIENTIFIC SESSIONS**

#### **MID-DAY**

#### 12:30pm-2:00pm

Highlighting the Emerging Role of Anti-Müllerian Hormone (AMH) in Ovarian Reserve, Assisted Reproduction, Polycystic Ovary Syndrome (PCOS), and Other Diseases

32431 Room: 204C

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 1.5

#### **MODERATOR/SPEAKER**

Candice Ulmer, PhD Centers for Disease Control and Prevention, Atlanta, GA

Developed in cooperation with Endocrinology Division

SESSION OVERVIEW: This session will discuss the clinical utility of anti-Müllerian hormone (AMH) as an emerging biomarker for health status and certain diseases. In addition, challenges in AMH quantitation and current standardization efforts to improve the interpretation of results will be discussed.

INTENDED AUDIENCE: This session is intended for clinical chemists, pathologists, medical technologists, industry scientists, lab supervisors/managers and manufacturers.

**LEARNING OBJECTIVES:** After this session, participants will be able to:

- 1. Summarize the current clinical use of AMH measurements and recent advancements that highlight AMH as a putative biomarker.
- 2. Highlight the emerging biomarker potential of AMH for various diseases.
- 3. Identify current challenges in AMH testing and describe current harmonization/ standardization efforts for AMH immunoassays.

#### **SPEAKERS**

The Role of AMH in Ovarian Reserve, Assisted Reproduction, and Ovulatory Dysfunction in Polycystic Ovary Syndrome Joely Straseski, PhD, DABCC, MT (ASCP), FAACC University of Utah & ARUP Laboratories, Salt Lake City, UT

The Emerging Clinical Biomarker Potential of AMH and Its Connection to Various Diseases William Winter, MD, DABCC, FAACC University of Florida, Gainesville, FL

Current Challenges in AMH Quantitation and the Importance of Standardization in Improving the Clinical Use of AMH as a Biomarker Candice Ulmer, PhD Centers for Disease Control and Prevention, Atlanta, GA

#### 12:30pm-2:00pm

**Employee Engagement: It's More** Than Simply a Commitment to Patient Care

32432 Room: 207AB

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 1.5

#### **MODERATOR/SPEAKER**

12:30pm-2:00pm

Analytics

Room: 205AB

ACCENT<sup>®</sup> Credits: 1.5

**MODERATOR/SPEAKER** 

Medicine, St. Louis, MO

Saint Louis University School of

32433

Sepsis: Novel Biomarkers, New

Presentation Level: INTERMEDIATE

Technology, and Predictive

Cherie Petersen, BA ARUP Laboratories, Salt Lake City, UT

team

**SPEAKER** 

INTENDED AUDIENCE: This session is intended for clinical chemists, pathologists, IVD scientists, clinical laboratory scientists, medical directors and clinicians.

LEARNING OBJECTIVES: After this session, participants will be able to:

- T. Scott Isbell, PhD, DABCC, FAACC

**SPEAKERS** 

David Ford, PhD

Rapid Sepsis Diagnosis with Deformability Cytometry Dino DiCarlo, PhD University of California, Los Angeles, Los Angeles, CA

The Use of Predictive Analytics in Sepsis Management T. Scott Isbell, PhD, DABCC, FAACC Saint Louis University School of Medicine, St. Louis, MO

**SESSION OVERVIEW:** Are you struggling with employee engagement and finally realizing it's not enough to just say, "We do it because of our commitment to patient care"? Employee engagement and positive workplace morale are products of linking your organizational mission to the specific and meaningful work laboratorians perform. During this session, we'll use laboratory case studies to discuss successful strategies for engaging and connecting laboratorians to the meaningful work they perform as part of the healthcare

**INTENDED AUDIENCE:** This session is intended for the spectrum of laboratory professionals in leadership positions, or those who aspire to be in leadership positions.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Discover factors that motivate and engage employees in the workplace.

2. Recognize strategies for connecting employees to the meaningful work being performed by your laboratory organization and team.

3. Discuss opportunities for promoting positive morale based on knowledge gleaned from laboratory-specific case studies.

#### Employee Engagement: It's More Than Simply a Commitment to Patient Care Cherie Petersen, BA

ARUP Laboratories, Salt Lake City, UT

SESSION OVERVIEW: This session will highlight recent advances in our understanding and approach to the diagnosis and management of sepsis. Sepsis is the leading cause of in-hospital mortality, and is defined as life-threatening organ dysfunction caused by a deregulated host response to infection. There will be a specific focus on the pathophysiology and the utility of neutrophils as emerging biomarkers of sepsis. In addition, novel technologies and diagnostic approaches will be presented, including the use of predictive analytics in sepsis management.

1. Describe the potential use of chlorinated lipids as a sepsis biomarker.

2. Describe the potential point-of-care (POC) application of assessing neutrophil biophysics.

3. Describe how predictive analytics may be a useful tool in the management of sepsis.

#### Novel Chlorinated Lipids in Sepsis

Saint Louis University School of Medicine, St. Louis, MO

#### **SCIENTIFIC SESSIONS**

#### **MID-DAY**

#### 12:30pm-2:00pm

Value-Added Partnerships between Clinical Laboratorians and **Emergency Medicine Professionals** to Improve Patient Care

32434 Room: 207CD

Presentation Level: BASIC ACCENT<sup>®</sup> Credits: 1.5

#### **MODERATOR/SPEAKER**

Zhen Zhao, PhD, DABCC, FAACC Weill Cornell Medicine, New York, NY SESSION OVERVIEW: This session will use case studies, debate and skit formats to illustrate the successful alignment of emergency department (ED) patient care goals with clinical laboratory medicine capabilities at one large academic medical center. Leadership from both departments have identified areas of improvement in care delivery models and have collaboratively developed innovative strategies to advance clinical excellence and outcomebased institutional goals. This interdepartmental leadership team will share their experiences in developing award-winning patient care models and will provide recommendations for successful implementation of process improvement projects between patient-facing and clinician-facing departments.

INTENDED AUDIENCE: This session is intended for pathologists, emergency department medical directors, laboratory directors, clinical chemists, technologists, IVD industry scientists, and students.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Describe both the traditional and the new emergency team-based workflows and care models.
- 2. Discuss strategies and solutions of clinical laboratory and ED collaboration to support the new ED care models.
- 3. Explain the process and methods for quality improvement in both clinical laboratory and ED.

#### **SPEAKERS**

Joint Effort: Quality Improvement in ED and the Clinical Laboratory Zhen Zhao, PhD, DABCC, FAACC Weill Cornell Medicine, New York, NY

Shared Mission: Aligning ED Goals with Clinical Laboratory Capabilities Peter Steel, MA, MBBS Assistant Professor, Weill Cornell Medical Center, New York, NY

On-Demand POCT: Ambulance and Helicopter Testing in the Field James Nichols, PhD, DABCC, FAACC Vanderbilt University Medical Center, Nashville, TN

#### **AFTERNOON**

#### 2:15pm-4:15pm

**Quantitative Proteomics in Clinical** Care: Development, Deployment and Future Directions

32216 Room: 205AB

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 2

#### **MODERATOR**

Daniel Holmes, MD University of British Columbia, British Columbia, Canada

SESSION OVERVIEW: Compared to small molecule assays, the barriers to implementing quantitative mass spectrometry (MS) protein assays are higher due to the nature of the analyte. Quantitative MS protein assays require digestion and/or immunopurification. The speakers will discuss the analytical challenges of quantitative protein analysis by mass spectrometry and discuss successfully deployed assays, highlighting the advantages, challenges, and future opportunities with this technology.

**INTENDED AUDIENCE:** This session is intended for clinical chemists, clinical pathologists or medical laboratory technologists involved in or overseeing mass spectrometry assay development for application in a clinical environment.

trypsinization.

# **SPEAKERS**

**Opportunities** Christa Cobbaert, PhD

Advantages and Challenges of Immunoglobulin G Subclass Measurement by Mass Spectrometry over Immunonephelometry Andre Mattman, MD, FRCP(c) St. Paul's Hospital, Vancouver, Canada

Solving a Clinical Challenge: The Absolute Quantification of B-Type Natriuretic Peptide Proteolysis, a Key Heart Failure Diagnostic and Therapeutic, in Human Plasma by CE-MS Jennifer Van Eyk, PhD Cedars-Sinai Medical Center, Los Angeles, CA





LEARNING OBJECTIVES: After this session, participants will be able to:

1. Delineate challenges related to polymorphisms, post-translational modification, peptide selection, peptide time courses, and sensitivity of protein MS methods.

2. Outline how quantitative MS assays for proteins can be standardized according to calibration hierarchies in ISO 17511, enabling traceable protein test results.

3. Discuss the particular challenges that the matrix plays in the calibration of assays involving

4. Discuss the clinical and diagnostic advantages of mass spectrometry in relation to apolipoproteins and immunoglobulin subclasses.

5. Understand how proteins existing in complex mixtures proteoforms, like B-type natriuretic peptide, represent both a challenge and an opportunity for diagnosticians.

#### Metrological Traceability and MS-Based Apolipoprotein Quantification: Challenges and

Leiden University Medical Center, Etten-Leur, Netherlands

#### **SCIENTIFIC SESSIONS**

#### **AFTERNOON**

#### 2:15pm-4:15pm

**Providing Rapid PTH Measurements** During Parathyroid Surgery: Challenges, Clinical Utilization, and Future Needs

32217 Room: 207AB

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 2

#### **MODERATOR/SPEAKER**

John Toffaletti, PhD, DABCC Duke University Medical Center, Durham, NC

SESSION OVERVIEW: Rapid measurements of PTH during parathyroidectomies help quide removal of the appropriate amount of tissue. This need, coupled with the lack of suitable instrumentation, creates significant operational challenges for laboratories. Because PTH testing is not available on a handheld device, most PTH measurements are done on traditional chemistry testing platforms, with some located near the operating room. In this session, we will present our challenges in providing this service. In addition, an endocrine surgeon will present a video and cases that describe how physicians utilize laboratory and other tests to guide surgical removal of the appropriate amount of parathyroid tissue.

INTENDED AUDIENCE: This session is intended for laboratory scientists, pathologists, clinicians and persons from industry who desire to develop or refine their understanding of parathyroid surgery and the needs and challenges of providing rapid intraoperative measurements.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Describe the available instrumentation for rapid measurements of PTH and what improvements are needed for future instruments.
- 2. Evaluate intraoperative PTH measurements for successful removal of appropriate parathyroid tissue or adenoma.
- 3. Refine their ability to provide rapid PTH measurements at a particular institution.
- 4. Describe the basic processes in surgical removal of excess parathyroid tissue and understand how intraoperative PTH measurements minimize the need for more expensive frozen sections and fine needle aspirates.
- 5. Describe how physicians evaluate imaging scans in preparation for parathyroid surgery, use intraoperative PTH measurements to guide removal of parathyroid tissue/adenoma, and evaluate the success of parathyroid surgery.

#### **SPEAKERS**

Current Challenges and Future Needs of Providing Intraoperative PTH Measurements John Toffaletti, PhD, DABCC

Duke University Medical Center, Durham, NC

#### Experience with Implementing a Rapid Intraoperative PTH Method at Geisinger Medical Center

Hoi-Ying Yu, PhD, DABCC, FAACC Geisinger Health System, Danville, PA

#### Challenges of Successful Parathyroidectomy: Video and Case Discussions

Sanziana Roman, MD University of California, San Francisco, San Francisco, CA

#### 2:15pm-4:15pm

#### **Racing Against Time: Point-of-Care Testing in Mobile Health Settings**

32218 Room: 206AB

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 2

#### **MODERATOR/SPEAKER**

2:15pm-4:15pm

32219

DABCC

Room: 208AB

What's New in 2019?

**MODERATOR/SPEAKER** Alicia Algeciras-Schimnich, PhD,

Mayo Clinic, Rochester, MN

Anna Fuezery, PhD, DABCC, FCACB Laboratory Medicine & Pathology, Edmonton, Canada

Developed in cooperation with Critical and Point-of-Care Testing Division

**Biomarkers of Alzheimer's Disease:** 

Andrew Sargeant, BSc

**SPEAKERS** 

patient care.

such settings.

Ping Wang, PhD

SESSION OVERVIEW: Alzheimer's disease (AD) is a complex degenerative brain disease and the most common cause of dementia. Although no treatment is currently available, significant discovery efforts are underway. Diagnosis of AD is based on clinical features and supplemented by determination of biomarkers of AD pathology. During this session, an overview of AD will be provided, followed by discussion of diagnostic and management criteria. A review of the current CSF biomarkers and the future of plasma biomarkers will be presented. The session will close with a summary of the challenges and opportunities for AD biomarkers in clinical practice and laboratory operations.

#### **SPEAKERS**

Douglas Galasko, MD

Early Detection of Alzheimer's Disease Pathology Using CSF and Blood-Based Biomarkers: Prospects and Challenges for Use in Clinical Practice

Leslie Shaw, PhD, DABCC

Clinical Laboratory Implementation of Alzheimer's Disease Biomarkers: Pre-Analytical and Analytical Considerations Alicia Algeciras-Schimnich, PhD, DABCC Mayo Clinic, Rochester, MN



Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 2

SESSION OVERVIEW: This session examines point-of-care testing (POCT) in mobile health settings. The session begins with a brief overview of mobile health, after which it delves into the details of supporting POCT in three specific programs: a stroke ambulance, paramedic vehicles and a hospital in the home service. The session concludes with a discussion of emerging technologies and their predicted impact on POCT in mobile settings.

**INTENDED AUDIENCE:** This session is intended for laboratory directors, clinical chemists, POCT coordinators and laboratory medicine trainees.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Define the concept of mobile health, list its key components, and explain its benefits to

2. Discuss the role of POCT in mobile health and the issues associated with its support in

3. Discuss emerging technologies and their predicted impact on POCT in mobile settings.

Point-of-Care Testing in Mobile Health: Where Are We Now and Where Do We Need to Go? Anna Fuezery, PhD, DABCC, FCACB Laboratory Medicine & Pathology, Edmonton, Canada

Point-of-Care Testing Projects in Mobile Settings-Learnings from Initiatives Supporting Australian Paramedic and Hospital in the Home Services

NSW Health Pathology, Newcastle, Australia

#### Emerging Point-of-Care Technologies for Mobile Diagnostics and Connected Health

University of Pennsylvania, Philadelphia, PA

INTENDED AUDIENCE: This session is intended for pathologists, clinical chemists, medical technologists, physicians, IVD industry scientists, trainees, residents, and students.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Describe basic aspects of Alzheimer's disease pathobiology, current diagnostic criteria, and disease management strategies.

2. Discuss current clinical practice involving Alzheimer's disease biomarkers.

3. Demonstrate knowledge of Alzheimer's disease biomarkers' advantages and limitations.

#### Current Clinical, Diagnostic and Staging Criteria for Alzheimer's Disease

University of California, San Diego, La Jolla, CA

Hospital of University of Pennsylvania, Philadelphia, PA

#### **SCIENTIFIC SESSIONS**

#### **AFTERNOON**

#### 2:15pm-4:15pm

**Opioids and Beyond: The Clinical** Laboratory's Role in the Opioid Epidemic

32220 Room: 204C

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 2

#### MODERATOR

Sara Love, PhD, DABCC Hennepin Healthcare, Minnepolis, MN

Developed in cooperation with TDM and Toxicology Division

SESSION OVERVIEW: Toxicology testing for opioid compliance and abuse impacts both clinicians and laboratorians, with increased testing demands across the scope of care. Accurate interpretation of results is often a source of discussion and generates questions from the patient care team. This session will describe the clinical needs and testing approaches for opioid assessment, providing common challenges and solutions for both community and specialty hospital laboratories. The session will use an interactive, casebased approach.

**INTENDED AUDIENCE:** This session is intended for medical technologists, laboratory supervisors and managers, laboratory directors, clinical toxicologists, clinicians, and industry scientists.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Lists common challenges/limitations encountered in opioid testing.

2. List two different practices that may be used to support toxicology testing for opioids.

3. Explain how teamwork between laboratorians and clinicians can help streamline toxicology testing.

4. Answer common clinical questions regarding opioid testing.

#### **SPEAKERS**

Opioids and Beyond: The Clinician Perspective Ann Arens, MD Hennepin County Medical Center, Minneapolis, MN

Opioids and Beyond: The Clinical Chemist Perspective Sarah Wheeler, PhD, NRCC, FAACC University of Pittsburgh Medical Center, Pittsburgh, PA

Opioids and Beyond: The Analytical Toxicologist Perspective Jennifer Colby, PhD, DABCC, FAACC Vanderbilt University Medical Center, Nashville, TN

Opioids and Beyond: Common Questions and an Interactive Series of Cases, Utilizing Audience Response Technology Ann Arens, MD Hennepin County Medical Center, Minneapolis, MN





#### 2:15pm-4:15pm

#### **Cardiovascular Precision Medicine:** The Laboratory's Role in Advancing **Personalized Patient Care**

32222 Room: 207CD

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 2

#### **MODERATOR/SPEAKER**

Jing Cao, PhD, DABCC, FAACC Texas Children's Hospital, Houston, TX

Developed in cooperation with Lipoproteins and Vascular Diseases Divisions; Personalized Medicine Division

#### **SPEAKERS**

professionals.

Alan Remaley, MD, PhD

Lipid Profile

Lp(a) Jing Cao, PhD, DABCC, FAACC

Alan Remaley, MD, PhD National Institutes of Health, Bethesda, MD

SESSION OVERVIEW: Mass spectrometry is a maturing platform for diagnosis and discovery. This late-breaking session highlights three areas where mass spectrometry allows for a better understanding of pathophysiology and expands our definition of "biomarker." Indicators of recent cannabis use, based on results from a clinical trial evaluating the effect of marijuana on driving performance, will be presented. The second talk demonstrates how a novel combination of elemental mass spectrometry enables massively multiplexed single cell analysis to provide insights into pathobiology. The last presentation reveals how activity metabolomics influences other omics and, by extension, reveals the active role of metabolites in disease states.

**INTENDED AUDIENCE:** This session is intended for clinical chemists, clinical and forensic toxicologists, pathologists, physicians, trainees, residents, and students.

- - events

#### **SPEAKERS**

Robert Fitzgerald, DABCC, NRCC, FAACC University of California, San Diego, San Diego, CA

Sean Bendall, PhD

Gary Siuzdak, PhD Scripps Research, La Jolla, CA



Room: 204A


2:15pm-4:15pm

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 2

#### **MODERATOR/SPEAKER**

#### Robert Fitzgerald, DABCC, NRCC, FAACC

University of California, San Diego, San Diego, CA



Marijuana, Metabolomics, and

Multiplexed Imaging—Late-

32224

SESSION OVERVIEW: Our increased understanding of common risk factors of cardiovascular diseases (CVD) has contributed to the declining mortality rate in the U.S. during the past several decades. Residual risk factors may now be addressed through precision medicine. This session will discuss the role of the laboratory and electronic medical record systems in advancing personalized medicine approaches for diagnosis and treatment of cardiovascular disease including a discussion of new lipid guidelines, implementing non-traditional CVD risk assessments, and the role of the laboratory in guiding physicians in their management of patients with CVD.

**INTENDED AUDIENCE:** This session is intended for laboratory professionals including laboratory directors, laboratory managers or supervisors, scientists, technologists, and IVD

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Discuss the salient features of new cholesterol guidelines and the emphasis on personalized medicine approaches to CVD risk.

2. Analyze benefits and drawbacks of novel CVD risk factor assays including apo B, Lp(a), CRP, microalbuminuria and the role of the clinical laboratory in identification of riskenhancing factors.

3. Discuss the role of the laboratory in harnessing tools and, along with data from electronic health records, in management of patients who are on non-statin lipid lowering therapies.

#### Survey on Laboratory Testing in Preventive Cardiovascular

National Institutes of Health, Bethesda, MD

#### Personalized Approaches in the New Cholesterol Guidelines—Moving Beyond the Standard

Sridevi Devaraj, PhD, DABCC, FAACC, FRSC Texas Children's Hospital and Baylor Medical Center, Houston, TX

#### Utility of Non-Traditional CVD Risk Factor Assays in Clinical Laboratories, Focus on Apo B and

Texas Children's Hospital, Houston, TX

#### Managing Cardiovascular Risk in the Era of Non-Statin Lipid Lowering Therapies

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Describe markers of recent marijuana use in blood, oral fluid, and breath samples.

2. Explain how multiple types of metabolomics data can be used to predict pathological

3. Describe how multiplexed ion beam imaging can be used as an improved tool for immunohistochemistry imaging of tissue for clinical diagnostics.

#### Markers of Recent Marijuana Use Relative to Driving Performance

Massively Multiplexed Single Cell Analysis to Predict and Control Pathobiology

Stanford University School of Medicine, Palo Alto, CA

#### Activity Metabolomics: Identifying Metabolites That Alter Physiology

#### **CHAIR'S INVITED SESSION**

#### 2:15pm-4:15pm

#### **Race, Genomics and Medicine**

32223 Room: 204B

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 2

#### MODERATOR

Timothy Amukele, MD, PhD Johns Hopkins School of Medicine, Baltimore, MD

SESSION OVERVIEW: Historically, the practice of medicine has used race as a biologic variable in the diagnosis, management and treatment of patients. Race continues to be used as a factor in the practice of medicine and scientific research; however, it has become clear that race as a biologic variable is not supported by genomics. This session will cover the history of race-based medicine, the current health disparities in genomic medicine, and the future of genomics research.

**INTENDED AUDIENCE:** This session is intended for clinicians, pathologists, laboratory directors, clinical chemists, fellows and trainees, medical technologists, and research scientists. Anyone involved in patient care, research and development, healthcare management, or health policy will benefit.

**LEARNING OBJECTIVES:** After this session, participants will be able to:

1. Appreciate human biologic diversity and its implications for evidence-based medicine.

- 2. Understand how statistical approaches inform hypotheses about essential differences between racial/ethnic groups.
- 3. Identify how ethnicity influences genetic risk.
- 4. Avoid common errors in clinical decision making based on misunderstandings of genetics.
- 5. Understand some of the emerging clinical areas in which genomic medicine is being implemented.

#### **SPEAKERS**

Foundations and Consequences of Race-Based Medicine: Primum Non Nocere Jay Kaufman, PhD McGill University, Montreal, Canada

Health Care Disparities Despite Best Intentions in the Genomic Era Isaac Kohane, MD, PhD Harvard University, Boston, MA

The Human Genome Project Was Just the Beginning: Research at "The Forefront of Genomics" Eric Green, MD, PhD National Human Genome Research Institute, Bethesda, MD







#### **SPECIAL SESSION**

4:30pm-6:00pm Room: Ballroom ABC

#### 2019 AACC Disruptive Technology Award Competition

12002 Presentation Level: BASIC | ACCENT® Credits: 1.5

Supported by LabCorp

SESSION OVERVIEW: The Disruptive Technology Award Competition searches for the next innovative testing solution that will improve patient care through diagnostic performance or access to high-guality testing. It provides an opportunity for early to mid-stage start-ups in the medical device, diagnostic, or digital health/health IT spaces to showcase their technology and present to a large audience and a panel of judges. Three finalists will present lectures showing detailed data supporting the performance of their novel development. They will be judged for clinical validity, patient impact, market opportunity, business model, competitive analysis, IP strength, regulatory plan, team strength and stage of development.

INTENDED AUDIENCE: This session is intended for clinical chemists, IVD industry scientists, laboratory directors, laboratory technologists, medical technologists and pathologists.

**LEARNING OBJECTIVES:** After this session, participants will be able to:

1. Describe and evaluate the latest advances in medical technologies. 2. Assess the technology level readiness of attractive innovations. 3. Assess what investors and strategic partners in this field are looking for from these ventures.

#### **JUDGES:**



#### Mary Amor

Head Ventures & Business Development, Siemens Healthineers, New York, NY

#### Kelly Chun



Vice President & Scientific Director, Specialty Medicine, Laboratory Corporation of America, Calabasas, CA

### Terry Fetterhoff



Senior Director, Technology Management, Head, U.S. Chief Technology Office, Hoffmann-La Roche, Inc., Pleasanton, CA

#### **FINALISTS:**



Tim Sweeney, MD, PhD Inflammatix, Burlingame, CA



Avishay Bransky, PhD

PixCell Medical Ltd., Yokneam Ilit, Israel



#### Scott Garrett

Senior Operating Partner, Water Street Healthcare Partners, Chicago, IL

#### Evan Norton

Divisional Vice President and Director of Abbott Ventures, Abbott Laboratories, Chicago, IL



Athurva Gore, PhD Singlera Genomics, La Jolla, CA

# TUESDAY **AUGUST 6**

## **PLENARY & SCIENTIFIC SESSIONS**



# **TUESDAY** | AUGUST 6

### **PLENARY SESSION**



#### Using Biomarkers to Tailor Treatment for Breast Cancer

8:45am-10:15am Room: Ballroom ABC

13001

**SESSION OVERVIEW:** Treatment of breast cancer has evolved in the past several years. The estrogen receptor has been used to select patients who are candidates for endocrine therapy. Genomic assays are currently being used to select patients who may not benefit from chemotherapy in the early-stage setting. Markers such as PIK3CA mutations, PD-L1 staining and ESR1 mutations select patients who may benefit from targeted therapies or may have tumors resistant to other therapies. Breast cancer evolves, and this evolution leads to emergence of resistance.

- prognosis.

#### Virginia Kaklamani, MD, DSc.

UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX

#### Presentation Level: BASIC | ACCENT<sup>®</sup> Credits: 1

INTENDED AUDIENCE: This session is intended for pathologists, lab directors, endocrinologists, clinical chemists, technologists, physicians, and IVD industry scientists with interests in breast cancer and breast cancer testing and therapy.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Understand the role of genomic assays for breast cancer prediction and

2. Understand the role of targeted endocrine therapy.

3. Understand novel agents for triple negative breast cancer.

**ROUNDTABLE SESSIONS** 

Registration fees apply for each course.

7:30am-8:30am (40000 Series) or 12:30pm-1:30pm (50000 Series)

Roundtable sessions are presented twice daily. Attendance is limited to 10 participants per session. Advance registration and session fees are required. AACC does not provide meals for these sessions. You will be able to purchase your own food in the convention center prior to the session.

ACCENT® Credit: 1.0 (per session) unless otherwise noted in the mobile app, or at www.2019aacc.org | ACC, Ballroom DE

SESSION #							
TITLE	AM	РМ	SPEAKER	LEVEL			
Challenges of Quality Control in Modern Analytical Systems	43101	53201	<b>Oswald Sonntag,</b> PhD, Sonntag, Eichenau, Germany	BASIC			
Artificial Intelligence and Data Science in Laboratory Medicine: Perspectives and Challenges	43102	53202	<b>Damien Gruson,</b> PhD, Cliniques Universitaires Saint-Luc, Kraainem, Belgium	INTERMEDIATE			
Serum Proteins following Autologous Hematopoietic Stem Cell Transplantation	43103	53203	<b>Gurmukh Singh,</b> MD, PhD, MBA, Augusta University Medical Center Inc., Augusta, GA	ADVANCED			
Take Uncertainty Estimation into Your Own Hands with a New NIST Statistical Application	43105	53205	Johanna Camara, PhD, NIST, Gaithersburg, MD	BASIC			
Can You Substitute Diesel with Gas in Your Car? The Story of Active Vitamin B12 and Total Vitamin B12	43106	53206	<b>Barnali Das,</b> MD, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India	BASIC			
Utility and Challenge of Intra-Operative Parathyroid Hormone Assays	43107	53207	<b>Jieli Li,</b> MD, PhD, MD Anderson Cancer Center, Houston, TX	BASIC			
Perspectives to Improve Clinically Relevant Intra- Individual Variability in Intact PTH Immunoassay Results from Patients on Dialysis	43108	53208	<b>Hana Klassen Vakili,</b> PhD, University of Texas Southwestern Medical Center, Dallas, TX	INTERMEDIATE			
Rule-Based Strategies for Laboratory Utilization Stewardship	43109	53209	<b>Ron Schifman,</b> MD, Southern Arizona VA Healthcare System, Tucson, AZ	INTERMEDIATE			
Optimizing Testing for Transgender Patients	43111	53211	<b>Grace Kroner,</b> PhD, University of Utah/ARUP Laboratories, Salt Lake City, UT	BASIC			
Let's Make It Easier to Get Things Right: Controlling Preanalytical Variation in Laboratory Testing	43112	53212	<b>Emily Garnett,</b> PhD, Baylor College of Medicine, Houston, TX	BASIC			
<b>Von Willebrand Disease: Laboratory Investigation and Clinical Correlation</b> Developed in cooperation with Hematology and Coagulation Division	43113	53213	<b>John Mitsios,</b> PhD, BioReference Laboratories, Elmwood Park, NJ	INTERMEDIATE			
Effective Clinical Decision Making through Use of Probability Theory	43114	53214	<b>Paul Johnson,</b> MPhD, DABCC, MT (ASCP), SUNY Upstate Medical University, Syracuse, NY	BASIC			
Non-Invasive Prenatal Testing: Utilization of Cell-Free DNA in Fetal Aneuploidy Screening and Beyond	43115	53215	<b>Anu Maharjan,</b> PhD, University of Utah, Salt Lake City, UT	BASIC			
Preeclampsia Screening and Diagnosis: A Novel Approach	43116	53216	<b>Saswati Das,</b> MD, Ram Manohar Lohia Hospital, Delhi, India	INTERMEDIATE			

Current Methods in Toxicology: What Approach Should My Lab Use for Urine Drug Testing?	43117	53217	<b>Melissa Budelier,</b> PhD, Washington University in St. Louis, St. Louis, MO	BASIC
ANA Testing: The Renaissance of Indirect Immunofluorescence Assay (IFA)	43120	53220	Vincent Ricchiuti, PhD, LabCorp, Dublin, OH	INTERMEDIATE
Emerging Trends in Glomerular Filtration Rate Measurements for Kidney Transplant Evaluation	43121	53221	<b>Rongrong Huang,</b> PhD, Houston Methodist Hospital, Houston, TX	BASIC
The CDC Vitamin D Standardization-Certification Program (CDC VDSCP)—Improving the Clinical Measurement of Total 25-Hydroxyvitamin D	43122	53222	<b>Otoe Sugahara,</b> PhD, Centers for Disease Control and Prevention, Atlanta, GA	INTERMEDIATE
The CDC Hormone Standardization (HoSt) Program— Improving Clinical Measurements of Testosterone and Estradiol	43123	53223	<b>Krista Poynter,</b> PhD, Centers for Disease Control and Prevention, Atlanta, GA	INTERMEDIATE
Assay Interference by Topical Pharmaceuticals: Challenges in Identifying and Eliminating Contaminants in the Laboratory Workspace	43124	53224	<b>Jonathan Genzen,</b> MD, PhD, University of Utah/ ARUP Laboratories, Salt Lake City, UT	BASIC
Moving towards ISO: Hospital Accreditation Differences between DNV and the Joint Commission	43125	53225	<b>Emily Ryan,</b> MSc, PhD, DABCC, The Medical Center Navicent Health, Macon, GA	BASIC
Thyroid Testing During Pregnancy: Current Recommendations and Pitfalls	43126	53226	<b>Aaron Geno,</b> PhD, Dartmouth-Hitchcock Medical Center, Lebanon, NH	BASIC
Copeptin and Its Role in the Assessment of Water Balance and Cardiac Disorders	43127	53227	<b>Joshua Bornhorst,</b> PhD, DABCC, Mayo Clinic, Rochester, MN	INTERMEDIATE
Estimating LDL Equations: Time to Ditch Friedewald?	43128	53228	<b>Joe El-Khoury,</b> PhD, DABCC, FAACC, Yale University, New Haven, CT	INTERMEDIATE
Innovative, High-Throughput Methods to Identify Novel Cancer Metabolites	43129	53229	<b>Andria Denmon,</b> PhD, Fullerton College, Fullerton, CA	ADVANCED
Macromolecules: Big Complexes That Cause Big Problems	43130	53230	<b>Sara Wyness,</b> ASCP, ARUP Laboratories, Salt Lake City, UT	BASIC
Quality Challenges for Global Laboratory Medicine	43131	53231	<b>Praveen Sharma,</b> PhD, All India Institute Of Medical Sciences, Jodhpur, India	BASIC
The Use and Misuse of Procalcitonin in Clinical Practice	43132	53232	<b>Nikolina Babic,</b> PhD, Medical University of South Carolina, Charleston, SC	BASIC
Regulatory and Ethical Considerations for Computational Pathology Data Use Developed in cooperation with Industry Division	43133	53233	<b>David McClintock,</b> MD, Michigan Medicine, Ann Arbor, MI	BASIC
The Electronic Health Record and Transgender Care Developed in cooperation with Informatics Division	43134	53234	<b>Sharon Geaghan,</b> MD, FRCP(c), ABP Informatics, Stanford University, Menlo Park, CA	BASIC
Detecting Small-Molecule Analytes in Oral Fluid by LC-MS/MS: Matrix-Specific Factors to Consider for Assay Development	43135	53235	<b>Adina Badea,</b> PhD, UCSF/SFGH, San Francisco, CA	BASIC

#### **MEET THE EXPERT**

10:30am-11:30 am

Using Biomarkers to Tailor Treatment for Breast Cancer

63101 Room: 210B

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 1

SESSION OVERVIEW: This session will provide an excellent opportunity for attendees to meet with Dr. Kaklamani in a more intimate setting and listen to her discuss her talk, "Using Biomarkers to Tailor Treatment for Breast Cancer."

**INTENDED AUDIENCE:** This session is intended for pathologists, lab directors, endocrinologists, clinical chemists, technologists, physicians, and IVD industry scientists with interests in breast cancer and breast cancer testing and therapy.

LEARNING OBJECTIVE: After this session, participants will be able to:

1. Understand the role of genomic assays for breast cancer prediction and prognosis. 2. Understand the role of targeted endocrine therapy.

3. Understand novel agents for triple negative breast cancer.

**SPEAKER** Virginia Kaklamani, MD, DSc. UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX

#### 10:30am-12:00pm

Medicina de Laboratorio Basada en la Evidencia: Que es y Cómo Aplicarla a la Práctica Clínica (Evidence-Based Laboratory Medicine: What Is It and How to Use It in the Clinical Practice)

33102 Room: 208AB

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 1.5

#### **MODERATOR/SPEAKER**

Eugenio Zabaleta, PhD

#### **SCIENTIFIC SESSIONS**

#### MORNING

#### 10:30am-12:00pm

**Relationships of Fructosamine**, Glycated Albumin, and 1,5-Anhydroglucitol to Hyperglycemia: Pros and Cons for Use as Adjunct Markers in Management of Diabetes

33101 Room: 204A

Presentation Level: **INTERMEDIATE** ACCENT<sup>®</sup> Credits: 1.5

#### **MODERATOR/SPEAKER**

Douglas Stickle, PhD, DABCC Jefferson University Hospital, Philadelphia, PA

SESSION OVERVIEW: Episodic hyperglycemia is known to be a risk factor for complications of diabetes beyond that of average glucose. Plasma concentrations of fructosamine, glycated albumin, and 1,5-anhydroglucitol have all been touted as markers for episodic hyperglycemia. This session will discuss pros and cons of these markers with respect to clinical utilization in management of diabetes. We will review the physiology of the relationships of these markers to hyperglycemia, with comparison/contrast to hemoglobin A1c. We will discuss current literature and claims for use of these markers, current recommendations and practice in use of these markers and the potential future uses.

INTENDED AUDIENCE: This session is intended for pathologists, lab directors, technologists and physicians who are involved in measurement or clinical use of hyperglycemic markers.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. List markers associated with hyperglycemia, supplemental to hemoglobin A1c.
- 2. Describe the physiological basis of the relationship of these markers to hyperglycemia.
- 3. Explain the limitations of these markers with respect to identification of episodic hyperglycemia.
- 4. Describe current recommendations and clinical practice in use of these markers.
- 5. Discuss anticipated future uses of these markers in diabetes management.

#### **SPEAKERS**

Relationships of Fructosamine, Glycated Albumin, and 1,5-Anhydroglucitol to Hyperglycemia: Comparisons to A1c Douglas Stickle, PhD, DABCC Jefferson University Hospital, Philadelphia, PA

Clinical Perspectives on Use of Fructosamine, Glycated Albumin, and 1,5-Anhydroglucitol in Management of Diabetes Kathleen Dungan, MD, MPH Ohio State University, Columbus, OH

SESSION OVERVIEW: (This presentation will be presented in Spanish.) The most important objective of evidence-based medicine (EBM) is to improve and optimize clinical decision making by using the best evidence available. Since many clinical decisions are influenced by laboratory results, it is vital for laboratorians to be involved in the development of evidencebased clinical practices at their institutions. The unique opportunities and challenges regarding the application of EBM to laboratory medicine will be discussed at this session.

evidence-based medicine.)

**SPEAKERS** 

OhioHealth Mansfield Hospital, Mansfield, OH

# Felix Fares Taie

INTENDED AUDIENCE: This session is intended for pathologists, lab directors, clinical chemists and medical technologists.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Explicar la importancia de la medicina basada en la evidencia. (Explain the importance of

2. Describir las herramientas disponibles en la historias clínicas electrónicas para la implementación de la medicina basada en la evidencia. (Describe the tools available in the electronic health record to implement EBM.)

3. Discutir porque los bioquímicos clínicos deben ser incluidos en el desarrollo de las prácticas clínicas basadas en la evidencia. (Discuss why laboratorians should be included in developing evidence-based clinical practices.)

Historias Clínicas Electrónicas: Como Implementar Medicina de Laboratorio Basada en la Evidencia Exitosamente (Electronic Health Record: How to Implement EBM Successfully) Eugenio Zabaleta, PhD

OhioHealth Mansfield Hospital, Mansfield, OH

Medicina de Laboratorio Basada en la Evidencia (Evidence-Based Laboratory Medicine)

Fares Taie Instituto de Análisis, Mar del Plata, Argentina







#### **SCIENTIFIC SESSIONS**

#### MORNING

#### 10:30am-12:00pm

**Chasing Lactate in Sepsis: What** Does It Mean, How Do We Use It, and Should We Reduce the Bloodletting?

33103 Room: 201AB

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 1.5

#### **MODERATOR/SPEAKER**

John Toffaletti, PhD, DABCC Duke University Medical Center, Durham, NC

SESSION OVERVIEW: With the evolving SEP-1 guidelines for sepsis diagnosis and management, blood lactate measurements have become a valuable indicator of deficits in oxygen metabolism and mitochondrial function that occur in sepsis, and help guide appropriate therapy. An elevated or rising lactate may signal a need for more aggressive medical interventions such as administering fluids, red blood cells, vasoactive agents, cardiac inotropes, supplemental oxygen, and/or antibiotics. However, the frequency of lactate testing and the criterium of >2 mmol/L being "elevated" are controversial. With over 60,000 institution-wide lactate measurements reported per year and the SEP-1 guidelines calling for lactate measured at 3 and 6 hours after sepsis onset, understanding the clinical needs and significance of elevated blood lactates can promote optimal management of critically ill patients and ensure more judicious use of this laboratory test.

INTENDED AUDIENCE: This session is intended for laboratory scientists, pathologists, clinicians and persons from industry.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Describe the biochemistry of lactate, specifically the mechanisms related to increased generation in sepsis.
- 2. Describe the pre-analytical factors that can affect lactate concentrations when collecting and handling specimens of blood.
- 3. Review the new SEP-1 criteria for sepsis diagnosis and management and the opposing viewpoints on the clinical value of these new guidelines.
- 4. Describe how clinicians use lactate and adjuvant tests to evaluate and monitor patients for possible sepsis and other causes of increased lactate concentrations.
- 5. Develop protocols to ensure more judicious use of lactate testing that will reduce costs.

#### **SPEAKERS**

#### Lactate Basics: Minimizing Pre-Analytical Errors and the Mechanisms of Lactate Production in Sepsis

John Toffaletti, PhD, DABCC Duke University Medical Center, Durham, NC

Testing Wisely: Clinical Use of Lactate and Adjuvant Tests to Guide Patient Management in Sepsis and How Recent Guidelines May Affect Test Utilization Craig Rackley, MD, ABIM

Duke University Medical Center, Durham, NC

#### 10:30am-12:00pm

#### Digital Medicine and the Connected Health Consumer: What You Need to Know

33104 Room: 206AB

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 1.5

#### **MODERATOR**

T. Scott Isbell, PhD, DABCC, FAACC

Saint Louis University School of Medicine, St. Louis, MO

- **SPEAKERS**

Medicine Shannon Haymond, PhD, DABCC, FAACC Lurie Children's Hospital of Chicago, Chicago, IL

Health Dashboard David Grenache, PhD, DABCC, MT (ASCP)

Stakeholder's Perspective Michael Kanter, MD



SESSION OVERVIEW: Technological innovations are potentially disruptive to laboratory testing and healthcare. Digital health is often described as the integration of digital technologies with healthcare that seeks to empower people to track their health, decrease inefficiencies, improve access, reduce costs, and increase the quality of care. Smartphones, wireless devices, and wearables provide the ability for consumers to monitor, analyze, report, and share fitness and health data via the internet. Social media allows consumers to network with one another, and compare wellness and information on health and disease states. Direct-to-consumer testing is also on the rise as consumers become more educated and proactive about their own health. Further, there is increased interest in the collection and commercialization of consumer and patient health data along with its subsequent mining for potential medical breakthroughs. This is an exciting time of advancement in our field, and its intersection with the public is unprecedented. As with all paradigm shifts, questions and debates arise, and there is a need to balance the hype and misconceptions with accurate and clear scientific information. This session will engage social media as a modality to moderate interactive discussions and guide dialogue among attendees.

INTENDED AUDIENCE: This session is intended for healthcare consumers, patients, clinical laboratory scientists, medical technologists, clinicians, pathologists, IVD industry scientists, medical directors, laboratory directors and clinical chemists.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Describe trends resulting from the emergence of digital medicine.

2. Discuss challenges and opportunities for laboratorians in the era of digital medicine.

3. Enhance experiences at professional meetings through engagement on Twitter.

#### Engaged and Empowered Patients: How Connectivity Is Advancing a Paradigm Shift in

### The Quantified Self: How Patients Are Using Technology to Create a Personalized Digital

Tricore Reference Laboratories, Albuquerque, NM

### The Value of Laboratory Medicine in Improving the Patient Care Experience: A Clinician

Kaiser Permanente School of Medicine, Pasadena, CA

#### **SCIENTIFIC SESSIONS**

#### MORNING

#### 10:30am-12:00pm

The Value Proposition: Actionable Strategies for Enhancing the Value of Laboratory Medicine

33105 Room: 207CD

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 1.5

#### **MODERATOR**

Robert Christenson, PhD, ABCC, FACB University of Maryland School of

Medicine, Baltimore, MD

Developed in cooperation with IFCC Committee for the Value Proposition in Laboratory Medicine (C-VPLM)

SESSION OVERVIEW: Laboratory medicine must shift from a volume-based service and commoditization to a value-based model of [Benefit or Outcome ÷ Cost], defined in terms of health outcomes, cost reductions, improved efficiencies and/or customer satisfaction. The value proposition framework will be articulated as a means for specifying unmet need(s), outcomes and monitoring metrics for analysis of benefits, costs and value. Ways for improving the laboratorian-stakeholder interface through actionable testing strategies in molecular oncology, and high-sensitivity cardiac troponin will be presented. The laboratory's role in improving the patient care experience will be discussed from a clinician's perspective.

INTENDED AUDIENCE: This session is intended for pathologists, laboratory directors, clinical chemistry professionals, managers at all levels, federal and state regulators, technologists, institutional leaders, IVD industry scientists, and industry leaders at all levels.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. List five elements of the value proposition framework.
- 2. Explain how to determine value of laboratory medicine testing.
- 3. Describe effective tools for enhancing value and explain a relevant example.
- 4. Develop a value propositon for a laboratory medicine topic of interest to their organization.

#### SPEAKERS

What Is a Value Proposition? The Value of Implementing High-Sensitivity Cardiac Troponin in the Emergency Department Robert Christenson, PhD, ABCC, FACB University of Maryland School of Medicine, Baltimore, MD

Molecular Oncology: Challenges, Rewards and Value Michael Oellerich, MD, FRCP, FAACC University Medical Center of the George-August-University, Göttingen, Germany

#### 10:30 am-12:00 pm

Integrating Laboratory Results to Increase Quality Care for Affected Newborns Identified through Newborn Screening: What Is the **Optimal Workflow?** 

33106 Room: 205AB

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 1.5

#### **MODERATOR/SPEAKER**

Veronica Luzzi, PhD, DABCC

Providence Regional Laboratories, Portland, OR

SESSION OVERVIEW: Newborn screening (NBS) is a state mandated public health program that uses laboratory testing to screen and diagnose disorders in newborns that can cause serious acute and chronic health problems. The complexity of this system makes it vulnerable to system failures, including delayed treatments, which can have devastating consequences. This session will provide an overview of the NBS system and provide insight into opportunities for improving delivery of care to this population of newborns.

**INTENDED AUDIENCE:** This session is intended for medical technologists, supervisors, laboratory directors, in-vitro diagnostic research and development scientists, and trainees.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Discuss the role of public health laboratories in newborn screening.
- 2. Explain the pathway of information for newborn screening lab orders, test results, followup protocols and coordination of care to affected infants.
- 3. Identify opportunities for and initiate quality improvement efforts in electronic data exchange for newborn screening.
- 4. Describe the relevance of delivering results in a timely and accurate manner to improve patient care in the context of newborn screening.

#### **SPEAKERS**

#### The Newborn Screening System from Specimen Collection to Delivery of Results Mary Carayannopoulos, PhD, DABCC

Rutgers Robert Wood Johnson University Medical School, New Brunswick, NJ

Implementation of Health Information Technology Solutions to Improve Delivery of Newborn Screening Results to Care Providers Veronica Luzzi, PhD, DABCC Providence Regional Laboratories, Portland, OR

#### 10:30am-12:00pm

Therapeutic Drug Monitoring in Alternative Specimens: Advantages, Pitfalls and Analytical Challenges

33107 Room: 204C

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 1.5

#### **MODERATOR/SPEAKER**

William Clarke, PhD, DABCC, FAACC Johns Hopkins University School of Medicine, Baltimore, MD

> Amitava Dasgupta, PhD, DABCC University of Texas–Houston Medical School, Houston, TX Analytical Approaches and Challenges for TDM Using Alternative Specimens

#### 10:30am-12:00pm

Impact of Hormones on Drug Testing: From the Bench to the Bedside

33108 Room: 207AB

Baltimore, MD

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 1.5

Claire Knezevic, PhD, DABCC

Johns Hopkins Medical Institutes,

#### **MODERATOR/SPEAKER**

drug classes.

#### **SPEAKERS**

Claire Knezevic, PhD, DABCC

Concentrations Mark Marzinke, PhD, DABCC Johns Hopkins University School of Medicine, Baltimore, MD

Eric Topol, MD

SESSION OVERVIEW: Oral fluid is an appealing matrix for therapeutic drug monitoring (TDM) because specimen collection is non-invasive and measurement of drugs in this specimen-type represents pharmacologically active free drug concentrations. In addition, TDM using dried blood spots is also gaining popularity due to the ease of collection and shipping, as well as the development of automated methods for drug analysis in dried blood spots. Less popular matrices for TDM analysis include interstitial fluid, tears, sweat and nasal mucus. This session will discuss the advantages and pitfalls of using various alternative specimens for TDM, including analytical challenges.

#### **SPEAKERS**

specimens.

INTENDED AUDIENCE: This session is intended for pathologists, clinical chemists, toxicologists and medical technologists.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Describe advantages and disadvantages of using alternative specimens for TDM.
- 2. List analytical challenges involved in TDM using alternative specimens.
- 3. Describe approaches to deal with interferences and other challenges with alternative

### Therapeutic Drug Monitoring in Alternative Specimens: An Overview

### William Clarke, PhD, DABCC, FAACC

Johns Hopkins University School of Medicine, Baltimore, MD

**SESSION OVERVIEW:** Synthetic and endogenous hormones are known to affect not only physiology but also the pharmacology and efficacy of various drugs. People ingest, inject, and absorb synthetic hormones for a variety of reasons, ranging from performance enhancement for sports; as gender-affirming hormonal therapies, contraception, and symptom relief (menopause/endometriosis); and to replace or supplement endogenous hormone production. This session will survey the ways in which synthetic hormones influence drug pharmacology and how this can impact the practice of medicine.

**INTENDED AUDIENCE:** This session is intended for laboratory directors, physicians, pharmacists and clinical laboratory scientists.

**LEARNING OBJECTIVES:** After this session, participants will be able to:

- 1. Identify scenarios in which exogenous hormonal use may occur.
- 2. Characterize the relationship between common hormonal contraceptives and therapeutic

3. Describe the influence of gender-affirming hormonal therapies on therapeutic drug classes, including antiretrovirals.

#### Interactions between Common Hormonal Contraceptives and Prescription Drugs

Johns Hopkins Medical Institutes, Baltimore, MD

#### The Influence of Estrogen-Based Gender-Affirming Hormonal Therapies on Drug

#### Direct-to-Consumer Genetic Testing: Pros and Cons

Scripps Research Translational Institute, La Jolla, CA

# **TUESDAY** | AUGUST 6

### **SCIENTIFIC SESSIONS**

### MORNING

#### 10:30am-12:00pm

**Clinical Chemistry's Hot Topics of** 2019

33109 Room: 204B

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 1.5

#### **MODERATOR**

Nader Rifai, PhD Children's Hospital, Boston, MA SESSION OVERVIEW: Advancements in miniaturization technology have revolutionized near patient testing and have been the subjects of numerous highly cited articles published in Clinical Chemistry and will be discussed in this session.

INTENDED AUDIENCE: This session is intended for pathologists, laboratory directors, clinical chemists, molecular diagnostics specialists, technologists and IVD industry scientists.

LEARNING OBJECTIVES: After attending this session, participants will be able to:

- 1. Describe the application of microfluidics and microbeads in digital analysis of proteins and nucleic acids.
- 2. Describe the main advances in mass spectrometry that led to miniaturizing it to bring it closer to the patient and away from the clinical laboratory.

#### **SPEAKERS**

#### Microfluidics-Enabled Digital Biology: Counting Nucleic Acid and Protein Molecules Michael Ramsey, PhD

The University of North Carolina at Chapel Hill, Chapel Hill, NC

#### Clinical Mass Spectrometry; Getting Closer to the Patient Livia Schiavinato Eberlin, PhD

University of Texas at Austin, Austin, TX

### **AFTERNOON**

#### 2:30pm-5:00pm

Breaking Down Gender from Cis to Trans

33216 Room: 207AB

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 2.5

#### **MODERATOR/SPEAKER**

Dina Greene, PhD, DABCC Kaiser Permanente Washington,

#### 10:30am-12:00pm

Challenges in the Diagnosis and Management of Polycystic **Ovary Syndrome: Multifaceted** Perspectives

33110 Room: 209AB

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 1.5

#### MODERATOR

Joesph Wiencek, PhD University of Virginia School of Medicine, Charlottesville, VA

Developed in cooperation with Endocrinology Division; Pediatric and Maternal-Fetal Division

SESSION OVERVIEW: Polycystic ovary syndrome (PCOS) is globally one of the most common endocrine-metabolic disorders and causes of female infertility. However, approximately two-thirds of women with PCOS report significant delays in establishing PCOS as the primary diagnosis and subsequent inadequate follow-up care. International evidence-based guidelines were recently developed to address some of these important challenges. In this session, we will highlight the recent guidelines and explore the evolving roles of patients, researchers, clinicians, laboratorians, and industry partners as they relate to advancing PCOS care. A panel including a physician, laboratorian, and patient advocate will provide balanced and unique perspectives into this complex disease.

**INTENDED AUDIENCE:** This session is intended for laboratory directors, trainees, IVD industry scientists, IVD regulatory bodies, clinical chemists, pathologists and technologists.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Describe the pathophysiology and diagnostic work-up of polycystic ovary syndrome (PCOS) from the perspective of the clinical expert.
- 2. Explain the importance of timely PCOS diagnosis.
- 3. Discuss the analytical aspects of diagnostic testing in the assessment of suspected PCOS. 4. Identify resources available for patients living with PCOS.

#### **SPEAKERS**

#### Polycystic Ovary Syndrome: The Clinical Perspective Christopher McCartney, MD

University of Virginia, Charlottesville, VA

Polycystic Ovary Syndrome: Learning the Diagnostic Playbook Joelv Straseski, PhD, DABCC, MT (ASCP), FAACC

University of Utah & ARUP Laboratories, Salt Lake City, UT

The Patient-Centered Approach to Advancing PCOS Research and Care Sasha Ottey, MHA, MT (ASCP) PCOS Challenge: The National Polycystic Ovary Syndrome Association, Atlanta, GA

#### 2:30pm-5:00pm

#### Making the Quantum Leap in **Clinical Chemistry Teaching**

33217 Room: 209AB

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 2.5

#### **MODERATOR/SPEAKER**

Joesph Wiencek, PhD University of Virginia School of Medicine, Charlottesville, VA

Developed in cooperation with Society for Young Clinical Laboratorians

SESSION OVERVIEW: Gender-affirming hormones are standard of care for transgender people who seek to medically transition. Sex hormones influence chemistry, hematology, and microbiology results. Our team has established transgender-specific reference intervals and performed pioneering investigations into the vaginal flora of transgender men and women. This session will empower the laboratory with the tools necessary for serving the transgender population.

INTENDED AUDIENCE: This session is intended for any individual who contributes to the laboratory profession.

**SPEAKERS** 

1. Define sex and gender.

2. List which reference intervals should be used for transgender men and women.

3. Compare the vaginal flora between cisgender women, transgender men, and transgender women.

Renton, WA

A Trans Inclusive Approach to EMR/LIS Reporting Martha Lyon, MSc, PhD, DABCC, FAACC Royal University Hospital, Saskatoon, Canada

SESSION OVERVIEW: Recent survey results show pathology residents typically do not have positive attitudes toward clinical chemistry. To possibly change this perspective, there needs to be a dynamic shift in the way we teach clinical chemistry. This scientific session will highlight current challenges, practical examples and medical education tools immediately available for clinical chemistry educators.

teaching clinical chemistry.

- chemistry.
  - chemistry sessions.

### **SPEAKERS**

Joesph Wiencek, PhD

Clinical Chemistry Residency Training Program at the Oklahoma University Medical Center Kenneth Blick, PhD University of Oklahoma Health Sciences Center, Oklahoma City, OK

Michael Laposata, MD, PhD

LEARNING OBJECTIVES: After this session, participants will be able to:

4. Diagram how EMR and LIS can be configured to include gender diversity.

#### Establishment of Prospective Hematology and Chemistry Reference Intervals for Transgender Men and Women

Dina Greene, PhD, DABCC Kaiser Permanente Washington, Renton, WA

The Vaginal Flora of Transgender Men and Women Gabrielle Winston-McPherson, PhD

Henry Ford Health System, Detroit, MI

INTENDED AUDIENCE: This session is intended for IVD industry scientists, regulators of IVDs, laboratory directors, clinical chemists, technologists and anyone with an interest in

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Identify current challenges in teaching clinical chemistry.

2. Discuss current active learning strategies being utilized in medical education.

3. Highlight next-generation educational techniques and approaches to teach clinical

4. Identify free educational resources that could be implemented immediately in clinical

#### Turning the Tide in Clinical Chemistry Education

University of Virginia School of Medicine, Charlottesville, VA

### Teaching Clinical Chemistry through Diagnostic Management Team Leadership Principles

University of Texas Medical Branch Galveston, Galveston, TX

# **TUESDAY** AUGUST 6

### **SCIENTIFIC SESSIONS**

### **AFTERNOON**

#### 2:30pm-5:00pm

Worldwide Challenges in POCT— A Focus on Molecular POCT

33218 Room: 210C

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 2.5

#### **MODERATOR/SPEAKER**

James Nichols, PhD, DABCC, FAACC Vanderbilt University Medical Center, Nashville, TN

Developed in cooperation with Critical and Point-of-Care Testing Division

#### 2:30pm-5:00pm

Interactive Pain Management Case **Studies: Clinician and Laboratory** Perspectives

33219 Room: 204C

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 2.5

#### **MODERATOR/SPEAKER**

Paul Jannetto, PhD, DABCC, MT (ASCP), FAACC Mayo Clinic, Rochester, MN

**SESSION OVERVIEW:** Point-of-care testing (POCT) for infectious diseases has seen recent advancements in accuracy from the development of novel molecular methods. This session will cover issues specific to POCT implementation, management and methodologies that are applicable worldwide.

**INTENDED AUDIENCE:** This session is intended for laboratory directors, medical technologists, laboratory supervisors/managers, industry research, development and sales, and government and laboratory accreditation staff and inspectors.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Understand the performance differences between rapid antigen and molecular point-ofcare testing for infectious diseases.
- 2. Describe benefits and challenges for POC test implementation within the practice.

3. Discuss guidelines and best practices from Europe and the United States for POC testing.

#### **SPEAKERS**

Solving the Challenges of POCT: People, Sites and Devices James Nichols, PhD, DABCC, FAACC Vanderbilt University Medical Center, Nashville, TN

Molecular Diagnostics at the POC: Overview and Perspectives from the United States with a Focus on Performance and Implementation in an End-User Express Care Clinic Setting Leslie Donato, PhD, DABCC Mayo Clinic, Rochester, MN

European Perspective for POCT—Challenges for Implementation in ED and ICU and New Guidelines and Best Practices from Europe Peter Luppa, MD

Klinikum Rechts der Isar, Munich, Germany

SESSION OVERVIEW: Pain is one of the most common reasons people seek care. Addiction and diversion of pain management medications is also a growing problem. Therefore, professional organizations and published recommendations include the use of laboratory tests, specifically urine drug testing. As a result, physicians are using a variety of urine drug tests to provide objective measures to effectively manage pain patients, assess compliance, and detect diversion. This session will discuss the advantages and limitations of these assays and use interactive case studies to directly apply this knowledge to correctly interpret patient test results using live interactions between a clinician and laboratorians.

INTENDED AUDIENCE: This session is intended for clinicians, pathologists, lab directors, clinical chemists, technologists, IVD industry scientists, residents and fellows.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Successfully integrate urine drug testing to support the treatment and monitoring of pain management patients.
- 2. Describe the limitations of various screening and quantitative urine drug tests.

3. Correctly interpret urine drug testing results from pain management patients.

#### **SPEAKERS**

Interactive Pain Management Case Studies: Understanding Metabolic Profiles, Drug Impurities, and Adulterated Urine Samples Paul Jannetto, PhD, DABCC, MT (ASCP), FAACC Mayo Clinic, Rochester, MN

Clinical Utilty and Limitations of Qualitative and Quantitatve Laboratory Testing for Pain Management He Sarina Yang, PhD, DABCC, FACB Quest Diagnostics, Valencia, CA

Interactive Pain Management Case Studies: Correctly Interpreting Urine Drug Test Results Nancy Bratanow, MD Midwest Comprehensive Pain Care, Milwaukee, WI

#### 2:30pm-5:00pm

#### Learning from Predictions: What We Need to Know about Machine Learning

33220

Room: 208AB

Presentation Level: **BASIC** 

ACCENT<sup>®</sup> Credits: 2.5

#### **MODERATOR/SPEAKER**

Min Yu, MD, PhD, DABCC University of Kentucky, Lexington, KY

MI

### **SPEAKERS**

Min Yu, MD, PhD, DABCC

Perspective Jonathan Chen, MD, PhD

James Harrison, MD, PhD University of Virginia, Charlottesville, VA

#### 2:30pm-5:00pm

#### Como Mantener la Alta Calidad de sus Resultados de Laboratorio (How to Maintain the High Quality of Your Laboratory Test Results)

33221 Room: 205AB

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 2.5

#### **MODERATOR/SPEAKER**

Van Leung-Pineda, PhD, DABCC Children's Healthcare of Atlanta, Atlanta, GA

Developed in cooperation with Latin American Working Group within AACC's Global Lab Quality Initiative

#### **SPEAKERS**

Veronica Luzzi, PhD, DABCC

Diseñando Buenas Estrategias Para el Uso Eficiente del Control Interno de Calidad (Designing Good Strategies for Effective Use of Internal Quality Control) Van Leung-Pineda, PhD, DABCC Children's Healthcare of Atlanta, Atlanta, GA

Como Solucionar Problemas de Metodo con Ensayos de Control de Calidad Externo (Aptitud) (How to Method Issues with Proficiency Testing Material) Juan David Garcia, MBA University of Miami-Houston, League City, TX

SESSION OVERVIEW: This session will provide a general overview of machine learning (ML) in laboratory medicine, focusing initially on key concepts, advantages, and opportunities. The second segment will explore the potential of ML to optimize the value of laboratory data in patient care. The last segment will address strategies for validating ML systems and monitoring their performance over time.

INTENDED AUDIENCE: This session is intended for pathologists, lab directors, clinical chemists, technologists and IVD industry scientists.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Recognize the strengths and limitations of ML techniques.

2. State the current landscape of ML applications in the laboratory medicine field.

3. Take advantage of ML, and identify projects and fields where ML approaches can facilitate optimal laboratory and clinical practice.

4. Plan initial and ongoing performance assessment programs for systems that incorporate

Laboratory Intelligence: Embracing Machine Learning University of Kentucky, Lexington, KY

### Machine Learning Approaches towards Effective Laboratory Test Utilization-Clinician

Stanford Department of Medicine, Stanford, CA Validation and Performance Monitoring of Machine Learning Systems

SESSION OVERVIEW: (This session will be presented in Spanish.) Laboratory methods and assays ideally demonstrate acceptable analytical performance throughout the test lifecycle (from test validation phase until its end of use in clinical practice). It is critical to implement strategies and tools to monitor the quality and method performance over time, which can identify analytical issues as they arise before negatively impacting patient results. This session will discuss three primary areas important to producing quality laboratory results, as well as strategies and tools that are complementary to monitoring the performance of a laboratory method. The quality monitoring and assurance topics will focus on lot-to-lot reagent variability, quality control, and proficiency testing.

INTENDED AUDIENCE: This session is intended for Spanish-speaking attendees, laboratory directors, medical technologists, supervisors, in-vitro diagnostic scientists, and laboratory medicine trainees/students.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Understand what concepts the reagent lot-to-lot, quality control and proficiency testing studies apply to.

2. Evaluate best practices to implement evaluation of between-reagent lot variation in the clinical laboratory.

3. Understand how to use laboratory data to implement better QC practices.

4. Learn to use PT testing to troubleshoot method problems.

Evaluacion de la Variacion Entre Lotes de Reactivo Siguiendo las Recomendaciones CLSI EP26-A (Evaluation of Reagent Lot Variation Following Recommendations from CLSI EP26-A)

Providence Regional Laboratories, Portland, OR

# **TUESDAY** | AUGUST 6

### **SCIENTIFIC SESSIONS**

### **AFTERNOON**

#### 2:30pm-5:00pm

**Micronutrient Testing for Nutritional Assessment** 

33222 Room: 207CD

Division

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 2.5

#### **MODERATOR/SPEAKER**

Sarah Hackenmueller, PhD, DABCC, FAACC University of Wisconsin, Madison, WI

Developed in cooperation with Nutrition

SESSION OVERVIEW: This session will focus on the clinical impetus and utility of laboratory testing for various vitamins and trace elements. Clinical testing of micronutrients occurs as part of broad nutritional assessments, evaluation of suspected deficiencies or toxicity, and for monitoring of parenteral nutrition. Appropriate ordering of micronutrient and vitamin testing, as well as interpretation of the results, requires an understanding of micronutrient distribution in the body and selection of appropriate specimen types. This session will review aspects of micronutrient intake and absorption, test utilization, analytical methodologies, and limitations associated with these analytes. Attendees will gain insight and strategies to successfully manage requests for micronutrient testing.

**INTENDED AUDIENCE:** This session is intended for clinical chemists, laboratory directors, pathologists, laboratory scientists, laboratory managers and trainees.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Describe micronutrient intake, absorption, and distribution in the body.

2. Discuss laboratory testing for micronutrient evaluation.

3. Recognize the value and limitations of vitamin and trace element analysis and results.

4. Evaluate the clinical utility of micronutrient testing for particular patients.

#### **SPEAKERS**

Micronutrients: Physiology and Pathophysiology Sarah Hackenmueller, PhD, DABCC, FAACC University of Wisconsin, Madison, WI

Vitamin Testing: Strategies for Success Elizabeth Frank, PhD, DABCC, MT (ASCP), FAACC ARUP Laboratories/University of Utah, Salt Lake City, UT

Trace Elements: Testing for Nutrition and Toxicity Vilte Barakauskas, PhD, DABCC, FCACB BCCWH, Vancouver, Canada

#### 2:30pm-5:00pm

#### **Quality Indicators that Determine** the Performance of NGS Assays in Precision Oncology

33223 Room: 201AB

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 2.5

#### **MODERATOR/SPEAKER**

Helen Fernandes, PhD, ABB, DABCC

Columbia University Medical Center, PGM Laboratory, New York, NY

Pathology Division

SESSION OVERVIEW: Next-generation sequencing (NGS) oncology assays characterize multiple genomic variants including single nucleotide variants (SNV), indels, fusions, copy number alterations and other measures such as microsatellite instability (MSI) and tumor mutation burden (TMB). The analytical performance of NGS assays are complicated by variables such as tissue fixation, cellularity, quantity, quality and heterogeneity. As the breadth of information interrogated in tumors increases, the need to select QA/QC metrics that ensure optimal functioning at multiple levels poses challenges. QA/QC metrics should ensure that the sequencing data obtained is reliable for interpretation of variants in clinical reports. Quality indicators can be customized, depending on the type of NGS assay, to ensure optimal performance and include, but are not limited to, specimen selection, sequencing qualifiers, inter-assay variability, control monitoring and variant classification. This session will help identify the QC metrics to address specific indications queried in NGS assays. Specific examples will be utilized to demonstrate how QC monitoring can identify performance and trends through the NGS process.

personnel

Developed in cooperation with Molecular

#### **SPEAKERS**

Dartmouth-Hitchcock Health, Lebanon, NH

Development and Implementation of Quality Control Programs for NGS Based Assays Andrea Ferreira-Gonzalez, PhD Virginia Commonwealth University, Richmond, VA

Using Quality Indicators to Understand Trends and Deviations in Genomic Assays Helen Fernandes, PhD, ABB, DABCC Columbia University Medical Center, PGM Laboratory, New York, NY

### FOLLOW AACC @ AACC AND USE THE HASHTAG **#2019AACC TO JOIN THE CONVERSATION.**





**INTENDED AUDIENCE:** This session is intended for laboratory directors, supervisors, laboratory technologists, pathologists, scientists, laboratory administrators and industry

**LEARNING OBJECTIVES:** After this session, participants will be able to:

1. Recognize that QC metrics can vary among different genomic assays.

2. Select meaningful quality indicators for individual NGS assays.

3. Identify trends that can inform assay performance.

Precision Medicine: High-Complexity Testing for the Management of the Cancer Patient Gregory Tsongalis, PhD, MSc, FAACC

71 www.2019aacc.org

# **TUESDAY** | AUGUST 6

### **SCIENTIFIC SESSIONS**

### **AFTERNOON**

#### 2:30pm-5:00pm

Institutional Laboratory Stewardship Programs: Best **Practices, Interventions, Informatics** 

33224 Room: 206AB

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 2.5

#### **MODERATOR/SPEAKER**

Jing Cao, PhD, DABCC, FAACC Texas Children's Hospital, Houston, ΤX

Developed in cooperation with Management Sciences and Patient Safety Division

SESSION OVERVIEW: Appropriate test utilization is an important part of patient care, and laboratory stewardship programs are becoming increasingly necessary as the availability and costs of laboratory testing increase. There are many approaches to improving laboratory test utilization, including systematic changes to electronic health records, computerized provider order entry systems, stakeholder engagement, provider feedback, and proactive review of test requests. This session will describe a framework of national guidelines for laboratory stewardship programs, discuss examples of clinical impact of stewardship programs on academic medical center hospitals, and illustrate steps for integration and prioritization of informatics resources at the institution level.

**INTENDED AUDIENCE:** This session is intended for laboratory professionals including lab directors, lab managers and supervisors, scientists, and technologists, as well as IVD professionals with an interest in laboratory test utilization.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Identify the four key areas required in implementing a successful laboratory stewardship program.
- 2. Compare the differences in patient care before and after test utilization initiatives.
- 3. Describe successful strategies for optimizing computerized provider order entry systems and alerts to guide appropriate laboratory stewardship.

#### **SPEAKERS**

When the Going Gets Tough, Get Guidelines: National Guidelines to Elevate Laboratory Stewardship Programs Jane Dickerson, PhD, DABCC

Seattle Children's Hospital, Seattle, WA

Test Utilization Strategies: Clinical Impact Sridevi Devaraj, PhD, DABCC, FAACC, FRSC Texas Children's Hospital and Baylor Medical Center, Houston, TX

Informatics Resources to Implement Effective Lab Test Stewardship Programs Lee Schroeder, MD, PhD University of Michigan, Ann Arbor, MI

#### Laboratory Stewardship Practices in Integrated Healthcare Systems

Jing Cao, PhD, DABCC, FAACC Texas Children's Hospital, Houston, TX

#### 2:30pm-5:00pm

Immunogenicity of Therapeutic **Monoclonal Antibodies: Analytical** and Clinical Perspectives

33225 Room: 210A

Presentation Level: BASIC ACCENT<sup>®</sup> Credits: 2.5

#### **MODERATOR/SPEAKER**

Maria Alice Willrich, MSc, PhD, DABCC, FAACC

Mayo Clinic, Rochester, MN

Developed in cooperation with Clinical and Diagnostic Immunology Division

#### 2:30pm-5:00pm

#### Autoantibody Testing in **Autoimmune Neurological Diseases**

33226 Room: 210B

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 2.5

#### **MODERATOR/SPEAKER**

John Mills, PhD, DABMGG, DABCC Mayo Clinic, Rochester, MN

discussed.

**INTENDED AUDIENCE:** This session is intended for clinical laboratory directors and pathologists, clinical technologists, IVD manufacturers, and pharmaceutical scientists.

anti-drug antibodies.

1. Explain the clinical impact of immunogenicity for therapeutic monoclonal antibodies. 2. Describe methods available for the assessment of monoclonal antibody therapeutics and 3. Discuss the challenges with test result interpretations in the setting of immunogenicity.

#### **SPEAKERS**

Clinical Outcomes Niels Vande Casteele, PharmD, PhD University of California, San Diego, La Jolla, CA

Mayo Clinic, Rochester, MN

for Biologics Melissa Snyder, PhD Mayo Foundation, Rochester, MN

SESSION OVERVIEW: Autoimmune neurology is an emerging subspecialty field with a focus on management of patients with immune-mediated diseases of the nervous system. Recent evidence suggests that autoimmune neurological diseases are far more common than traditionally believed. With the increased awareness of these diseases and identification of a growing number of disease-associated autoantibody biomarkers, there is an increased demand for autoantibody testing. This session will provide an overview of autoimmune neurological disorders, antibody-disease associations, current testing methodologies, antibody testing profiles and efforts to improve test utilization.

INTENDED AUDIENCE: This session is intended for laboratory directors, pathologists, clinicians, clinical chemists, supervisors, medical technologists, residents/fellows, IVD industry scientists, and other healthcare professionals.

1. Identify clinical features associated with autoimmune neurological conditions.

### **SPEAKERS**

Andrew McKeon, MD Mayo Clinic, Rochester, MN

Laboratory Methods for Detection of Neural Autoantibodies John Mills, PhD, DABMGG, DABCC Mayo Clinic, Rochester, MN

Panels Allison Chambliss, PhD, DABCC, FAACC Keck School of Medicine of USC, Los Angeles, CA

SESSION OVERVIEW: Immunogenicity is the property of a substance to illicit an immune response. Immmunogenicity to monoclonal antibody-based therapies may lead to production of anti-drug antibodies (ADAs) and inactivation of the therapeutic effects of the drug. Analytical methods and challenges, pharmacological and clinical evidence of their impact, and controversies in the interpretation of test results in the context of ADAs will be

LEARNING OBJECTIVES: After this session, participants will be able to:

### Not All Anti-Drug Antibodies Are Created Equal: Impact on Drug Pharmacokinetics and

#### Methodologies used in the Clinical Laboratory for Assessment of Anti-Drug Antibodies and **Therapeutic Monoclonal Antibodies**

Maria Alice Willrich, MSc, PhD, DABCC, FAACC

#### Controversies in Interpretation of Anti-Drug Antibodies Testing and Drug Quantitation Assays

LEARNING OBJECTIVES: After this session, participants will be able to:

2. Describe the testing methodologies currently used for detection of autoantibodies targeting neural antigens.

3. Describe strategies to improve test utilization.

#### Autoimmune Neurology: Paraneoplastic Disorders and Beyond

#### Should I Approve This? Tackling an Increased Demand for Autoimmune Neurology Antibody

# **TUESDAY** AUGUST 6

### **SCIENTIFIC SESSIONS**

### **AFTERNOON**

#### 2:30pm-5:00pm

**Storytelling with R: Application** Showcase

33227 Room: 204B

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 2.5

#### **MODERATOR/SPEAKER**

Shannon Haymond, PhD, DABCC, FAACC Lurie Children's Hospital of Chicago, Chicago, IL

Developed in cooperation with Informatics Division

SESSION OVERVIEW: This session will demonstrate the versatility and power of the R statistical programming language in application to clinical laboratory medicine by showcasing tools that have been built and implemented by the speakers. Applications will focus on utilizing R for data reporting and visualization.

**INTENDED AUDIENCE:** This session is intended for pathologists, laboratory directors, clinical chemists, medical technologists and laboratory administrators.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Describe ways that R can be used for creating automated and reproducible data analysis workflows in clinical laboratories.
- 2. Discuss the process for building an interactive application or dashboard using R.
- 3. Evaluate and solve clinical laboratory problems using computational thinking.

#### **SPEAKERS**

Enhancing Management of Laboratory Operations with R Stephen Master, MD, PhD, FAACC Children's Hospital of Philadelphia, Philadelphia, PA

Automated Reporting of Key Laboratory Performance Indicators Using R Janet Simons, MD Providence Health Care, Vancouver, Canada

Monitoring Mass Spectrometry System Performance Using R Dashboards Shannon Haymond, PhD, DABCC, FAACC Lurie Children's Hospital of Chicago, Chicago, IL

Set It and Forget it: Enabling Dashboards Using Database Connections in R Patrick Mathias, MD, PhD University of Washington School of Medicine, Seattle, WA

Comparing Different Statistical Approaches for Reference Intervals Using R Shiny Dustin Bunch, PhD Yale-New Haven Hospital, New Haven, CT

Reproducible Research and Manuscript Preparation Using R and the Bookdown Package Daniel Holmes, MD University of British Columbia, British Columbia, Canada





#### 2:30pm-5:00pm

#### **Clinical Endocrine Assays: What Endocrinologists Will Ask You**

33228 Room: 204A

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 2.5

#### MODERATOR

David Sacks, MD National Institutes of Health, Bethesda, MD

Developed in cooperation with Endocrine Society

## Ty Carroll, MD

**SPEAKERS** 

Neil Binkley, MD

#### 2:30pm-5:00pm

#### **Blood Gas Testing: Basics and** Beyond

33229 Room: 210D

Chicago, IL

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 2.5

#### **MODERATOR/SPEAKER**

Brenda Suh-Lailam, PhD, DABCC, FAACC Lurie Children's Hospital of Chicago,

clinical settings. **SPEAKERS** 

Foundations of Blood Gases

Gary Horowitz, MD Tufts Medical Center, Boston, MA

Overcoming Challenges of Blood Gas Testing in Different Locations Brenda Suh-Lailam, PhD, DABCC, FAACC Lurie Children's Hospital of Chicago, Chicago, IL

SESSION OVERVIEW: Endocrinologists frequently contact the clinical lab for guidance on test selection and interpretation. An informal survey of clinicians attending the Endocrine Society Annual Conference identified some common areas of confusion, including biochemical markers of bone turnover in osteoporosis, interpretation of ACTH and cortisol assay results in challenging patients, and clinical evaluation of vitamin D metabolite assay results. This symposium will address these topics to prepare clinical laboratorians to answer the questions in these areas.

**INTENDED AUDIENCE:** This session is intended for pathologists, laboratory directors, clinical chemists, technologists, IVD industry scientists, students, trainees and endocrinologists.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Evaluate the different biochemical markers of bone turnover in metabolic bone disease.

2. Explain current issues with assays and tests of pituitary-adrenal function in patients with suspected, endogenous hypercortisolism.

3. Compare and contrast different methods of measuring the clinical useful metabolites of the vitamin D pathway.

#### Biochemical Markers of Bone Turnover in Osteoporosis

Angela Cheung, MD, PhD, FRCPC University of Toronto, University Health Network, Toronto, Canada

#### Cushing's Syndrome: Interpreting Assay Results in Challenging Patients

Medical College of Wisconsin, Menomonee Falls, WI

#### Clinical Evaluation of Vitamin D and Metabolite Assay Results

University of Wisconsin School of Medicine and Public Health, Madison, WI

**SESSION OVERVIEW:** Blood gas analyses are essential for the management of critically ill patients. This session will review the basics of blood gas testing, discuss approaches for ensuring quality in blood gas analyses, and provide guidance on overcoming challenges associated with blood gas analyses in different clinical settings.

INTENDED AUDIENCE: This session is intended for pathologists, lab directors, physicians, nurses, clinical chemists, point-of-care coordinators and technologists.

**LEARNING OBJECTIVES:** After this session, participants will be able to:

1. Identify the major acid-base disturbances.

2. Define oxygen content, oxygen saturation, and fractional oxyhemoglobin.

3. Describe how to ensure quality in blood gas analysis.

4. Explain how to overcome challenges associated with performing blood gases in different

Implementing Blood Gas Analysis at the Point of Care

Nichole Korpi-Steiner, PhD, DABCC University of North Carolina, Chapel Hill, NC

### **PLENARY & SCIENTIFIC SESSIONS**







# WEDNESDAY | AUGUST 7

### **PLENARY SESSION**



### **Towards Precision Medicine**

8:45am-10:15am Room: Ballroom ABC

14001

**SESSION OVERVIEW:** The session will introduce the concept of precision medicine, particularly with reference to clinical genomics, using specific patient examples, including from the Undiagnosed Diseases Network. Algorithmic approaches to human genome interpretation will be discussed and areas where current technologies fall short of clinical-grade test quality will be highlighted. Newer technologies such as long-read sequencing and new algorithms for improving test performance in complex areas of the genome will be introduced. Finally, near-term opportunities for predictive and preventive genomic medicine will be examined in the context of changing healthcare delivery environments.

- examples.

- rare disease.
- the healthcare system.



### Euan Ashley, BSc, MB ChB, FRCP, DPhil, FAHA, FACC, FESC

Stanford Center for Inherited Cardiovascular Disease, Stanford, CA

Presentation Level: **BASIC** | ACCENT<sup>®</sup> Credits: 1

**INTENDED AUDIENCE:** This session is intended for pathologists, lab directors, clinical chemists, molecular biologists, technologists, physicians, and IVD industry scientists with interests in genomics and precision medicine.

**LEARNING OBJECTIVES:** After this session, participants will be able to:

1. Understand what is meant by precision medicine and be able to provide

2. Understand the opportunity and challenge represented by our ability to sequence whole human genomes at scale for clinical medicine.

3. Understand areas of need in the development of clinical genomics and the power and limitations of the human reference genome.

4. Understand the current state of the art in the application of clinical genomics to

5. Understand how genomics will move from rare disease to affect every patient in

ROUNDTABLE SESSIONS

7:30am-8:30am (40000 Series) or 12:30pm-1:30pm (50000 Series)

Registration fees apply for each course.

Roundtable sessions are presented twice daily. Attendance is limited to 10 participants per session. Advance registration and session fees are required. AACC does **not** provide meals for these sessions. You will be able to purchase your own food in the convention center prior to the session.

ACCENT® Credit: 1.0 (per session) unless otherwise noted in the mobile app, or at www.2019aacc.org | ACC, Ballroom DE

SESSION #				
TITLE	AM	РМ	SPEAKER	LEVEL
Drug Interference—The Unsolved Problem	44101	54201	Oswald Sonntag, PhD, Sonntag, Eichenau, Germany	BASIC
The Trials and Triumphs of HIV Testing	44102	54202	<b>Vera Tesic,</b> MD, ABMM, University of Chicago, River Forest, IL	INTERMEDIATE
Grow Your Tribe: Tools to Help You Foster Employee Engagement	44103	54203	<b>Kenneth Hoekstra,</b> MSc, PhD, ABB, FAACC, Quest Diagnostics, Sedro-Woolley, WA	BASIC
Changing the Culture to a Culture of Change: Case Studies and Approaches to Empowering Change and Improvement Developed in cooperation with Management Sciences and Patient Safety Division	44104	54204	<b>Jack Zakowski,</b> PhD, FAACC, IVD Consulting LLC, Yorba Linda, CA	INTERMEDIATE
The CDC Clinical Standardization Programs— Improving the Measurement of Free Thyroxine	44105	54205	<b>Ashley Ribera,</b> Centers for Disease Control and Prevention, Atlanta, GA	INTERMEDIATE
HIV Diagnostics: Past, Present and Future	44107	54207	Vincent Ricchiuti, PhD, LabCorp, Dublin, OH	INTERMEDIATE
Vitamin D Measurements: How Much of This Sunshine Vitamin Testing Is Credible?	44109	54209	<b>Rachita Nanda,</b> MD, MAMS, AIIMS Raipur, Raipur, India	BASIC
Evaluation and Management of Interfering Substances in a Multicenter Setting: Focus on Lipemia	44110	54210	<b>Neval Akbas,</b> PhD, Medpace Reference Laboratories, Cincinnati, OH	INTERMEDIATE
Auto-Validation Rule Testing to Ensure Continuous Quality and Reliability	44111	54211	<b>Angela Martin,</b> ASCP, Norton Healthcare, Louisville, KY	BASIC
Sample Collection Devices as a Source of Pre- Analytical Errors: Impact of Collection Tube Components on Clinical Assays	44113	54213	<b>Raffick Bowen,</b> MHA, PhD, FCACB, DABCC, MLT(CSMLS), FAACC, Stanford Health Care, Stanford, CA	INTERMEDIATE
Developing an Individualized Quality Control Plan (IQCP)	44114	54214	<b>Evrim Erdogan,</b> PhD, DABCC, FAACC, Baystate Health System, Springfield, MA	INTERMEDIATE
Umbilical Cord Testing—Moving Beyond Blood Gases	44115	54215	<b>Amy Karger,</b> MD, PhD, DABCC, University of Minnesota, Minneapolis, MN	BASIC
A Case of Suspected Macroprolactinemia: Collaboration between Laboratorians and Clinicians in Interpreting Unexpected Test Results	44116	54216	<b>Christina Pierre,</b> PhD, University of Virginia, Charlottesville, VA	BASIC
Quality Assurance: Instrument Performance Comparison in a Multiple-Platform Testing Environment	44118	54218	<b>Yifei Yang,</b> PhD, DABCC, University of Utah & ARUP Laboratories, Salt Lake City, UT	BASIC

Strategies for Preventing Them44122Validation and Implementation of Automated Analyzers across Multiple Laboratory Sites— A Practical Approach44123Predictive Analytics in the Clinical Laboratory44124Emerging Biomarkers in Dementia—Challenges and Opportunities44125Diagnosing Inborn Errors of Metabolism: Challenging Cases in Biochemical Genetics44126Pharmacogenomics and Mass Spectrometry in the Clinical Lab: A Fledgling Partnership44128Reference Intervals for Thyroid Function Tests During Pregnancy44130Supporting Opioid Addiction Programs with Unexpected Testing—Ethanol Metabolite Test Development in an Appalachian Laboratory44131Experiences Implementing Moving Averages to Assist with Quality Assurance44132Managing the Wild Wild West of Point-of-Care Testing44133Label-Free Immunoassay: A New Horizon for the Quantitation of Proteins and Therapeutic Monoclonal Antibodies?44136Preanalytical Challenges and Analytical Interference in Cancer Patient44136	Review of Reference Intervals across Four Hospital Laboratories	44119
Strategies for Preventing Them44122Validation and Implementation of Automated Analyzers across Multiple Laboratory Sites— A Practical Approach44123Predictive Analytics in the Clinical Laboratory44124Emerging Biomarkers in Dementia—Challenges and Opportunities44125Diagnosing Inborn Errors of Metabolism: 		44120
Analyzers across Multiple Laboratory Sites— A Practical Approach44123Predictive Analytics in the Clinical Laboratory44124Emerging Biomarkers in Dementia—Challenges and Opportunities44125Diagnosing Inborn Errors of Metabolism: Challenging Cases in Biochemical Genetics44126Pharmacogenomics and Mass Spectrometry in the Clinical Lab: A Fledgling Partnership44129Supporting Opioid Addiction Programs with Unexpected Testing—Ethanol Metabolite Test Development in an Appalachian Laboratory44130Improving the Measurement of Parathyroid Hormone (PTH) and Related PTH Variants through the Development of a Reference Measurement Procedure Developed in cooperation with Partnership for the Accurate Testing of Hormones (PATH)44132Experiences Implementing Moving Averages to Assist with Quality Assurance44134Preanalytical Challenges and Analytical Interference in Cancer Patient44136Preanalytical Challenges and Analytical Interference in Cancer Patient44136How Do We Get Physicians to Order the Right44137	Pre-Analytical Pitfalls in Hemostasis Testing and Strategies for Preventing Them	44122
Emerging Biomarkers in Dementia—Challenges and Opportunities44125Diagnosing Inborn Errors of Metabolism: Challenging Cases in Biochemical Genetics44126Pharmacogenomics and Mass Spectrometry in the Clinical Lab: A Fledgling Partnership44128Reference Intervals for Thyroid Function Tests 	Validation and Implementation of Automated Analyzers across Multiple Laboratory Sites— A Practical Approach	44123
and Opportunities44123Diagnosing Inborn Errors of Metabolism: Challenging Cases in Biochemical Genetics44126Pharmacogenomics and Mass Spectrometry in the Clinical Lab: A Fledgling Partnership44128Reference Intervals for Thyroid Function Tests During Pregnancy44129Supporting Opioid Addiction Programs with Unexpected Testing—Ethanol Metabolite Test Development in an Appalachian Laboratory44130Improving the Measurement of Parathyroid Hormone (PTH) and Related PTH Variants 	Predictive Analytics in the Clinical Laboratory	44124
Challenging Cases in Biochemical Genetics44128Pharmacogenomics and Mass Spectrometry in the Clinical Lab: A Fledgling Partnership44128Reference Intervals for Thyroid Function Tests During Pregnancy44129Supporting Opioid Addiction Programs with Unexpected Testing—Ethanol Metabolite Test Development in an Appalachian Laboratory44130Improving the Measurement of Parathyroid Hormone (PTH) and Related PTH Variants through the Development of a Reference Measurement Procedure Developed in cooperation with Partnership for the Accurate Testing of Hormones (PATH)44132Managing the Wild Wild West of Point-of-Care Testing44133Label-Free Immunoassay: A New Horizon for the Quantitation of Proteins and Therapeutic Monoclonal Antibodies?44135Preanalytical Challenges and Analytical Interference in Cancer Patient44136How Do We Get Physicians to Order the Right44137	Emerging Biomarkers in Dementia—Challenges and Opportunities	44125
the Clinical Lab: A Fledgling Partnership44123Reference Intervals for Thyroid Function Tests During Pregnancy44129Supporting Opioid Addiction Programs with Unexpected Testing—Ethanol Metabolite Test Development in an Appalachian Laboratory44130Improving the Measurement of Parathyroid 	Diagnosing Inborn Errors of Metabolism: Challenging Cases in Biochemical Genetics	44126
During Pregnancy44129Supporting Opioid Addiction Programs with Unexpected Testing—Ethanol Metabolite Test Development in an Appalachian Laboratory44130Improving the Measurement of Parathyroid Hormone (PTH) and Related PTH Variants 	Pharmacogenomics and Mass Spectrometry in the Clinical Lab: A Fledgling Partnership	44128
Unexpected Testing—Ethanol Metabolite Test Development in an Appalachian Laboratory44130Improving the Measurement of Parathyroid Hormone (PTH) and Related PTH Variants through the Development of a Reference Measurement Procedure Developed in cooperation with Partnership for the Accurate Testing of Hormones (PATH)44131Experiences Implementing Moving Averages to Assist with Quality Assurance44132Managing the Wild Wild West of Point-of-Care Testing44133Label-Free Immunoassay: A New Horizon for the Quantitation of Proteins and Therapeutic Monoclonal Antibodies?44135Preanalytical Challenges and Analytical Interference in Cancer Patient44136How Do We Get Physicians to Order the Right44137	Reference Intervals for Thyroid Function Tests During Pregnancy	44129
Hormone (PTH) and Related PTH Variants through the Development of a Reference Measurement Procedure44131Developed in cooperation with Partnership for the Accurate Testing of Hormones (PATH)44132Experiences Implementing Moving Averages to 	Supporting Opioid Addiction Programs with Unexpected Testing—Ethanol Metabolite Test Development in an Appalachian Laboratory	44130
Assist with Quality Assurance44132Managing the Wild Wild West of Point-of-Care Testing44133Label-Free Immunoassay: A New Horizon for the Quantitation of Proteins and Therapeutic Monoclonal Antibodies?44134Preanalytical Challenges and Analytical Interference in Cancer Patient44135Drug-Induced Liver Injury: Recognition, Classification and Evaluation44136How Do We Get Physicians to Order the Right44137	, , , ,	44131
Testing44133Label-Free Immunoassay: A New Horizon for the Quantitation of Proteins and Therapeutic Monoclonal Antibodies?44134Preanalytical Challenges and Analytical Interference in Cancer Patient44135Drug-Induced Liver Injury: Recognition, Classification and Evaluation44136How Do We Get Physicians to Order the Right44137	Experiences Implementing Moving Averages to Assist with Quality Assurance	44132
the Quantitation of Proteins and Therapeutic Monoclonal Antibodies?44134Preanalytical Challenges and Analytical Interference in Cancer Patient44135Drug-Induced Liver Injury: Recognition, Classification and Evaluation44136How Do We Get Physicians to Order the Right44137		44133
Interference in Cancer Patient       44133         Drug-Induced Liver Injury: Recognition,       44136         Classification and Evaluation       44136         How Do We Get Physicians to Order the Right       44137	the Quantitation of Proteins and Therapeutic	44134
Classification and Evaluation 444130 How Do We Get Physicians to Order the Right 44137	Preanalytical Challenges and Analytical Interference in Cancer Patient	44135
- 44137	Drug-Induced Liver Injury: Recognition, Classification and Evaluation	44136
	How Do We Get Physicians to Order the Right Test?	44137

54219	<b>Alison Bransfield,</b> MS, Bon Secours Hospital, Cork, Ireland	INTERMEDIATE
54220	Run Zhang Shi, MD, PhD, Stanford Medical Center Clinical Laboratories, Palo Alto, CA	INTERMEDIATE
54222	<b>Anna Merrill,</b> PhD, DABCC, University of Iowa, Iowa City, IA	BASIC
54223	<b>Kika Veljkovic,</b> PhD, FCACB, LifeLabs, Toronto, Canada	INTERMEDIATE
54224	<b>Niklas Krumm,</b> MD, PhD, University of Washington, Seattle, WA	BASIC
54225	<b>Erin Schuler,</b> PhD, University of Kentucky, Lexington, KY	INTERMEDIATE
54226	Irene De Biase, MD, PhD, ABMG, University of Utah/ARUP Laboratories, Salt Lake City, UT	INTERMEDIATE
54228	<b>Grace Williams,</b> PhD, Dartmouth-Hitchcock Medical Center, Lebanon, NH	BASIC
54229	<b>Sonia La'ulu,</b> ASCP, ARUP Laboratories, Salt Lake City, UT	BASIC
54230	<b>Danyel Tacker,</b> PhD, DABCC, FAACC, West Virginia University Hospitals, Morgantown, WV	BASIC
54231	<b>Candice Ulmer,</b> PhD, Centers for Disease Control and Prevention, Atlanta, GA	BASIC
54232	Adam McShane, PhD, DABCC, Cleveland Clinic, Cleveland, OH	INTERMEDIATE
54233	<b>Edward Leung,</b> PhD, DABCC, FAACC, Children's Hospital Los Angeles, Los Angeles, CA	INTERMEDIATE
54234	<b>Y. Ruben Luo,</b> PhD, University of California, San Francisco, San Francisco, CA	ADVANCED
54235	<b>Lakshmi Ramanathan,</b> PhD, Memorial Sloan- Kettering Cancer Center, New York, NY	BASIC
54236	<b>Jada (Yu) Zhang,</b> MD, PhD, San Francisco General Hospital, San Francisco, CA	INTERMEDIATE
54237	<b>Eugenio Zabaleta,</b> PhD, OhioHealth Mansfield Hospital, Mansfield, OH	INTERMEDIATE

### **MEET THE EXPERT**

#### 10:30am-11:30am

**Towards Precision Medicine** 

64101 Room: 210B

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 1

SESSION OVERVIEW: This session will provide an excellent opportunity for attendees to meet with Dr. Ashley in a more intimate setting and listen to him discuss his talk, "Towards Precision Medicine.'

INTENDED AUDIENCE: This session is intended for pathologists, lab directors, clinical chemists, molecular biologists, technologists, physicians and IVD industry scientists with interests in genomics and precision medicine.

LEARNING OBJECTIVES: After this session participants will be able to:

- 1. Understand what is meant by precision medicine and be able to provide examples.
- 2. Understand the opportunity and challenge represented by our ability to sequence whole human genomes at scale for clinical medicine.
- 3. Understand areas of need in the development of clinical genomics and the power and limitations of the human reference genome.
- 4. Understand the current state of the art in the application of clinical genomics to rare disease
- 5. Understand how genomics will move from rare disease to affect every patient in the healthcare system.

#### **SPEAKER**

Euan Ashley, BSc, MB ChB, FRCP, DPhil, FAHA, FACC, FESC Stanford Center for Inherited Cardiovascular Disease, Stanford, CA

### **SCIENTIFIC SESSIONS**

### MORNING

#### 10:30am-12:00pm

#### Putting QC into Practice

34101 Room: 204C

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 1.5

#### **MODERATOR/SPEAKER**

Lorin Bachmann, PhD, DABCC, MT (ASCP) Virginia Commonwealth University, Richmond, VA

SESSION OVERVIEW: This session will focus on real-world, practical approaches for implementing a QC program. Topics covered include determining QC target values and standard deviations, determining frequency of analysis, choosing QC multi-rule strategies, establishing QC acceptance criteria, and innovative approaches for improving the efficiency of QC review. Practical procedures for evaluation of lot changes of reagent, calibrator and QC materials will be presented, and solutions to commonly encountered problems will be explored. Performance monitoring approaches such as among-instrument assessment and using commutable certified reference materials will be explained. Case studies and realworld examples will be used to demonstrate the concepts presented in the session.

INTENDED AUDIENCE: This session is intended for pathologists, laboratory directors, laboratory managers, clinical laboratory scientists, pathology residents and fellows, physicians, and industry scientists.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Design a QC program that integrates practice guideline recommendations with practical approaches specific for an individual laboratory.
- 2. Identify and address common QC practices that can inadvertently lead to erroneous conclusions about laboratory results quality.
- 3. Troubleshoot and resolve issues commonly encountered when changing lots of QC, calibrator and reagents.
- 4. Develop tools to efficiently manage routine QC and performance monitoring review.

#### **SPEAKERS**

Putting QC into Practice Greg Miller, PhD, DABCC Virginia Commonwealth University, Richmond, VA

Beyond QC: Ongoing Performance Monitoring Lorin Bachmann, PhD, DABCC, MT (ASCP) Virginia Commonwealth University, Richmond, VA

#### 10:30am-12:00pm

#### **Strategies and Tactics for Practical** Test Utilization Management

34102 Room: 205AB

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 1.5

#### **MODERATOR/SPEAKER**

Ron Schifman, MD Southern Arizona VA Healthcare System, Tucson, AZ

setting.

**SPEAKERS** 

**INTENDED AUDIENCE:** This session is intended for laboratory managers, administrators, laboratory directors and pathologists.

#### 10:30am-12:00pm

#### Intellectual Property and Landmark Patent Lawsuits: The Role of U.S. Patents for Clinical Laboratory **Diagnostic Tests**

34103

Room: 206AB

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 1.5

#### MODERATOR

Alan Wu, PhD University of California, San Francisco, San Francisco, CA

1. Predict whether a new diagnostic technology is patentable.

#### SPEAKERS

Jonathan Loeb, PhD Dechert LLP, Mountain View, CA

Robert Cook-Deegan, MD Arizona State University, Washington, DC

SESSION OVERVIEW: This session will present simple and practical techniques for rapid implementation of test utilization improvements. An interactive format will be used to examine participants' current test stewardship activities as the contextual framework for demonstrating various easy-to-apply techniques that address common, real-world test utilization problems. Examples include ways to avoid ordering mistakes, use of prerequisite testing protocols, test menu and nomenclature structure, reducing misinterpretation risks, a simple process to identify over-ordering of specific test(s), and guidance for investigating common and easily solved problems. Pre-registrants will receive a form to collect data from their laboratory for use at this session.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Apply various practical and effective laboratory stewardship techniques in their practice

2. Describe the benefit of readily available data indicators to check local test utilization practices and identify potential problems.

3. List the most common reasons for test ordering problems and specific method(s) for resolving each type.

#### Laboratory Stewardship: A Very Practical Approach

#### Ron Schifman, MD

Southern Arizona VA Healthcare System, Tucson, AZ

#### Simple Techniques for Effective Test Ordering Practices Peter Perrotta, MD

West Virginia University, Morgantown, WV

SESSION OVERVIEW: With reference to laboratory diagnostics, recent court decisions have altered 30 years of jurisprudence affecting what can and cannot be patented (e.g., Cleveland Clinic v True Health, Myriad v AMP, Mayo v Prometheus, and Sequenom v Ariosa). This has introduced incoherence, induced uncertainty, and dampened enthusiasm for private investments. Academics, industry, and investors must understand the reasons that courts intervened to change U.S. law about patentable subject matter. In addition, the session will cover the current limits of patent law, as well as the implications for current practice and future prospects for molecular diagnostics.

INTENDED AUDIENCE: This session is intended for pathologists, lab directors, clinical chemists, technologists, industry-based scientists and IVD investors.

LEARNING OBJECTIVES: After this session, participants will be able to:

2. Know what type of data they will need to generate to support a patent.

3. Explain why the courts seem to disfavor certain technologies, such as diagnostics and computer software, and favor others, such as new drugs.

4. Discuss the rationale for recent Supreme Court and appellate-level federal court decisions that have limited patentable subject matter in molecular diagnostics.

5. Apply findings from the history and legal background to daily operations of molecular testing labs, and to future scenarios for developing and performing molecular diagnostics.

#### What Do You Have to Do to Patent a Diagnostic Test These Days?

### Why Have Courts Balked? Understanding Court Decisions on Molecular Diagnostics

### **SCIENTIFIC SESSIONS**

### MORNING

#### 10:30am-12:00pm

Surviving the Regulatory and Accreditation Landscape: The Must-**Know Secrets for Success!** 

34104 Room: 207CD

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 1.5

#### **MODERATOR/SPEAKER**

Brad Karon, MD, PhD, FAACC Mayo Clinic, Rochester, MN

Developed in cooperation with College of American Pathologists

SESSION OVERVIEW: This session will be an interactive, case-based session for new and experienced laboratory directors, managers, supervisors and quality personnel focusing on regulatory and accreditation issues that put laboratories at risk. Participants will get practical tips to handling challenging issues such as proficiency testing, competency assessment, delegation of duties, and others.

INTENDED AUDIENCE: This session is intended for laboratory directors, administrators, managers, supervisors and quality personnel.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. List the most recent regulatory issues adversely impacting laboratories.
- 2. Explain how the laboratory's ordering, performing, resulting and investigation/response to proficiency testing can be optimized to avoid regulatory/compliance penalties.
- 3. Describe new regulatory/compliance trends related to competency assessment, personnel requirements, and delegation of duties that have caused regulatory/compliance problems for laboratories.

#### **SPEAKERS**

What Every New Laboratory Leader Needs to Know about Laboratory Accreditation and Regulation Charles Eby, MD

Washington University, St. Louis, MO

What's New in Laboratory Accreditation and Regulation: Just When You Thought You Knew Where the Landmines Were Brad Karon, MD, PhD, FAACC Mayo Clinic, Rochester, MN





#### 10:30am-12:00pm

Getting by with a Little Help from My Friends: "Speed Dating" with Peers to Troubleshoot Common Issues in the Clinical Laboratory

34105

Room: 201AB

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 1.5

#### **MODERATOR/SPEAKER**

#### Steven Cotten, PhD, DABCC, FAACC

University of North Carolina at Chapel Hill, Chapel Hill, NC

#### readiness. **SPEAKERS**

operations.

### System

Jane Dickerson, PhD, DABCC

Specimens in the Clinical Lab Mark Marzinke, PhD, DABCC

Corinne Fantz, PhD, DABCC Roche Diagnostics Corp., Atlanta, GA

10:30am-12:00pm **Towards Improved Cardiovascular** Disease (CVD) Risk Screening and Prevention by Improving **Measurement of Blood Lipids** 

34106

Room: 204A

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 1.5

#### **MODERATOR/SPEAKER**

Uliana Danilenko, PhD Centers for Disease Control and Prevention, Atlanta, GA

## and prevention.

### **SPEAKERS**

Uliana Danilenko, PhD

from the Working Group Hubert Vesper, PhD Centers for Disease Control, Atlanta, GA

Peter Wilson, MD

SESSION OVERVIEW: Bring your knowledge and real-world experience to work through commonly encountered matters related to clinical pathology. This interactive session will provide a "speed-dating" workshop format for discussing issues encountered by laboratorians. Attendees will rotate tables between four topics covering identifying problem specimens, discontinuing or changing testing methods, harmonization of an analyte across a health system, and improving point-of-care testing accountability. Attendees will pair up with others to discuss the pre-defined scenarios. At the end, the host at each table will provide a high-level summary with a hand-out and facilitate further discussion.

**INTENDED AUDIENCE:** This session is intended for trainees, pathologists, laboratory directors, clinical chemists, technologists and others involved with managing laboratory

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Identify workflow strategies to manage specimen exception handling.
- 2. Prioritize considerations in the discontinuation of in-house laboratory testing.
- 3. Mitigate common challenges with analyte harmonization across labs and health systems.
- 4. Recommend effective strategies to improve point-of-care compliance and inspection

#### One Is the Loneliest Number: Analyte Method Harmonization or Lack Thereof in a Health

Steven Cotten, PhD, DABCC, FAACC University of North Carolina at Chapel Hill, Chapel Hill, NC

#### Should I Stay or Should I Go? Discontinuing Fractionated 25-OH Vitamin D

Seattle Children's Hospital, Seattle, WA

I've Got Ninety-Nine Problems and a Sample Is One: Managing and Tracking Problem

Johns Hopkins University School of Medicine, Baltimore, MD

### Every Breath You Take: Approaches to Enhancing POC Compliance and Accountability

SESSION OVERVIEW: This session will discuss the current state of standardization and harmonization efforts directed towards biomarkers of cardiovascular disease, specifically blood lipids and lipoproteins. The importance of developing updated analytical performance criteria, as well as the clinical implications, will be highlighted. Clinical, pre-analytical, and analytical aspects of lipid measurements will also be addressed.

INTENDED AUDIENCE: This session is intended for laboratory directors, clinical chemists, physicians and IVD industry scientists.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Summarize current programs and materials available to improve blood lipids measurements.

2. Identify current analytical and pre-analytical challenges of CVD biomarkers testing. 3. Describe emerging CVD biomarkers that aid with clinical decisions for CVD risk screening

#### Current State of Cardiovascular Disease Biomarkers Standardization

Centers for Disease Control and Prevention, Atlanta, GA

### Revision of the Analytical Performance Criteria for Blood Lipids Measurement: An Update

#### Lipid Measurements and Clinical Care: The National Lipid Association Perspective

Emory University School of Medicine, Atlanta, GA

### **SCIENTIFIC SESSIONS**

### MORNING

#### 10:30am-12:00pm

**Beautiful Skin but Erroneous Lab** Results: The AACC Academy's **Guidance Document on Biotin** Interference

34107 Room: 207AB

Presentation Level: BASIC ACCENT<sup>®</sup> Credits: 1.5

#### **MODERATOR/SPEAKER**

Patrick Kyle, PhD, ABFT, DABCC, FAACC University of Mississippi Medical

#### 10:30am-12:00pm

Center, Jackson, MS

Journal of Applied Laboratory Medicine's 2019 Hot Topics: Sepsis Diagnosis and Management: **Role of Novel Biomarkers and** Procalcitonin Confounders

34108 Room: 201CD

Presentation Level: ADVANCED ACCENT<sup>®</sup> Credits: 1.5

#### **MODERATOR/SPEAKER**

Robert Christenson, PhD, ABCC, FACB

University of Maryland School of Medicine, Baltimore, MD

Developed in cooperation with Journal of **Applied Laboratory Medicine** 

SESSION OVERVIEW: This session reviews the highlights of the AACC Academy's recent guidance document on biotin interferences with clinical laboratory assays. The mechanisms of biotin interference with both competitive and non-competitive assays and methods to identify suspected interferences will be discussed. Steps that clinicians and laboratorians can take to reduce or eliminate biotin interferences will also be presented.

**INTENDED AUDIENCE:** This session is intended for clinicians, pathologists, clinical chemists, medical laboratory scientists and laboratory administrators.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Identify types of assays that could exhibit biotin interference.

2. List methods to help identify suspected biotin interference.

3. Design methods to reduce or mitigate potential biotin interference.

#### SPEAKERS

Beautiful Skin but Erroneous Lab Results: The AACC Academy's Guidance Document on Biotin Interference

Angela Ferguson, PhD, DABCC, FAACC Children's Mercy Hospitals and Clinics, Kansas City, MO

Patrick Kyle, PhD, ABFT, DABCC, FAACC University of Mississippi Medical Center, Jackson, MS

SESSION OVERVIEW: Sepsis, a widespread medical emergency, occurs in ~6% of hospitalizations but causes one-third of hospital deaths. How the biomarkers iNOS and human neutophil lipocalin may assist in guiding urgent, life-saving management of early sepsis will be discussed. Also, procalcitonin measurement may be useful; pros, cons and limitations will be discussed

INTENDED AUDIENCE: This session is intended for pathologists, laboratory directors, clinical chemistry professionals, laboratory managers, microbiologists, physicians and other clinical professionals in emergency medicine, ICU, infectious disease, as well as federal and state regulators, medical laboratory scientists, IVD industry scientists and IVD decisionmakers.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Define criteria for sepsis diagnosis and explain the qSOFA scoring system for risk assessment
- 2. Describe the pros and cons of procalcitonin for acute sepsis diagnosis and for ruling in and ruling out viral infection.
- 3. Explain a plausible role of iNOS in the pathophysiology of sepsis and critically discuss its possible use as an early sepsis diagnostic.
- 4. Describe HNL as a biomarker and list three ways it might be utilized for differential diagnosis of early sepsis.

#### **SPEAKERS**

Inducible Nitrous Oxide Synthase in Sepsis: Bad Actor but Promising Diagnostic Richard Sweet, MD UCSF Medical Center, San Francisco, CA

Human Neutophil Lipocalin: Use in Early Diagnosis and Monitoring of Acute Infections Robert Christenson, PhD, ABCC, FACB University of Maryland School of Medicine, Baltimore, MD

Procalcitonin Pros, Cons and Confounders Jessica Colon-Franco, PhD, DABCC Cleveland Clinic, Solon, OH

#### 10:30am-12:00pm

Moving Beyond Immunoassays for the Poisoned Patient: Analytical Approaches and Interactive Case Studies

34109 Room: 208AB

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 1.5

#### **MODERATOR/SPEAKER**

Amitava Dasgupta, PhD, DABCC University of Texas–Houston Medical School, Houston, TX

## **SPEAKERS**

detection

Case Studies

Kara Lynch, PhD, DABCC, FAACC ZSFG Clinical Laboratory, San Francisco, CA

SESSION OVERVIEW: Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a maturing technique for diagnostic laboratories. An introduction of testing protocols using LC-MS/MS has been introduced at AACC University (The Secrets to Success: Implementing Robust LC-MS/MS Methods in the Clinical Laboratory); this course intends build on that session by exploring experimental pathways of more esoteric assays (i.e., clinical protein analysis) as well as considerations for operational execution of LC-MS/MS in the clinical lab.

**INTENDED AUDIENCE:** This session is intended for users of liquid chromatography-tandem mass spectrometry technology (laboratory technicians, scientists and lab directors).

1. Evaluate the validation protocols utilized in their laboratory to ensure scientific rigor is applied to de novo assays on liquid chromatography platforms. Presentation Level: ADVANCED

workflows.

MS/MS.

**SPEAKERS** 

Brian Rappold

#### **MODERATOR/SPEAKER**

Brian Rappold LabCorp, Raleigh, NC

ACCENT<sup>®</sup> Credits: 2.5

Developed in cooperation with Mass Spectrometry and Separation Sciences Division

Liquid Chromatography-Tandem

Mass Spectrometry, Advanced

Russell Grant, PhD LabCorp, Burlington, NC

**AFTERNOON** 

2:30pm-5:00pm

Topics

34216

Room: 207CD

SESSION OVERVIEW: Urine toxicology testing has significant limitations when a patient presents with a potential overdose or poisoning. Many illicitly manufactured drugs and novel psychoactive substances, including synthetic amphetamines, cannabinoids, and opioids, such as fentanyl analogs, are not detected by routine drug testing. This session will emphasize how to effectively communicate with clinicians for further testing, describe analytical tools used for monitoring the poisoned patient, and highlight the complexity of the current overdose epidemic in the United States through interactive case studies (audience response).

**INTENDED AUDIENCE:** This session is intended for pathologists, clinical chemists, toxicologists and medical technologists.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Understand circumstances when routine toxicology testing may fail to identify the causative agent in a poisoned patient.

2. Communicate effectively with ordering physicians to identify the probable cause of negative toxicology results and decide what further testing should be conducted.

3. Describe the advantages and disadvantages of different analytical approaches for drug

4. Interpret clinical symptoms and analytical results associated with illicitly manufactured drugs and novel psychoactive substances, including synthetic amphetamines, cannabinoids, and opioids.

The Poisoned Patient: How to Communicate with Clinicians and Guide Further Testing Amitava Dasgupta, PhD, DABCC University of Texas-Houston Medical School, Houston, TX

Moving Beyond Urine Toxicology Immunoassays: Analytical Testing Strategies and Interactive

LEARNING OBJECTIVES: After this session, participants will be able to:

2. Apply experimental paradigms to the development and optimization of LC-MS/MS

3. Understand better the unique challenges presented by analysis of human matrices by LC-

#### Liquid Chromatography-Tandem Mass Spectrometry, Advanced Topics

LabCorp, Raleigh, NC Andrew Hoofnagle, MD, PhD University of Washington, Seattle, WA

### **SCIENTIFIC SESSIONS**

### **AFTERNOON**

#### 2:30pm-5:00pm

Better Diagnoses, Improved **Patient Outcomes through Patient-Centered Laboratory Medicine** 

34217 Room: 204B

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 2.5

#### **MODERATOR/SPEAKER**

Danielle Freedman, MBCh, MD, FRCPath Luton & Dunstable Hospital, Luton, Bedfordshire, United Kingdom

SESSION OVERVIEW: Every nine minutes, someone in a U.S. hospital dies because of an incorrect or delayed medical diagnosis. The reduction of diagnostic error and unnecessary or harmful procedures, the focus on improved patient outcomes, and the shift from volume to value are key themes of 21st-century medicine. The clinical laboratory has a pivotal role in all these areas. This session will explore the broad linkage of laboratory testing to patient outcomes. The discussion will include the value of point-of care testing, and will indicate new approaches to delivering patient-centered laboratory medicine.

**INTENDED AUDIENCE:** This session is intended for medical technologists, clinical chemists, pathologists, laboratory supervisors/managers, laboratory directors and industry scientists.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Describe the factors that influence the link between laboratory testing and patient outcomes.
- 2. Review the changes in delivery of diagnostic medicine envisaged in the National Academies' report "Improving Diagnosis in Health Care" (2015).
- 3. Explain the role of the diagnostic management team (DMT) in improving test selection and results interpretation.
- 4. Discuss the application of the DMT approach to specific clinical problems.
- 5. Summarize the evidence relating to the impact of point-of-care testing on patient outcomes.

#### **SPEAKERS**

#### Overview: Linking Laboratory Medicine to Patient Outcomes Michael Hallworth, MA, MSc, FRCPath Shrewsbury, United Kingdom

The New Diagnostic Team—Moving Forward Michael Laposata, MD, PhD

#### University of Texas Medical Branch Galveston, Galveston, TX From Hemoglobins to Toxicology: The Diagnostic Management Team and Interpretive

Services in Action James Nichols, PhD, DABCC, FAACC Vanderbilt University Medical Center, Nashville, TN

The Value of Point-of-Care Testing—Does It Improve Outcomes? Danielle Freedman, MBCh, MD, FRCPath Luton & Dunstable Hospital, Luton, Bedfordshire, United Kingdom

#### 2:30pm-5:00pm

Tackling Infectious Disease Testing and Interpretation: Considering the Perspectives of the Core Clinical Laboratory and Point-of-Care Testing

34218

Room: 204A

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 2.5

#### **MODERATOR/SPEAKER**

2:30pm-5:00pm

34219

Room: 205AB

ACCENT<sup>®</sup> Credits: 2.5

**MODERATOR/SPEAKER** 

Renal Tubules in Acid/Base

**Disorders and Blood Pressure** 

**Regulation: We Don't Get Respect!** 

Presentation Level: INTERMEDIATE

University of Florida, Gainesville, FL

Nicole Tolan, PhD, DABCC Brigham and Women's Hospital, Boston, MA

2. Consider the medical significance of infectious disease testing and identify the clinical scenarios where clinical chemistry/POC testing interpretations add value to patient care. 3. Evaluate current testing recommendations in light of specific case-based examples to potentially improve their own practice in infectious disease testing and interpretation.

#### **SPEAKERS**

Nicole Tolan, PhD, DABCC

### Testina

Gary Horowitz, MD Tufts Medical Center, Boston, MA

SESSION OVERVIEW: Renal tubular disorders are underappreciated and often not well understood due to the biological and clinical complexities of the disease. Presentation of the pathophysiology of renal tubular disorders, as well as interpretation of relevant clinical laboratory tests, will empower attendees to appropriately guide discussions with clinicians surrounding the role of the renal tubules in acid/base balance and blood pressure regulation and ultimately impact test utilization. This session will use a case-based format to solicit interactive discussion among participants.

INTENDED AUDIENCE: This session is intended for pathologists, pathology trainees, laboratory directors, clinical chemists, medical technologists and IVD industry scientists.

William Winter, MD, DABCC, FAACC disorders.

#### **SPEAKERS**

Renal Tubules and Blood Pressure Regulation Neil Harris, MBChB, MD, FAACC University of Florida, Gainesville, FL

Renal Tubular Acid/Base Disorders William Winter, MD, DABCC, FAACC University of Florida, Gainesville, FL

SESSION OVERVIEW: This workshop-style, interactive session will use practical, case-based scenarios along with audience participation techniques to help attendees identify best practices in infectious disease testing and interpretation. For each infectious disease covered (HIV, HCV, HBV, C. diff, flu and syphilis), speakers will briefly present the relevant analytical and clinical considerations for evaluating testing methods, determining necessary reflex confirmations, and demonstrating the value of personalized reporting and interpretation of results. Breakout sessions will then follow each presentation and include roundtable discussions of case examples for attendees to determine how to best optimize workflows, reduce unnecessary costs, and ultimately, support quality patient care.

**INTENDED AUDIENCE:** This session is intended for clinical chemists, pathologists, laboratory directors, laboratory technologists, point-of-care professionals, industry scientists and regulatory agency representatives.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Examine the principles of various infectious disease testing methods to appreciate their limitations in the screening or diagnosis of infectious diseases.

Evaluating the Clinical Considerations and Method Limitations for HIV, HCV and Flu Testing Brigham and Women's Hospital, Boston, MA

Evaluating the Clinical Considerations and Method Limitations for HBV, C. Diff and Syphilis

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Explain to clinicians the physiology of renal acid/base balance.

2. Assist clinicians in test selection and interpretation regarding renal tubular acid/base

3. Explain to clinicians the physiology of renal tubular blood pressure regulation. 4. Assist clinicians in test selection and interpretation regarding renal tubular disorders causing hypo or hypertension.

### **SCIENTIFIC SESSIONS**

### **AFTERNOON**

#### 2:30pm-5:00pm

**Patient-Based Quality Control Techniques: Statistical Power from** and for the Masses

34220 Room: 206AB

Presentation Level: INTERMEDIATE ACCENT® Credits: 2.5

#### **MODERATOR/SPEAKER**

Mark Cervinski, PhD, DABCC, FAACC Dartmouth-Hitchcock Medical Center, Lebanon, NH

#### 2:30pm-5:00pm

The Devil Is in the Details: **Coagulation Testing for Different** Patient Populations

34221 Room: 204C

Presentation Level: **BASIC** ACCENT® Credits: 2.5

#### **MODERATOR/SPEAKER**

Anna Merrill, PhD, DABCC University of Iowa, Iowa City, IA

Developed in cooperation with Hematology and Coagulation Division SESSION OVERVIEW: This session will describe the evolution of patient-based quality control techniques from theory into practice, and will include a comparison of the strengths and weaknesses of techniques such as the average of normals and patient moving averages. The session will include the differing unique perspectives of the hospital-based laboratory and high-throughput large reference laboratory. Examples where patient-based quality control successfully detected the onset of analytic error prior to traditional quality control events will be presented in a case-based format.

INTENDED AUDIENCE: This session is intended for laboratory directors, clinical chemistry fellows and trainees, clinical chemists, clinical pathologists, laboratory technologists, and IVD industry representatives.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Describe the evolution of patient-based quality control from theory into practice.

2. List common patient-based quality control techniques and contrast the limitations of each.

- 3. Explain the limitations of patient-based quality control techniques in regard to error detection of low volume tests, skewed distributions and other data challenges.
- 4. Evaluate which patient-based quality control techniques are applicable to their patient populations and analyte menu.

#### **SPEAKERS**

#### Background and Recent Developments in Moving Average Quality Control

Huub van Rossum, PhD

The Netherlands Cancer Institute, Antoni Van Leeuwenhoek Hospital Amsterdam, Amsterdam, Netherlands

Development, Implementation and Validation of Moving Averages in a Hospital-Based Laboratory Mark Cervinski, PhD, DABCC, FAACC

Dartmouth-Hitchcock Medical Center, Lebanon, NH

Patient-Based Quality Control: Experience from a Large U.S.-Based Reference Laboratory James Fleming, PhD, MSc, NRCC, FACB

LabCorp, Elon, NC

SESSION OVERVIEW: Disorders in coagulation present various clinical and analytical challenges. The landscape of treatment and laboratory monitoring for these disorders is rapidly changing. This session will focus on clinical and laboratory aspects of coagulation in commonly encountered patient populations: patients with liver disease, patients taking direct oral anticoagulants (DOACs), and patients with autoimmune disorders, including thyroid disease.

INTENDED AUDIENCE: This session is intended for pathologists, clinical chemists, laboratory technologists, fellows in clinical chemistry, and residents.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Discuss the "rebalancing" of hemostasis in liver disease and the anticipated effect on routine coagulation tests.
- 2. Describe the impact of direct oral anticoagulants on common coagulation tests.
- 3. Explain the proposed pathophysiology for the association between coagulation disorders and autoimmune/thyroid disease.
- 4. Recognize the limitations of the CoaguChek point-of-care instruments for monitoring anticoagulation in various patient populations.

#### **SPEAKERS**

#### Coagulation Testing in Patients with Liver Disease Anna Merrill, PhD, DABCC University of Iowa, Iowa City, IA

Coagulation Testing in Patients Taking Direct Oral Anticoagulants Lindsay Bazydlo, PhD, DABCC, FAACC University of Virginia, Charlottesville, VA

Coagulation Testing in Patients with Thyroid and Other Autoimmune Disorders Olajumoke Oladipo, MD, DABCC, FAACC

Penn State Milton S. Hershey Medical Center, Hershey, PA

#### 2:30pm-5:00pm

#### **Overcoming the Challenges of ANA** Testing

34223 Room: 207AB

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 2.5

#### **MODERATOR/SPEAKER**

Melissa Snyder, PhD Mayo Clinic, Rochester, MN

Developed in cooperation with Clinical and Diagnostic Immunology Division

## Xavier Bossuyt, MD

testina.

**SPEAKERS** 

testina.

Melissa Snyder, PhD Mayo Clinic, Rochester, MN

SESSION OVERVIEW: Implementing multi-analyte tests that combine biomarkers, patient demographics and clinical information into an algorithm to generate a disease risk score is becoming increasingly common in clinical laboratories. This session will center on the clinical utility and implementation considerations of established multi-analyte strategies along with highlighting emerging multi-analyte testing approaches.

scientists.

Room: 209AB

#### Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 2.5

**Clinical Applications of Established** 

and Emerging Multi-Analyte Testing

#### **MODERATOR/SPEAKER**

2:30pm-5:00pm

Approaches

34224

Alicia Algeciras-Schimnich, PhD, DABCC Mayo Clinic, Rochester, MN

### **SPEAKERS**

Mayo Clinic, Rochester, MN

Preeclampsia and Sepsis Jessica Colon-Franco, PhD, DABCC Cleveland Clinic, Solon, OH

Peter Kavsak, PhD



SESSION OVERVIEW: Antinuclear antibody (ANA) testing presents the clinical laboratory with many unique challenges, from methodological differences to clinical applications. This session will include an overview of ANA testing with a focus on clinical interpretation, a methodological comparison between immunofluorescence and immunoassays, and a discussion on the advantages and limitations of laboratory automation related to ANA

**INTENDED AUDIENCE:** This session is intended for clinical laboratory directors and pathologists, clinical technologists, IVD manufacturers, and pharmaceutical scientists.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Identify the three primary methods available to the clinical laboratory for ANA detection. 2. Describe the parameters that a lab would consider when selecting a method for ANA

3. List advantages and limitations of automation of ANA by IFA.

#### Clinical and Laboratory Strategies for Improved ANA Testing: Polishing the Gold Standard Immunofluorescence ANA Mark Wener, MD, ABMLI, ABIM, ABIM-RHEUM

University of Washington Medical Center, Seattle, WA

#### ANA Detection by Indirect Immunofluorescence and by Immunoassay

UZ-KU Leuven Medical Center, Leuven, Belgium

### Can Automation Bring ANA Testing out of the Dark Room and into the Modern Laboratory?

INTENDED AUDIENCE: This session is intended for laboratory directors, clinical chemists, medical laboratory scientists, laboratory administrators, physicians and IVD industry

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. List the regulatory and infrastructure considerations related to the adoption of multi-
- analyte assays with algorithmic analyses (MAAA) in clinical laboratories.
- 2. Describe the clinical utility of MAAA in cancer.
- 3. Describe emerging MAAA approaches for the diagnosis of acute and chronic diseases, including sepsis and liver diseases.
- 4. Describe emerging MAAA approaches in the setting of acute coronary syndrome.

#### Applications of MAAA in Oncology: Clinical Utility and Implementation Considerations Alicia Algeciras-Schimnich, PhD, DABCC

### Scoring the Utility of Emerging Multi-Analyte Tests across Diseases—from Liver Fibrosis to

#### Choosing Wisely with Laboratory Tests in Patients with Possible Acute Coronary Syndrome: The Evidence for a Clinical Chemistry Score

McMaster University & Juravinski Hospital and Cancer Centre, Hamilton, Canada

### 89 www.2019aacc.org

### **SPECIAL SESSION**

2:30pm-5:00pm

Room: 210A

#### Healthcare Forum: Laboratory Stewardship in Healthcare Innovation

34225

Presentation Level: INTERMEDIATE | ACCENT<sup>®</sup> Credits: 2.5

#### MODERATOR

Loretta Doan, PhD

AACC, Washington, DC

Developed in cooperation with Policy and External Affairs Core Committee

SESSION OVERVIEW: The session will address the current shifts in healthcare delivery and payments away from volumebased fee-for-service models toward value-based models with bundled or capitated payments. To be successful, the new models will require collaboration and cooperation across the entire spectrum of providers and healthcare professionals, each of whom has a unique role in providing high-value, cost-efficient care. This session will address the framework of the shifting models, the needs of integrated healthcare systems, and tools for laboratory directors to implement successful laboratory stewardship programs.

INTENDED AUDIENCE: This session is intended for laboratory directors, laboratory managers, medical technologists, and other laboratory and industry personnel responsible for regulatory, payment and compliance issues.

LEARNING OBJECTIVES: After this session, participants will:

- 1. Understand the new value-based healthcare environment.
- 2. Know how laboratories can help healthcare systems achieve common objectives.
- 3. Understand how laboratories demonstrate the value of their services.

4. Learn what tools are available for guiding appropriate test utilization and improving care.

#### **SPEAKERS**

How Healthcare Is Changing and What That Means for Patients Shantanu Agrawal, MD, MPhil

National Quality Forum, Washington, DC

What Integrated Healthcare Systems Need from Laboratory Stewardship Programs Jonathan Gleason, MD Carilion Clinic, Roanoke, VA

PLUGS: A National Movement, Forum, and Resources for Laboratory Stewardship Programs Jane Dickerson, PhD, DABCC Seattle Children's Hospital, Seattle, WA

### **SPECIAL SESSION**

4:00pm-5:00pm Room: Hall A, Poster Theater

### Laboratory Feud: Science and Practice Core Committee vs. Education Core Committee

Presentation Level: **BASIC** 

SESSION OVERVIEW: This session will use the "Family Feud" game show-style format in which two teams (five members of the AACC Science and Practice Core committee vs. five members of the Education Core Committee) will compete in an educational challenge covering various laboratory medicine topics. It will be not only educational, but also provide a platform for the audience to become more familiar with some of our AACC leaders.

INTENDED AUDIENCE: This session is intended for all AACC members including pathologists, lab directors, clinical chemists, technologists, IVD industry scientists, residents and fellows.

**LEARNING OBJECTIVES:** After this session, participants will be able to:

1. List various clinical biomarkers and their clinical utility.

2. Identify the most commonly used/abused drugs.

3. Recognize common factors that can affect laboratory test results.

#### MODERATOR

Paul Jannetto, PhD, DABCC, MT (ASCP), FAACC Mayo Clinic, Rochester, MN

#### SCIENCE AND PRACTICE CORE COMMITTEE TEAM

Team Captain: Lakshmi Ramanathan, PhD Memorial Sloan-Kettering Cancer Center, New York, NY

Kerstin Halverson, MS Instrumentation Laboratory, Farmington, MN

Amy Pyle-Eilola, PhD Nationwide Children's Hospital, Columbus, OH

Joesph Wiencek, PhD University of Virginia School of Medicine, Charlottesville, VA

Yan Victoria Zhang, PhD, DABCC University of Rochester Medical Center, Rochester, NY

#### EDUCATION CORE COMMITTEE TEAM

Team Captain: Elizabeth Frank, PhD, DABCC, MT (ASCP), FAACC ARUP Laboratories/University of Utah, Salt Lake City, UT

Steven Cotten, PhD, DABCC, FAACC University of North Carolina at Chapel Hill, Chapel Hill, NC

Andrew Don-Wauchope, MD, MBChB, FRCPE LifeLabs, Toronto, Canada

Veronica Luzzi, PhD, DABCC Providence Regional Laboratories, Portland, OR

Hubert Vesper, PhD Centers for Disease Control, Atlanta, GA










# THURSDAY AUGUST 8

### **PLENARY & SCIENTIFIC SESSIONS**





**PLENARY SESSION** 



### **Extreme Molecular Diagnostics**

Carl Wittwer, MD, PhD Salt Lake City, UT

8:45am-10:15am Room: Ballroom ABC

15001

SESSION OVERVIEW: Extreme molecular diagnostics takes only seconds. With very short turn-around times, pre-analytical and post-analytical challenges are minimized, point-of-care testing makes sense, and high-throughput is not necessary. Real-time "extreme" PCR in <15 seconds (35 cycles, 60-bp human genomic DNA) is specific, sensitive, and high yield. High-speed melting analysis (4 seconds) allows single base genotyping and variant scanning. Rapid reverse transcription and sample preparation will enable sample-to-answer diagnostics in <1 minute. The value of point-of-care testing depends on how quickly it can be performed.

technology.

1. Explain what is meant by extreme PCR.

analysis.

3. Understand the implications of extreme molecular diagnostics for clinical testing.



Professor of Pathology, University of Utah,

### Presentation Level: BASIC | ACCENT® Credits: 1

INTENDED AUDIENCE: This session is intended for pathologists, lab directors, molecular biologists, clinical chemists, technologists, physicians, and IVD industry scientists with an interest in molecular diagnostics and nucleic acid amplification

LEARNING OBJECTIVES: After this session, participants will be able to:

- 2. Describe the technology underlying extreme PCR and high-speed melting

# THURSDAY | AUGUST 8

### **MEET THE EXPERT**

#### 10:30am-11:30am

**Extreme Molecular Diagnostics** 

65101 Room: 210B

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 1

SESSION OVERVIEW: This session will provide an excellent opportunity for attendees to meet with Dr. Wittwer in a more intimate setting and listen to him discuss his talk, "Extreme Molecular Diagnostics."

INTENDED AUDIENCE: This session is intended for pathologists, lab directors, molecular biologists, clinical chemists, technologists, physicians and IVD industry scientists with an interest in molecular diagnostics and nucleic acid amplification technologies.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Explain what is meant by extreme PCR.

2. Describe the technology underlying extreme PCR and high-speed melting analysis. 3. Understand the implications of extreme molecular diagnostics for clinical testing.

#### **SPEAKER**

Carl Wittwer, MD, PhD Professor of Pathology, University of Utah, Salt Lake City, UT

#### 10:30am-12:00pm

**Plasma Microvesicles: A Treasure** Trove of Novel Biomarkers for **Disease Diagnosis** 

35102 Room: 201AB

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 1.5

Alan Wu, PhD University of California, San Francisco, San Francisco, CA

### **SCIENTIFIC SESSIONS**

### MORNING

#### 10:30am-12:00pm

**Return of Individual Specific** Research Results to Participants: The National Academies of Sciences, Engineering and Medicine Report

35101 Room: 206AB

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 1.5

#### **MODERATOR/SPEAKER**

James Nichols, PhD, DABCC, FAACC Vanderbilt University Medical Center, Nashville, TN

SESSION OVERVIEW: Research drives scientific discovery and advances laboratory medicine. While HIPAA grants research participants access to their study results, CLIA requires minimal quality standards if research results are intended for clinical care. This session will explore this regulatory conflict and the impact of recommendations from the recent National Academies of Sciences, Engineering and Medicine report on hospital and academic laboratory operations.

**INTENDED AUDIENCE:** This session is intended for research staff, principle investigators, laboratory medical directors, and IVD industry and government personnel involved in funding, managing and conducting clinical and basic research studies.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Examine the evidence on benefits and risks of returning individual results to research participants.
- 2. Appreciate the ethical, social, operational and regulatory aspects of returning individual research results to participants.
- 3. Identify if and when it is appropriate to return individual results to research participants.

#### **SPEAKERS**

Returning Individual Research Results to Participants: A Clinical and Research Laboratory Perspective

James Nichols, PhD, DABCC, FAACC Vanderbilt University Medical Center, Nashville, TN

Returning Individual Research Results to Participants: Guidance for a New Research Paradigm Jeffrey Botkin, MPH, MD University of Utah, Salt Lake City, UT

**SESSION OVERVIEW:** As a means of communication, cells secrete biological materials through the formation and shedding of microvesicles. These circulating extracellular nanoparticles contain proteins and nucleic acids that are specific to the host cell. Methods are available for isolation of microvesicles from plasma. Analysis of microvesicle content provides a source of biomarkers for disease detection.

**INTENDED AUDIENCE:** This session is intended for academic and industry-based researchers who develop and validate new biomarkers for disease detection, clinical laboratory directors and scientists who implement novel technologies and assays, and regulatory personnel who would like to learn about the future direction of lab diagnostics.

**SPEAKERS** 

Ischemia Alan Wu, PhD

#### **MODERATOR/SPEAKER**

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Explain what microvesicals are and how they may be used.

2. Explain how microvesicle analysis can be used for detection of reversible myocardial injury.

3. Explain how microvesical analysis can be used for cancer detection using uveal melanoma as an example.

4. Explain the role of microvesicle-associated nitric oxide synthase in the pathophysiology of sepsis and how it can be used as a diagnostic marker.

#### Detection of Cardiac Troponin in Microvesicles for Detection of Reversible Myocardial

University of California, San Francisco, San Francisco, CA

Proteomic Discovery of Extracellular Vesicle Proteins for Prostate Cancer and Uveal Melanoma Alex Rai, PhD, DABCC, FAACC

Columbia University, New York, NY

Detection of Inducible Nitric Oxide Synthase (iNOS) in Circulating Microvesicles as a Biomarker to Detect and Diagnose the Onset of Sepsis Richard Sweet, MD

UCSF Medical Center, San Francisco, CA







# THURSDAY | AUGUST 8

### **SCIENTIFIC SESSIONS**

### MORNING

10:30am-12:00pm

#### Artery Hot Topics 2019

35103 Room: 204B

Presentation Level: **BASIC** ACCENT<sup>®</sup> Credits: 1.5

#### MODERATOR

Allison Chambliss, PhD, DABCC, FAACC Keck School of Medicine of USC, Los Angeles, CA

SESSION OVERVIEW: Using AACC's online forum, Artery, as a metric, we have identified three common areas of ambiguity facing today's clinical laboratorians: individualized guality control plans, oral glucose tolerance testing, and drugs of abuse immunoassay screening. Relevant to each of these challenges, this session will provide essential scientific background, current regulations and/or practice guidelines, and practical opportunities for resolution.

INTENDED AUDIENCE: This session is intended for pathologists, laboratory directors, clinical chemists, laboratory managers and supervisors, technologists, and IVD industry scientists who are involved with clinical laboratory testing.

LEARNING OBJECTIVES: After this session, participants will be able to:

- 1. Describe the CMS standards and requirements related to the Individualized Quality Control Plan (IQCP).
- 2. Develop concrete strategies for minimizing pre-analytical errors in oral glucose tolerance testing.
- 3. Discuss modern complications of urine drug screening practices.

#### **SPEAKERS**

You Do WHAT?!?: Individualized Quality Control Tiffany Roberts, PhD, DABCC, FAACC, DABHI University of Louisville, Louisville, KY

#### Gestational Glucose Screening: The Sweet Smell of Best Practices

Sean Campbell, PhD Montefiore Medical Center, Bronx, NY

Did a Literal Reading of a Package Insert During an Inspection Expose a Valid Point about Urine Drug Screens? Danyel Tacker, PhD, DABCC, FAACC

West Virginia University Hospitals, Morgantown, WV

#### 10:30am-12:00pm

**Removing Laboratory Barriers to** Improve Kidney Disease Testing and Diagnosis

35104 Room: 204C

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 1.5

#### MODERATOR

Lakshmi Ramanathan, PhD Memorial Sloan-Kettering Cancer Center, New York, NY

Developed in cooperation with Management Sciences and Patient Safety Division

SESSION OVERVIEW: Chronic Kidney Disease (CKD) is a public health issue. Over 80% of the 30 million people with CKD are undiagnosed in primary care, including almost 50% of patients in kidney failure. The National Kidney Foundation, the nation's leading laboratories and prominent pathology organizations are collaborating to remove laboratory test ordering and reporting barriers to CKD testing. This session brings perspectives on this collaboration from patients, nephrologists, pathologists and primary care physicians.

**INTENDED AUDIENCE:** This session is intended for clinical chemists, clinical pathologists, residents, fellows, clinical laboratory scientists, medical technologists, research scientists, and laboratory supervisors and managers.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Describe the clinical and cost implications of timely recognition of CKD.

2. Recognize the pre-analytical and analytical limitations of currently available tests.

3. Understand how clinical laboratory testing can be applied in CKD population health.

#### **SPEAKERS**

#### Understanding CKD in a Population Health Model Joseph Vassalotti, MD Kidney Foundation, New York, NY

Removing Laboratory Barriers to CKD Detection and Monitoring Greg Miller, PhD, DABCC

Virginia Commonwealth University, Richmond, VA

A Patient's Perspective on CKD Diagnosis and Quality of Life David Rosenbloom, BA USC University Hospital, Los Angeles, CA

#### 10:30am-12:00pm

**Opportunities and New** Approaches to Guide Utilization of Urine-Based Testing for Diagnosis of Infectious Disease

35105 Room: 205AB

Presentation Level: INTERMEDIATE ACCENT<sup>®</sup> Credits: 1.5

#### **MODERATOR/SPEAKER**

10:30am-12:00pm

ACCENT<sup>®</sup> Credits: 1.5

**MODERATOR/SPEAKER** 

Developed in cooperation with

You

35106

Room: 204A

Hemostatic Disorders That Can Kill

Presentation Level: INTERMEDIATE

William Winter, MD, DABCC, FAACC

University of Florida, Gainesville, FL

Hematology and Coagulation Division

Melanie Yarbrough, PhD Washington University, St. Louis, MO

#### **SPEAKERS**

Audrev Schuetz, MD, MPH Mayo Clinic, Rochester, MN

laboratories

Melanie Yarbrough, PhD

David Warren, MD, MPH

SESSION OVERVIEW: Dangerous common thrombotic disorders require early recognition, diagnosis, and treatment because they are amenable to treatments that result in positive patient outcomes. This session will discuss common thrombotic disorders, including heparininduced thrombocytopenia (HIT) and the anti-phospholipid syndrome (APLS). For these disorders, a selected combination of a few tests may be more helpful than a "shotgun" battery of coagulation testing. These coagulation tests are not necessarily esoteric laboratory assays, and often results may be within the reference range even in serious conditions. It is essential that laboratorians become familiar with these life-threatening conditions in order to prioritize their workload within a busy core laboratory and have productive discussions with the clinical hematology team in order to provide them with appropriate guidance and interpretation.

**LEARNING OBJECTIVES:** After this session, participants will be able to:

1. Explain to clinicians and other laboratorians the biology and pathophysiology of heparininduced thrombocytopenia (HIT) and the anti-phospholipid syndrome (APLS).

#### **SPEAKERS**

University of Florida, Gainesville, FL

Heparin-Induced Thrombocytopenia Neil Harris, MBChB, MD, FAACC University of Florida, Gainesville, FL

96 www.2019aacc.org

### value-based care.

SESSION OVERVIEW: Recent advances in urine collection devices and diagnostic testing have provided opportunities for clinical laboratories to improve upon stagnant practices that may have deleterious effects on test utilization and result quality. This case-based session will highlight the importance of pre-analytical variables in urine testing, describe the impact of reflex algorithms on urine culture utilization, and describe how laboratory-based initiatives to reduce unnecessary urine testing can support value-based care and impact patient care.

INTENDED AUDIENCE: This session is intended for laboratory directors, clinical chemists, laboratory administrators, laboratory managers and supervisors, pathology trainees, pathologists, physicians, and medical technologists.

LEARNING OBJECTIVES: After this session, participants will be able to:

1. Describe optimal urine collection and transport guidance for infectious disease testing. 2. Explain the workflow and advantages of reflex algorithms for urine culture in clinical

3. Describe the impact of diagnostic stewardship for urine cultures on patient outcomes and

Innovations and Considerations for Pre-Analytical Variables in Urine-Based Testing

Implementation and Impact of Reflex Algorithms on Urine Culture Utilization

Washington University, St. Louis, MO

Laboratory-Directed Initiatives to Reduce Catheter-Associated Urinary Tract Infections and Support Value-Based Care: A Physician's Perspective

Washington University School of Medicine, St. Louis, MO

INTENDED AUDIENCE: This session is intended for clinical chemists, laboratory directors, medical technologists, trainees and pathologists.

2. Create an awareness of the essential laboratory features and test-selection criteria relative to these life-threatening thrombotic disorders.

3. Evaluate the causes of a prolonged aPTT, which can (paradoxically) signal both a lifethreatening bleeding disorder and a thrombotic disorder.

The Anti-Phospholipid Syndrome William Winter, MD, DABCC, FAACC

# AACC BOOTH, MEMBER LOUNGE & STORE

### **AACC BOOTH**

Stop by and visit booth #4353 on the Expo show floor to learn how AACC is at the forefront of new approaches in laboratory medicine, as well as addressing the complexity of an evolving healthcare landscape and promoting new thinking and new skills.

### **AACC MEMBER LOUNGE**

AACC members are invited to visit the Member Lounge located at the AACC booth #4353 on the Expo show floor. This members-only benefit provides a place to recharge between sessions, mingle with colleagues and enjoy light refreshments.

#### AACC Booth/Member Lounge Hours

Tuesday–Wednesday	9:30am–5:00pm
Thursday	9:30am–1:00pm

#### **Member Lounge Activities**

Tuesday, August 6	
SYCL Meet & Greet	1:00pm–2:00pm
Artery Happy Hour	3:00pm–5:00pm
(RSVP required — see the Artery for details)	

#### Wednesday, August 7

SYCL Meet & Greet	 1:00pm–2:00pm

### **AACC STORE**

Plan to visit the AACC store, located in Lobby B, to browse some of AACC's bestsellers and AACC merchandise for purchase, including t-shirts, wearables and gifts.

#### AACC Store Hours

Sunday-Wednesday ......9:00am-5:00pm Thursday......9:00am-1:00pm



# AACC

### HELP THE NEXT GENERATION OF LABORATORY MEDICINE SCIENTISTS

AACC's International Travel Grant Program is a way for you to give back to the clinical chemistry profession. Through your generous donations, emerging laboratory scientists from outside the U.S. and Canada are supported and encouraged to contribute to excellence in the profession. These grants bring laboratorians from all over the world to the AACC Annual Scientific Meeting, allowing them to network with colleagues, attend cutting-edge scientific sessions and tour the AACC Clinical Lab Expo.



"Having the chance to meet and talk to the experts in the field of laboratory medicine through AACC has been one of the most important things in my professional life." — Manjula Dissanayake, Sri Lanka



"AACC's events and publications are the most cutting-edge in global laboratory medicine, and they illuminate our research." — Weiyan Zhou, China

### **DONATE TODAY**

### **HERE'S HOW:**

- Go to www.aacc.org/about-aacc/access/contribute.
- Email us at itg@aacc.org.

Thank you to all our donors who made these grants possible this year. A list of recent donors is found at www.aacc.org/about-aacc/access/donors.

# **ACCESS PROGRAM**

# **SPEAKER** INDEX

	101000
Adcock, Dorothy	
Agrawal, Shantanu	
Akbas, Neval	44110/54210
Algeciras-Schimnich, Alicia	
Ali, Mahesheema	
Amukele, Timothy	
Apple, Fred	
Arens, Ann	
Ashley, Euan	-
Astles J. Rex	
Babic, Nikolina	
Bachmann, Lorin	
Badea, Adina	
Barakauskas, Vilte	
Barbhuiya, Mustafa	
Baron, Jason	
Bazydlo, Lindsay	
Bendall, Sean	
Berte, Lucia	
Binkley, Neil	
Blick, Kenneth	
Booth, Ronald	
Bornhorst, Joshua	
Bossuyt, Xavier	
Botelho, Julianne	
Botkin, Jeffrey	
Bowen, Raffick	
Bransfield, Alison	
Bransky, Avishay	
Bratanow, Nancy	
Brown, Florence	
Bryksin, Janetta	
Budelier, Melissa	
Bunch, Dustin Burnham, Carey-Ann	
-	
Camara, Johanna	22104 25102
Campbell, Sean	42108/52208
Campbell, Sheldon	
Cao, Jing	32222, 33224
Carayannopoulos, Mary	
Carroll, Ty	
Cervinski, Mark	34220
Chadburn, Amy	191003
Chambliss, Allison	33226, 35103
Chang, Tyllis	
Chen, Jonathan	
Cheung, Angela	
Christenson, Robert	
Clarke, William	
Cobbaert, Christa	32216
Colby, Jennifer	32220
Colon-Franco, Jessica	
Cook-Deegan, Robert	
Cotten, Steven	

Countryman, Sky	
Dangott, Bryan	
Danilenko, Uliana	
Das, Barnali	
Das, Saswati	
Dasgupta, Amitava	33107, 34109, 42104/52204
De Biase, Irene	
Deignan, Josh	193015
Denmon, Andria	
Devaraj, Sridevi	32222, 33224
DiCarlo, Dino	32433
Dickerson, Jane	34105, 34225
Doan, Loretta	
Don-Wauchope, Andrew	LF
Donato, Leslie	
Dungan, Kathleen	
Eby, Charles	
El-Khoury, Joe	
Erdogan, Evrim	
Evans, Susan	
Fantz, Corinne	
Fares Taie, Felix	
Feng, Sheng	
Ferguson, Angela	
Fernandes, Helen	
Ferreira-Gonzalez, Andrea	
Fitzgerald, Robert	
Fleming, James	
Ford, David	
Frank, Elizabeth	•
Freedman, Danielle	
Fuezery, Anna	
Galasko, Douglas	
Garcia, Juan David	
Garg, Uttam	
Garnett, Emily	
Geaghan, Sharon	
Geno, Aaron Genzen, Jonathan <b>192009,</b>	43126/53226
Gherasim, Carmen	
Gleason, Jonathan	
Gochman, Nathan	
Gore, Athurva	
Grant, Russell	
Green, Eric	
Greene, Dina	
Grenache, David	
Gronowski, Ann	
Gruson, Damien	42102/52202, 43102/53202
Hackenmueller, Sarah	
Hackenmueller, Saran Hagenkord, Jill	
Hagenkord, Jill Hallworth, Michael	
Halverson, Kerstin	192007, LF

Harris, Neil	
Harrison, James	
Haymond, Shannon 193	017, 33104, 33227
Herman, Daniel	
Hoekstra, Kenneth	44103/54203
Hollander, Judd	
Holmes, Daniel 193	017, 32216, 33227
Hoofnagle, Andrew	34216
Horowitz, Gary	33229, 34218
Huang, Rongrong	43121/53221
Isbell, T. Scott	32433, 33104
Jaffe, Allan	192008
Jannetto, Paul	33219, LF
Johnson, Paul	
Kaklamani, Virginia	
Kanter, Michael	
Karger, Amy	
<b>3</b> · ,	
Karon, Brad	•
Kataria, Yachana	
Kaufman, Jay	
Kavsak, Peter	
Keren, David	
Klassen Vakili, Hana	43108/53208
Kline, Jeffrey	
Knezevic, Claire	33108
Koch, David	
Kohane, Isaac	32223
Korenberg, Julie	12001, 62102
Korpi-Steiner, Nichole	33229
Kroner, Grace	43111/53211
Krumm, Niklas	
Kyle, Patrick	34107
La'ulu, Sonia	
Ladwig, Paula	
Laposata, Michael	
Leung, Edward	
Leung-Pineda, Van 33	
-	
Li, Danni	
Li, Jieli	
Lippi, Giuseppe	
Little, Randie	
Lockwood, Christina	
Loeb, Jonathan	
Love, Sara	
Luo, Y. Ruben	
Luppa, Peter	33218
Luzzi, Veronica	33106, 33221, LF
Lynch, Kara	34109
Lyon, Martha	33216
Maharjan, Anu	
Mann, Peggy	
Martin, Angela	
Marzinke, Mark	
Master, Stephen	
-	
Mathias, Patrick	102012 22027

	er
McClintock, David	. 193014, 42128/ 52228 43133/5323
McCay Margan	
	32105 33220
	44132/54232
	32102
	42124/52224
	09, 34221, 44122/54222
	33220
Mitsios, John	191003, 43113/53213
Moore, James	
Moyer, Ann	193015, 42131/5223
Mumford, Jeanne	192007
	44109/54209
Nichols, James	
	34217, 3510
Oladipo, Olajumoke	34221, 42110/52210
Orth, Matthias	
Orton, Dennis	
Ottey, Sasha	
Pagaduan, Jayson	42115/5221
Perrotta, Peter	34102
Petersen, Cherie	32432
Pierre, Christina	44116/54216
Poynter, Krista	43123/53223
	42125/52225, LI
	33103
	35102
	35104, 44135/54235, L
	33109
-	193010
	34210
	32222
	32104
	44105/5420
RICCHIUTI, VINCENT	43120/53220 44107/54207
Rifai Nader	33109
-	3510
	42134/52234
1 . 1	
1	
	43125/5322
	32106, 33228
Santani, Avni	
Sargeant, Andrew	
Schiavinato Eberlin, Li	ivia
Schifman, Ron	34102, 43109/53209
	42107/52207
Schreiber, William	
Schreiber, William Schroeder, Lee	
Schroeder, Lee	33224
Schroeder, Lee Schuetz, Audrey	

Simons, Janet Simundic, Ana-Mar Singh, Gurmukh. Siuzdak, Gary Skala, Kimberly Smy, Laura . Snyder, Melissa Sonntag, Oswald Steel, Peter Stickle, Douglas. Straseski, Joely Sugahara, Otoe Suh-Lailam, Brenda Sweeney, Tim.. Sweet, Richard.

Shaw, Leslie Shi, Run Zhang

Tacker, Danyel. Tesic, Vera.. Toffaletti, John.. Tolan, Nicole... Tsongalis, Gregory Turner, Katherine Ulmer, Candice Valent, Amy . van der Gugten, Gr Van Eyk, Jennifer van Rossum, Huub Van Wijk, Xander Vande Casteele, Ni Vassalotti, Joseph Veljkovic, Kika..

LF = Laboratory Feud: Science and Practice Core Committee vs. Education Core Committee

	44120/54220
	33227
ria	
	43103/53203
	32224
	42109/52209
	33225, 34223
	42103/52203,
43101/53201	, 44101/54201
	32431, 33110
	43122/53222
	33229
	34108, 35102
	, 44130/54230
	44102/54202
	32217, 33103
	42127/52227
	, 44131/54231
	42119/52219
	33225
	44123/54223

Vesper, Hubert	-
Walt, David	11001, 62101
Wang, Ping	
Warren, David	
Wener, Mark	
Wheeler, Sarah	
Wiencek, Joesph	33110, 33217, LF
Wiley, Carmen	
Williams, Christopher	
Williams, Grace	44128/54228
Willrich, Maria Alice	
Wilson, Peter	
Winston-McPherson, Ga	brielle
Winter, William	
Wittwer, Carl	15001, 65101
Wu, Alan 34103	, 35102, 42101/52201
Wurzer, Cathy	
Wyer, Lou Ann	
Wyness, Sara	43130/53230
Yang, He Sarina	
Yang, Yifei	
Yarbrough, Melanie	
Yenice, Sedef	
Yu, Hoi-Ying	
Yu, Min	
Zabaleta, Eugenio	33102, 44137/54237
Zakowski, Jack	44104/54204
Zhang, Jada (Yu)	44136/54236
Zhang, Yan Victoria	LF
Zhao, Zhen	
Zucker, Marcia	







# **ACCENT® CREDIT** & CERTIFICATE OF ATTENDANCE

### **ACCENT® CE CREDITS**

The American Association for Clinical Chemistry (AACC) designates this live activity for a maximum of 30.0 ACCENT® continuing education (CE) credit hours towards the AACC Clinical Chemist's Recognition Award. AACC is an approved CE provider for clinical laboratory professionals licensed in states that require documentation of CE, including California, Florida, Louisiana, Montana, Nevada, New York, North Dakota, Rhode Island, Tennessee, and West Virginia. ACCENT<sup>®</sup> credit is also recognized by several organizations: AAB, ABCC, ACS, AMT, ASCLS, ASCP, ASM, CAP, IFCC, and NRCC.

For number of ACCENT<sup>®</sup> credits available per session, see session descriptions in this Program Guide, or visit the mobile app or www.2019aacc.org and click on "Conference Program.'

**Credit amounts are subject to change.** For the most up-to-date information on credits available by session, check the mobile app or visit www.2019aacc.org and select "Conference Program."

### JOINT ACCREDITATION STATEMENT



In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the American Association for Clinical Chemistry (AACC). The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LAST NAME

BADGE #

### PHYSICIAN CONTINUING MEDICAL **EDUCATION (CME)**



The Postgraduate Institute for Medicine designates this live activity for a maximum of 30.0 AMA PRA Category 1 Credits<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For information about AMA PRA Category 1 Credits<sup>™</sup> per session, go to the CME Session Info icon in the mobile app or www.aacc.org/AMcredits19.

### **CONTINUING EDUCATION CREDIT** AND CERTIFICATE OF ATTENDANCE **INSTRUCTIONS**

- 1. To claim your credits and/or to obtain your Certificate of Attendance, click the Claim CE/CME Credits icon in the mobile app.
- 2. Log in using your last name and AACC Customer Number (or badge number).
- 3. For CE and CME credits, you will be required to evaluate each session attended; then print (or save) your Verification of Participation (credit) certificate.
- 4. Sessions that you attend where your name badge is scanned will automatically appear in your session list. You may add more sessions and you may delete sessions.
- 5. Credits may be claimed at any time, i.e., at the end of each session, each day, or after the meeting ends.
- 6. Credits may be claimed using a computer, laptop, tablet, smartphone or other electronic device. Computers will be available on site at the AACC booth #4353 in the Expo.
- 7. Credits for the 2019 AACC Annual Scientific Meeting must be claimed by June 1, 2020, with the exception of credits claimed by California- and Florida-licensed laboratory professionals (see information below.)

#### Special Instructions for California- and Florida-Licensed Laboratory Professionals Receiving ACCENT<sup>®</sup> Credit

If you would like AACC to report your credits to your state licensing agency (Laboratory Field Services for California and CE BROKER for Florida), you must:

- Claim your credits within 30 days of the AACC Annual Scientific Meeting; and
- Enter your California or Florida license number in the appropriate box when claiming your ACCENT® credits.

#### Eligibility to Earn Continuing **Education Credit**

You must be registered for the Annual Scientific Meeting to be eligible to earn continuing education credit (ACCENT® or AMA PRA Category 1 Credit<sup>™</sup>) for the following scientific sessions of the AACC Annual Scientific Meeting: AACC University, Plenary, Symposia, Roundtable, Poster Session and Meet the Expert Sessions. Individuals registered as Guest/Spouse or Expo Only are not eligible to earn credit.

# **FREQUENTLY ASKED OUESTIONS**

How do I get credit for the scientific sessions (Plenary, AACC University, Symposia, Poster Session, Meet the Expert, and Roundtable Sessions)?	Click on the Claim ( AMcredits19 and for and then print (or s
What is the deadline for claiming credits or getting a Certificate of Attendance for the 2019 AACC Annual Scientific Meeting?	The deadline for cl this year's meeting laboratory profession
Do I need to take any additional steps for my ACCENT® credit if I am a licensed laboratory professional in California or Florida?	Yes, if you would lil agency (Laboratory you must enter you ACCENT® credits. Scientific Meeting.
What's the difference between ACCENT® credit and AMA PRA Category 1 Credit™?	ACCENT <sup>®</sup> credit is Credit <sup>™</sup> is for physi
Can I obtain my continuing education credits or Certificate of Attendance on-site at the Annual Scientific Meeting?	Yes, there will be a also use your own device.
How do I get my Certificate of Attendance for the 2019 AACC Annual Scientific Meeting?	Click on the Claim ( AMcredits19 and for You will need your badge.
Who can answer additional questions about continuing education credit?	Contact the AACC

SCIENTIFIC MEETING

AACC ID: 256543

John

Doe

ABC Company Inc.

Bourne MA

**CONFERENCE** 

203430

CE/CME Credits icon in the mobile app or go to www.aacc.org/ follow the instructions to evaluate each session you attended save) your Verification of Participation (credit) certificate.

claiming credits and getting your Certificate of Attendance for a is June 1, 2020, with the exception of California and Florida ionals (see further information below).

ike AACC to report your credits to your state health licensing ry Field Services for California and CE BROKER for Florida), our license number in the appropriate box when you claim your Credits must be claimed within 30 days of the AACC Annual

s for clinical laboratory professionals, and AMA PRA Category 1 sicians only.

a computer in the AACC booth #4353 in the Expo. You may computer, laptop, tablet, smartphone, or other electronic

CE/CME Credits icon in the mobile app or go to www.aacc.org/ follow the instructions to obtain your Certificate of Attendance. AACC Customer Number (or badge number) located on your

C Education Team at education@aacc.org.

Visit the AACC Booth #4353 for more information.



# **POINT-OF-CARE TESTING** Professional Certification

Point-of-Care Testing Professional Certification documents that healthcare professionals working in point-of-care testing have proven expertise in this area and are among the top in their field.

This certification is valuable for those in the clinical setting as well as industry and academia.

### The exam tests mastery and knowledge of:

- Test Selection
- Quality Management
- USA Regulatory Compliance and Safety

### APPLICATION ACCEPTED: JULY 1-SEPTEMBER 16, 2019

LEARN MORE AT www.aacc.org/CPP



Better health through laboratory medicine.

# PROUD SPONSOR OFILE BABORATO SCIENTIST.

### THANK YOU FOR BEING OUR INSPIRATION IN LIGHTING THE WAY WITH DIAGNOSTICS

Providing laboratories with innovative technologies and reliable automation solutions, Sysmex shares your ongoing commitment to the advancement of healthcare. Join us at this year's AACC expo to learn how Sysmex is expanding our portfolio beyond hematology. We designed the UN-2000<sup>™</sup> Automated Urinalysis System and PS-10<sup>™</sup> Sample Preparation System for Flow Cytometry to further streamline laboratory processes. Software solutions like Caresphere<sup>™</sup> Laboratory Management and BeyondCare<sup>SM</sup> Quality Monitor provide powerful metrics that can be accessed when and where you need them. Developing science-centric tools like our Advanced Clinical Parameters (ACP) and next generation educational programs like Virtual Instructor-Led Training (VILT), Sysmex is proud to continuously develop the products and services that allow more time for laboratory scientists to focus on laboratory science.

See us at AACC booth #1063 or visit **Sysmex.com/AACC2019** 



#### 10 OF THE TOP 10 U.S. HOSPITALS USE SYSMEX HEMATOLOGY SOLUTIONS\*

HEMATOLOGY URINALYSIS FLOW CYTOMETRY BEYONDCARE SOLUTIONS

© 2019 Sysmex America Inc. \*U.S. News & World Report 2018-2019, America's Best Hospitals

